DHS SCIENCE AND TECHNOLOGY

Master Question List for COVID-19 (caused by SARS-CoV-2)

Weekly Report

05 January 2021

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at HACTechnologyCenter@hq.dhs.gov.

Homeland Security

Science and Technology

FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following "master question list" that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, "What is the infectious dose?" and "How long does the virus persist in the environment?" The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a "quick reference" tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a "living document" that will be updated as needed when new information becomes available.

Table of Contents

Infectious Dose – How much agent will make a healthy individual ill?

What do we know?

The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).

Non-human primates

- A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (10^6 $TCID_{50}$ total dose).[591]
- Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75×10^6 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1×10^6 PFU intranasally.[428]
- Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (10^6 $TCID_{50}$).[167] Rhesus macaques infected with 2,600,000 $TCID_{50}$ of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.[478] A small study infected Rhesus macaques via ocular inoculation (1×10^6 $TCID_{50}$), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission. Interpretation is limited due to the small scale.[166]
- African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes),[748] mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU),[285] and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.[70]
- Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.[327]
- Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.[427] Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.[785]

Rodents and other animal models

- The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 $TCID_{50}$ (~3.5 PFU).[596] Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.[467]
- Golden Syrian hamsters exposed to 80,000 $TCID_{50}$ (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).[631] Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies,[121] and were also capable of infecting individuals in separate cages.
- Transgenic (hACE2) mice became infected after timed aerosol exposure (36 $TCID_{50}$/minute) to between 900 and 1080 $TCID_{50}$ (~630-756 PFU). All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 $TCID_{50}$, ~504 PFU).[54] This paper has methodological caveats (e.g., particle size).
- Ferrets infected with 316,000 $TCID_{50}$[346] or 600,000 $TCID_{50}$[582] of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.[346, 582] Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.[346] In a separate ferret study, 1 in 6 individuals exposed to 10^2 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to $>10^4$ PFU became infected.[604]

Modeling estimates

- The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called "bottleneck" size);[641] using epidemiological data, sequencing data, and statistics, the average "bottleneck" size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.[552]
- Modeling aerosol exposures from 5 case studies suggests the inhalation ID_{50} for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.[555]

Related Coronaviruses

- Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections,[97] with a plausible intranasal ID_{50} of 10 $TCID_{50}$ (~7 PFU).[77, 486] The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
- The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).[158, 161]
- Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection. Infection with higher doses result in severe syndromes.[19, 142, 395, 781]

What do we need to know?

We need to know the infectious dose for humans by all possible exposure routes in order to inform models, develop diagnostics and countermeasures, and inform disinfection efforts.

- Human infectious dose by aerosol, surface contact (fomite), fecal-oral routes, and other potential routes of exposure
- Most appropriate animal model(s) to estimate the human infectious dose for SARS-CoV-2
- Does exposure dose determine disease severity?
- What is the ratio of virus particles/virions to PFU for SARS-CoV-2?

Transmissibility – How does it spread from one host to another? How easily is it spread?

What do we know?

SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.[36, 82, 270, 473]

- As of 1/5/2021, pandemic COVID-19 has caused at least 85,837,100 infections and 1,856,520 deaths globally.[324] In the US, there have been 20,825,423 confirmed COVID-19 cases and 353,640 confirmed deaths,[324] though both cases[33] and fatalities are underestimates.[507, 747] Estimates of human transmissibility (R_0) range from 2.2 to 3.1.[440, 523, 586, 755, 780]
- A variant of SARS-CoV-2, called B.1.1.7 (also VUI or VOC 202012/01), is associated with a 50-75% higher transmission rate than other strains,[156] corresponding with an increase in the reproduction number (R) of 0.4-0.7.[692]
- SARS-CoV-2 can spread via aerosol or "airborne" transmission beyond 6 ft in certain situations[737] such as enclosed spaces with inadequate ventilation.[111] The risk of infection from fomites is believed to be low.[286]
- Exhaled breath may emit 10^5-10^7 genome copies per person per hour;[436] the amount of infectious virus remains unknown.
- Vertical transmission from mother to fetus is possible[196, 691] but rare.[663]

Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.[397]

- Individuals may be infectious for 1-3 days prior to symptom onset.[40, 718] Pre-symptomatic[71, 351, 642, 652, 760, 784] or asymptomatic[50, 306, 435] patients can transmit SARS-CoV-2.[423] Between 15-56%[577] of infections may be caused by pre-symptomatic transmission,[102, 290, 419, 779] and 75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.[629] Most transmission occurs before symptoms begin and within 5 days of symptom onset.[128]
- Asymptomatic individuals can transmit disease as soon as 2 days after infection.[651] There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.[65, 87, 660]

Infection risk is particularly high indoors.[58]

- SARS-CoV-2 may be spread by conversation and exhalation[12, 392, 612, 645] in indoor areas such as restaurants.[402] Positive SARS-CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants[224] or worked in an office.[220] Clusters are often associated with large indoor gatherings,[383, 524] including bars, restaurants,[772] and gyms.[124]
- Very few outbreaks have occurred in outdoor settings.[88]

Household transmission is rapid,[17] and household contacts spread infection more than casual community contacts.[491]

- On average, 16.6%[437] to 18%[349] of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the "attack rate"). Attack rates are higher for symptomatic index cases, spouses of index cases, and adults,[437] though transmission to children may be underestimated.[266] 75% of household infections occurred within 5 days of illness onset in the index case.[266]
- In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.[393]
- Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.[336]

Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.

- Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).[16, 191, 375, 380, 703]

Rates of transmission on public transit are unclear but appear low,[253] but the US CDC recommends masks during travel.[626]

- Several studies have identified plausible transmission on airplanes.[49, 134, 295, 343, 480] Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.[632]
- On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.[303] Outbreaks have also occurred on public buses.[434]

Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.

- The role of children in SARS-CoV-2 transmission is unclear. There is evidence of high transmission in the home,[310, 379, 393, 525] at school,[267, 320] and in the community.[294, 547, 635] However, there have also been suggestions that children are both less susceptible to COVID-19[437] and less infectious.[793]
- It may be that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.[254] Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.[154, 527, 654] After schools reopened in Italy, attack rates were low in preschool (0%) and elementary school children (0.38%), but in middle and high school students (6.5%).[369] Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
- Children are also less likely than adults to test positive for COVID-19 via RT-PCR[728] despite being infected,[182, 669] underestimating pediatric COVID-19 infections.[154, 452] Serological studies in Germany,[293] Spain,[667] and Italy[84] found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.[65] Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood[452] by age is crucial to understand the role of children.

Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.[408, 763]

What do we need to know?

We need to know the relative contribution of different routes of transmission (e.g., fomites, aerosols, droplets).

- How common is transmission from bodily fluids like semen,[394] urine,[653] and feces?[683]
- How infectious are young children compared to adults?
- What is the emission rate of infectious particles while breathing, talking, coughing, singing, or exercising?

Host Range – How many species does it infect? Can it transfer from species to species?

What do we know?

SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.[400, 414, 416] Current evidence suggests a direct jump from bats to humans is plausible.[72]

- Early genomic analysis indicates similarity to SARS-CoV-1,[790] with a suggested bat origin.[143, 790]
- Positive samples from the South China Seafood Market strongly suggests a wildlife source,[114] though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.[60, 144, 759, 771]
- Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago,[365] and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.[399] However, a survey of 334 pangolins did not identify coronavirus nucleic acid in 'upstream' market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network. These data suggest that pangolins are incidental hosts of coronaviruses.[386]

SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.

- Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,[751] potentially explaining its high transmissibility.
- Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range.[453]
- Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.[152]

Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.

- Infected mink have been linked to human infections in workers at mink farms.[514]
- In the US, researchers experimentally exposed big brown bats (*Eptesicus fuscus*) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.[279]
- Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (10^4 or 10^5 $TCID_{50}$)[197] and are able to transmit virus to uninfected deer mice through direct contact.[262] Their capacity as a reservoir species is unknown.
- Rabbits are susceptible to SARS-CoV-2 via the intranasal route (dose = 10^4-10^6 $TCID_{50}$) and develop asymptomatic infections, though infectious virus can be found in the nose for up to 7 days after exposure.[482] Their reservoir potential is unknown.
- Bank voles (*Myodes glareolus*) seroconvert after SARS-CoV-2 exposure, but do not exhibit clinical symptoms and do not transmit infection to others.[679]

Several animal species are susceptible to SARS-CoV-2 infection.

- Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.[121, 346] In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.[1] SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.[368] Infected mink in the US have been linked to human infections.[4]
- Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques,[591] African green monkeys,[748] and Rhesus macaques.[428]
- Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (10^5 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.[237]
- Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route[628] or a combination of routes[278]), and can transmit the virus to other cats via droplet or short-distance aerosol.[628]
- Wild cats (tigers and lions)[716] can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.[442, 777] Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.[57] Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.[106]
- Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens,[628] 100,000 PFU for pigs,[628] ~70,000 PFU for pigs and chickens[613] all via intranasal route).[628] When pigs were inoculated by the oronasal route (10^6 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.[544]
- Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.[650]
- Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.[680]
- Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies[73] but exhibited no clinical symptoms.[628, 638]
- In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no evidence exists of transmission from dogs or cats to humans.[531]

What do we need to know?

We need to know the best animal model for replicating human infection by various exposure routes.

- What is the intermediate host(s) (if any)?
- Which animal species can transmit SARS-CoV-2 to humans?
- Can SARS-CoV-2 circulate in animal reservoir populations, potentially leading to future spillover events?

Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?

What do we know?

On average, symptoms develop 5 days after exposure with a range of 2-14 days. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease.

- By general consensus, the incubation period of COVID-19 is between 5[376] and 6[719] days.[764] Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.[376] However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.[558] This could mean that 5-10% of individuals undergoing a 14-day quarantine are still infectious at the end.[558]
- There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U-shaped relationship between incubation period length and patient age[352] while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.[404]
- Individuals can test positive for COVID-19 even if they lack clinical symptoms.[50, 120, 271, 662, 784]
- Individuals can be infectious while asymptomatic,[112, 598, 662, 784] and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.[40, 344, 795]
- Peak infectiousness may be during the incubation period, one day before symptoms develop.[290] Infectious virus has been cultured in patients up to 6 days before the development of symptoms.[40]
- Of individuals quarantining after a COVID-19 contact in the home, 81% of those testing negative on day 7 also tested negative on day 14; 19% of individuals undergoing a 7-day quarantine, then, were at risk of developing and potentially transmitting COVID-19.[594] The percentage of individuals at risk declined to 7% for those still asymptomatic and test-negative 10 days after contact.[594] This indicates that quarantines of less than 14 days still carry some risk of disease and transmission, and that care should be taken after completing a shortened quarantine period (e.g., wearing a mask, avoiding close contact).[594]

It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.

- A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.[119]
- While the amount of virus needed to infect another individual is unknown, mild-moderate COVID-19 cases appear to be infectious for no longer than 10 days after symptom onset, while severely ill or immunocompromised patients may be infectious for 20-70 days[45] after symptom onset; individuals can also transmit infection before symptoms appear.[697]
- Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.[304]

The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.

- On average, there are approximately 4[181] to 7.5[396] days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval). Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.[180, 561, 764]
- The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation,[24] meaning individuals tend to transmit virus for less time.
- The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.[263]

Individuals can shed virus for several weeks, though it is not necessarily infectious.

- Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).[431]
- Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.[387]
- Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.[719]
- Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.[696] The duration of the infectious period is unknown,[696] though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.[696]
- Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.[789]

What do we need to know?

We need to know the incubation duration and length of infectivity in different patient populations.

- What is the average infectious period during which individuals can transmit the disease?
- How soon can asymptomatic patients transmit infection after exposure?
- Does the incubation period correlate with disease severity or exposure dose?

Clinical Presentation – What are the signs and symptoms of an infected person?

What do we know?

Most symptomatic cases are mild, but severe disease can be found in any age group.[9] Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.[512] Fever is most often the first symptom.

- Most symptomatic COVID-19 cases are mild (81%).[662, 740] Fever,[38, 271] cough,[271] and shortness of breath[113, 125, 305] are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.[151] In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).[194] Chills, muscle pain,[479] sore throat, loss of taste or smell,[116, 533, 761] gastrointestinal symptoms,[593] neurological symptoms,[407] and dermatological symptoms[151] also occur with COVID-19,[113] and atypical symptoms such as unexplained limb pain may also present with COVID-19.[146] Headaches are common, may persist for weeks, and may be associated with shorter disease duration.[101]
- In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.[347] Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.[379]
- COVID-19 generally begins with fever, then cough and malaise.[370] In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.[769] Only 20% of emergency department patients testing positive for COVID-19 had fevers >100°F.[689] In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.[340]
- Initial assessments suggest that the B.1.1.7 (UK) and 501Y.V2 (South Africa) SARS-CoV-2 variants do not alter severity.[749]

COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission[758] and mortality rates.[546]

In the US, 34% of hospitalized patients required ICU admission, and 12.6% of hospitalized patients died from COVID-19.[464]

- Higher SARS-CoV-2 RNA loads at initial screening or upon admission have been associated with greater risk of death.[85, 259, 438, 726] Individuals of any age can develop severe symptoms and require ICU care.[515] Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness,[741] potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.[476]
- SARS-CoV-2 attacks blood vessels in the lung,[92] leading to clotting complications and ARDS.[15, 687] Clotting affects multiple organs[567] and is present in 15-27% of cases.[430] COVID-19 also causes pneumonia,[519] cardiac injury,[630] secondary infection, kidney damage,[39, 649] pancreatitis,[30] arrhythmia, sepsis, stroke,[454, 538] respiratory complications,[681] and shock.[271, 305, 699, 787]
- COVID-19 symptoms commonly persist for weeks[661] to months[100] after initial onset. Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.[272] Around 9% of hospitalized patients experience at least 1 hospital readmission within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.[377] In Italy, 22% of hospitalized COVID-19 patients developed secondary bacterial or fungal infections.[198] Rates were higher in ventilated patients, those given common antibiotics (piperacillin/tazobactam), and those given IL-6 inhibitors (such as tocilizumab) or JAK inhibitors (e.g., baricitinib).[198]

Between 16% and 76% of cases are asymptomatic throughout the course of their infection,[87, 94, 366, 378, 387, 461, 497, 511, 657, 671] though changing symptom definitions make it difficult to compare asymptomatic fractions through time.[455]

The case fatality rate (CFR) is unknown, but adults >60[529] and those with comorbidities are at elevated risk of death.[662, 787]

- Cardiovascular disease, obesity,[18, 540] hypertension,[775] diabetes,[451] cancer,[704] down syndrome,[140] and respiratory conditions all increase the CFR.[662, 787] Prior kidney disease may increase disease severity,[504] though age may be the dominant factor.[500]
- The CFR increases with age (data from China and Italy): 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.[509]
- In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.[273] An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.[69]

Minority populations and essential workers are disproportionately affected by COVID-19.[471]

- Black, Asian, and Minority Ethnic populations, including children,[52] acquire SARS-CoV-2 infection at higher rates than other groups[228, 261, 518, 554] and are hospitalized[244, 557] and die disproportionately.[297, 456] Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.[750] Social vulnerability is associated with greater SARS-CoV-2 transmission risk.[153]
- Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women[64] and are less likely to present with fever and myalgia,[26] but have higher rates of preterm delivery.[746] Severity in pregnant women may be associated with underlying conditions[26] and may be predicted early.[465] Preterm births are more likely in symptomatic patients.[163]
- In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.[481]

Children are susceptible to COVID-19,[176] though generally show milder[126, 429] or no symptoms.

- 21% to 28% of children (<19 years old) may be asymptomatic.[429, 526, 559] Most symptomatic children show mild or moderate symptoms.[260, 526] Severe symptoms in children[418] and infants[86, 429] are more likely in those with complex medical histories.[624]
- A rare inflammatory condition in children (MIS-C)[251] is linked to COVID-19 infection;[587, 670] the prevalence of is unknown. Children with both severe and moderate initial symptoms can progress to MIS-C,[250] but gastrointestinal symptoms appear common in those that do.[214] Black children are overrepresented among MIS-C patients.[385]

What do we need to know?

We need to know the true case fatality rate, asymptomatic fraction, and the duration of debilitating symptoms.

- We need to understand the mechanism and clinical implication of chronic COVID syndrome.[51]
- What are the pathogenic pathways of SARS-CoV-2 infection in children,[487] and why are their clinical manifestations different (typically milder) from adults?[248]

Protective Immunity – How long does the immune response provide protection from reinfection?

What do we know?

Infected patients show productive immune responses, but the duration of any protection is unknown.[29, 732] Reinfection is possible. The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.

- In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).[432]
- Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.[216, 273, 589, 592] Mild COVID-19 infections can induce detectable immune responses for at least 3 months.[592] Antibody levels increase with disease severity[666] and are largely unaffected by patient age.[216] A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.[714]
- Neutralizing antibody responses are present within 8-19 days after symptom onset[422, 656] and can persist for months.[695] Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.[619] The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.[245] Asymptomatic cases generate weaker antibody responses to SARS-CoV-2.[133]
- Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.[618]
- Strong, early inflammatory immune responses are associated with more severe clinical presentation.[164] There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.[477] A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.[477]
- SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.[506] T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.[796] While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA). [239, 627]
- Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients; asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.[381]
- In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.[186] Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.[96, 756]

Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.

- Researchers in Hong Kong[356] and the US[665] have identified COVID-19 reinfections. Reinfections have been either less[356] or more severe[665] than the initial infection. The infectiousness of re-infected individuals is unknown.
- Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days[168] or 35 days[123] after initial exposure resulting in no clinical symptoms. Ferrets infected with 10^2-10^4 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.[604]

The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.[490]

- Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.[447] Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.[493] Cross-reactivity from seasonal coronaviruses also enhances the immune response toward the S2 unit of the SARS-CoV-2 Spike protein.[493]
- Two studies identified key components of the adaptive immune system ($CD4^+$ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.[80, 265] These studies also identified Spike protein responses in $CD4^+$ T cells of ~30-40% of unexposed patients,[265] suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.[80, 265] Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross-reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.[382]
- Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.[620] Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2,[553] though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.[673]

What do we need to know?

We need to know the frequency and severity of reinfection, as well as the protective effects of immune components.

- How do different components of the immune response contribute to long-term protection?
- How does initial disease severity affect the type, magnitude, and timing of any protective immune response?
- Given different immunological responses for men compared to women,[658] as well as for adults compared to children,[722] are distinct diagnostic tests or medical treatments required for the different groups?
- How long does protective immunity last for children compared to adults?

Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?

What do we know?

Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals. Screening solely by temperature or other symptoms is unreliable.

- As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests,[230] which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection[199] and at-home diagnostic assays for SARS-CoV-2 infection.[232-233] The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza,[208] and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.[188, 231]
- The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.[117]
- The timing of diagnostic PCR tests impacts results. The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.[361] Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.[412]
- The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.[443] After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.[443]
- The UK variant B.1.1.7 affects the S-gene portion of some PCR diagnostic assays, though most assays use multiple SARS-CoV-2 targets and diagnostic accuracy is not expected to be affected.[749]
- Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened),[175] and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.[390]
- Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid,[707] although evidence is mixed.[742] Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.[782] Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.[90] Newer tests target up to three viral components, demonstrating high sensitivity and specificity.[93]
- Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR,[603] and other work examining breath-based samplers is ongoing.[623]
- Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.[284]
- Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.[725]
- The CRISPR-Cas12a system is being used to develop fluorescence-based COVID-19 diagnostic tests.[173, 308, 705] India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.[6]
- Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.[457]
- Immunological indicators[46, 190, 236, 243, 289, 307, 489, 545, 643, 655, 700, 774] blood glucose levels,[706] oxygen levels[348] and bilirubin levels[421] may help identify future severe cases,[135] and decision-support tools for diagnosing severe infections exist.[450, 636, 754]
- Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.[556]
- High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.[539] A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.[74, 234]
- Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.[184]

Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.

- Repeated serological testing is necessary to identify asymptomatic[551] and other undetected patients.[610]
- Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.[372, 727] Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.[409] Lateral flow assay results differ more from ELISA when administered early in disease course (e.g., 3-7 days after symptom onset).[287] The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.[204]
- In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.[195]
- SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance,[21] and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.[534]

What do we need to know?

We need to identify additional factors that affect the accuracy of serological or PCR-based diagnostic tests.

- What is the relationship between disease severity and the timing of positive serological assays?
- Are certain subpopulations (e.g., those with blood cancers)[498] more likely to show false-negative tests?
- How likely are children of different ages to test positive via RT-PCR?
- Are wearable devices capable of indicating COVID-19 before self-reported symptom onset?[640]

Medical Treatments – Are there effective treatments?

What do we know?

There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality. Remdesivir may reduce symptom duration in hospitalized patients,[63] and may reduce mortality when combined with other treatment regimens (e.g., baricitinib).[334]

- The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older,[210] with an Emergency Use Authorization for other patient groups.[201, 495]
- A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.[520] An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.[713]

Hydroxychloroquine provides limited to no clinical benefit.[217, 617]

- Hydroxychloroquine (HCQ) does not prevent infection as either pre-[14, 247, 562] or post-exposure prophylaxis,[75, 459] does not benefit mild-moderate COVID-19 cases,[104, 508] was associated with adverse cardiac events in severely ill patients,[338] does not reduce mortality,[3] and increases mortality when combined with azithromycin.[217] The FDA revoked its EUA on 6/15/20.[200]

Corticosteroids may significantly reduce mortality in severely ill[521] and ventilated patients,[127] especially if given early.[668]

- Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen,[300] and no benefits in patients who did not need oxygen or ventilation.[300]
- A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.[647] High doses may be beneficial in severely ill patients.[528]
- The benefits of glucocorticoids may depend heavily on patient inflammation.[337] In several studies, high doses of steroids were associated with elevated mortality,[411, 469] though low-moderate doses can reduce mortality in patients with ARDS.[753]

Convalescent plasma treatment is safe and may be effective when administered early,[27] though evidence is mixed.[532]

- A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.[311, 330] Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission,[609] and donor plasma with higher antibody levels appears more effective.[331, 445, 568] Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).[634]
- On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.[211]

Anticoagulants may reduce COVID-19 mortality in hospitalized patients.

- Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.[484] Anticoagulant use was associated with lower mortality in the severely ill,[522] but the correct dose is critical to avoid complications.[318] High doses of anticoagulants may be effective in critically ill patients.[329] Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.[165]

The benefits of tocilizumab are unclear,[608] and it can increase hospital stay time and the risk of secondary infection.[393]

- While tocilizumab appears to show a 12% reduction in mortality in treated patients,[441] a randomized clinical trial found no effects on mortality,[291] and other evidence suggests that it may be beneficial only in certain circumstances.[292, 466, 485, 648]

Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.

- Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.[406] Regeneron's REGN-COV2 treatment has been associated with reductions in symptom duration[572] and viral load.[721] However, data from both Eli Lilly and Regeneron suggest that their antibody treatments may not work well for hospitalized patients[433] or those with high oxygen requirements.[571]
- Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.[573]
- A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity,[468] though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.[520]
- Nitazoxanide may reduce viral loads when administered early in the course of the disease.[590] Anakinra has shown clinical benefits in small observational studies,[103, 138] and may be effective with methylprednisolone.[76] Favipiravir may reduce the duration of clinical symptoms[174] and reduce the time for viral clearance.[238, 677] Statins[446, 605] and RAAS inhibitors[711] (for hypertension) do not appear to elevate COVID-19 risk.[32, 472, 576, 644] Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.[659] Acalabrutinib may improve patient oxygenation,[595] and is being included in large clinical trials (SOLIDARITY).[362] Colchicine may reduce rates of intubation and mortality.[611] Fluvoxamine may reduce clinical symptoms.[389] There is no clinical benefit from ritonavir/lopinavir.[99, 242, 264, 403] Ivermectin reduced viral shedding duration in a small clinical trial (n=72).[20] IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).[607] Androgen has been suggested as a factor in disease severity in men,[257, 470, 698] and treatment options are in trial.[258, 449] Insulin use may increase mortality risk compared to other type 2 diabetes treatments[770] such as metformin.[79, 325, 364]

What do we need to know?

We need clear, randomized trials for treatment efficacy in patients with both severe and mild/moderate illness.

- Does time to viral clearance correlate with symptom severity or time to symptom resolution?
- What treatment, or combination of treatments, is most effective for different disease severities and patient demographics?

Vaccines – Are there effective vaccines?

What do we know?

Several vaccine candidates have shown promising Phase III trial results, and two are currently being administered under US FDA Emergency Use Authorization.

- In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).[177]

Candidates that have received or applied for approval in the US:

- Pfizer/BioNTech – mRNA vaccine named BNT162b2 (also called Tozinameran[734] and Comirnaty[189])
  - Vaccine is given as 2 shots, 21 days apart.[541]
  - At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), the vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.[550] Efficacy was 94% for those individuals over 65.[550]
  - There were 43,661 study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.[542] Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).[543] No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).[543] Other common side effects included pain at the injection site and muscle pain.[543]
  - After reports of two allergic reactions in UK healthcare workers,[597] the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine,[448] but should talk to their doctor and be observed for 30 minutes after vaccination.[597]
  - Storage and shipping requirements are -70°C; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2–8°C) conditions.[543]
  - Pfizer and BioNTech received Emergency Use Authorization from the US FDA for individuals 16 and older.[206] The WHO issued an Emergency Use Listing for this vaccine, accelerating approval and distribution in many countries.[738]
- Moderna – mRNA vaccine named mRNA-1273[463]
  - Vaccine is given as 2 shots, 28 days apart.[463]
  - At the conclusion of Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.[47] Efficacy was consistent across age, race, ethnicity, and sex.[47] Vaccine-induced antibodies persisted for at least 119 days.[739]
  - There were 30,000 study participants, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.[463] Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).[463] Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.[463]
  - The vaccine can be shipped and stored at standard freezer temperatures (-20°C) for 6 months, and is expected to be stable under refrigeration (2-8°C) for 30 days and at room temperature for 12 hours.[462]
  - Moderna was granted an EUA from the US FDA for individuals 18 and older.[205] It has also been approved in Canada.[98]

Phase III Trials (testing for efficacy):

- The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.[43] None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.[588] The vaccine appears safe, and instills a robust immune response across age groups.[563] The vaccine is given in two doses, 1 month apart.[43] The Phase III trial included 23,000 participants, all over 18.[43] The vaccine is stable at 2-8°C for up to 6 months.[43] This vaccine has been approved for use in the UK, Argentina, and India.[59]
- Russia's Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.[241] No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.[95]
- Many vaccine candidates are undergoing Phase III trials, including those from Sinovac (CoronaVac),[637] Janssen (with Johnson and Johnson),[322] CanSino (Ad5-nCoV),[791] Novavax (NVX-CoV2373, including a US arm),[496] Medicargo (with GlaxoSmithKline, called CoVLP),[268] Anhui Zhifei Longcom (with the China Academy of Medical Sciences),[786] CureVac (CVNCoV),[149] Institute of Medical Biology,[616] Clover Biopharmaceuticals,[141] Zydus Cadila,[314] and Kazakhstan's RIBSP (QazCovid).[580]
- India approved Bharat Biotech's vaccine Covaxin, despite no published Phase III safety or efficacy data.[59]
- China's Beijing Institute of Biological Products, in conjunction with Sinopharm, have reported 79% efficacy of their BBIBP vaccine, which has been approved for use by the Chinese government; no published Phase III data exist yet.[717]

What do we need to know?

We need published results from Phase I-III trials in humans to assess vaccine efficacy and safety, and length of immunity.

- We need a high-level overview of vaccine administration rates for initial and booster doses in different populations.
- How much do different vaccines reduce individual transmission risk?
- What is the protective efficacy of a single dose of each vaccine in use in the US, and does it vary by age group?
- Does dosing with two different vaccines for initial and booster doses affect protective efficacy (e.g., Pfizer then Moderna)?
- How long after initial dosing are booster doses effective (e.g., 4, 6, 12, 20 weeks)?

Non-pharmaceutical Interventions (NPIs) – Are public health control measures effective at reducing spread?

What do we know?

Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission.

- Social distancing and other policies quickly reduced spread throughout China,[357, 360, 363, 425, 439, 702] Europe,[246, 335] and the US.[355] Delaying control measures increases outbreak duration[179] and mortality.[767] Reductions in transmission appear 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.[401]
- Tiered restrictions in the UK resulted in 2-44% reductions in transmission, depending on restriction severity.[157]
- US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.[622] Modeling suggests that widespread use of facemasks is effective at reducing transmission[492] even when individual mask efficiency is low,[187] though their benefits are maximized when most of the population wears masks.[225]
- In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.[147] School closures and cancellation of large gatherings had smaller effects.[147] Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.[332] Adherence to social distancing policies depends on income.[720] Telework policies may reduce new cases.[220]
- Mobility[226, 371] and physical contact rates[323] decline after public health control measures are implemented. Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.[48, 283] Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.[475]
- A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.[215, 353] School closures alone appear insufficient,[321, 363] though likely reduced mortality in the UK[581] and the US.[44]
- Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.[124] Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.[341]
- Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies,[275] and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.[309] In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.[513]

Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.[533]

- The US CDC has indicated that face masks inhibit transmission by both reducing the number of exhaled particles from infectious individuals, as well as reducing the number of inhaled particles when worn by uninfected individuals.[110] The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.[298]
- Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.[178]
- Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.[299]
- A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.[89]

Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.[743]

- Eliminating superspreading events can result in slower case growth while easing broadly restrictive interventions.[333]
- Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.[118]
- There are multiple types of superspreading events, and different policies are required to mitigate risks from each.[28]

Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.

- In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.[652] Contact tracing and high levels of testing and physical distancing[359] may limit COVID-19 resurgence.[23, 218]
- Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.[240]
- Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.[672] Testing is critical to balancing public health and economic costs.[672] Rolling interventions may be necessary.[765] Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.[281]
- Synchronizing public health interventions across US state lines may reduce the total number of required interventions.[599]
- Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.[601]
- SARS-CoV-2 variants with higher transmission rates (e.g., B.1.1.7) may require additional restrictions to reduce transmission, as their reproduction numbers may not go below replacement (R = 1) with standard restrictions.[692]

What do we need to know?

We need to understand measures that will limit spread in the winter, particularly in indoor environments.

- How effective are school closures when COVID-19 prevalence in the community is high? Low?
- What is the benefit of "cocooning" high-risk individuals in terms of averted deaths and hospitalizations?[708]

Environmental Stability – How long does the agent live in the environment?

What do we know?

SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.[61] Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.

Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.

- Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).[68] Persistence is reduced with warmer temperatures (37°C), and enhanced at colder temperatures (4°C).[282]
- SARS-CoV-2 was shown to be stable up to 7 days (25-27°C; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.[420] At 22°C, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.[282]
- SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22°C.[132] After 3 hours (22°C, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.[132]
- At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).[8, 315, 621]
- SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23°C, 40% RH)[684] and infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH)[132] and other PPE for at least 72 hours at 22°C .[277]
- SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.[474]

In the absence of sunlight, SARS-CoV-2 can persist on surfaces for weeks.

- In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20°C and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.[585] This value is longer than other stability estimates,[131, 585, 684] potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.[585] In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.[569]
- The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity, also considering UV light.[171]

Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.

- It does not appear that pollen or air particulates are carriers of SARS-CoV-2,[183] despite some country-level associations.[55]

SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.

- DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.[170] Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.[783]
- Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 µm mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).[615] In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.[615] Humidity alone had no significant impact on aerosolized virus survival.[615]
- SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 µm, tested at 21-23°C and 65% RH),[684] retaining infectivity for up to 16 hours in appropriate conditions (23°C, 53% RH, no sunlight).[212]

Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.

- RNA in clinical samples collected in viral transport medium is stable at 18-25°C or 2-8°C for up to 21 days without impacting real-time RT-PCR results.[639] RNA in clinical samples is also stable at 4°C for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL). Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25°C) resulted in unstable sample concentrations.[536]

There is currently no evidence that SARS-CoV-2 is transmitted to people through food.

- There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections,[317, 730] though several outbreaks have a hypothesized food origin.[280] Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.[578]
- SARS-CoV-2 is susceptible to heat treatment (70°C) but can persist for at least two weeks at refrigerated temperatures (4°C).[131, 566] SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20°C.[223]

What do we need to know?

We need to quantify the duration of SARS-CoV-2 infectivity on surfaces, not simply the presence of RNA.

- It is unclear how viability of SARS-CoV-2 is affected across the food supply chain.[768]
- Does the composition (e.g., organic compounds, metals) of airborne particulate matter affect SARS-CoV-2 stability?[715]
- Can SARS-CoV-2 contaminated wastewater cause infections?[410, 560]

Decontamination – What are effective methods to kill the agent in the environment?

What do we know?

Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.

- A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.[61] However, the levels of decontamination necessary to affect transmission *per se* are still unknown.[61]
- Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.[358]
- Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.[130]
- EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.[192]
- Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.[510] Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.[345] Chlorhexidine digluconate may be ineffective.[42]
- Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).[66]
- Efforts are ongoing to create paint-on surfaces[62] or other surface coatings[193] that can rapidly inactivate SARS-CoV-2.
- Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.[235]
- A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme®) effectively inactivated SARS-CoV-2 *in vitro*; additional tests are necessary to determine any clinical benefit.[274]
- Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.[606]
- Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).[22, 674]
- In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity;[646] Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.[729]
- Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.[78]
- Masks with laser-induced graphene may facilitate decontamination, particularly when masks are exposed to sunlight.[25]
- Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.[150]
- Due to the lack of documented transmission via fomites, widespread decontamination of surfaces (e.g., streets, sidewalks) may not be necessary.[488]

Several methods exist for decontaminating N95 respirators[502] and other PPE.

- Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor): UV radiation, heating to 70°C, and vaporized hydrogen peroxide (VHP).[222] Ethanol (70%) was associated with loss of physical integrity.[222] Dry heat and UV decontamination can also be used under certain conditions.[221]
- Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light,[633] wet heat (using a multicooker),[172] and methylene blue plus light.[388]
- Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.[583] Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.[202]
- The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals,[81] though fit failure after reuse remains a concern.[405]
- Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.[535] Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.[11] Stacking respirators may increase decontamination rates without compromising efficiency.[602] Peracetic acid may be effective in combination with VHP.[326]
- The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.[675]
- A Canadian technology ("D-Pod") using heat and UVC for PPE is being manufactured for North American distribution.[249]
- A thermal inactivation model for SARS-CoV-2 provides estimates of infectivity reduction based on time and temperature.[766]
- Forced air ozone reactors may be able to decontaminate surgical gowns, though SARS-CoV-2 tests are needed.[139, 417]

What do we need to know?

We need additional SARS-CoV-2 decontamination studies, particularly with regard to PPE and other items in short supply.

- Does contamination with human fluids/waste alter disinfectant efficacy profiles?
- We need to know how to efficiently and effectively decontaminate whole rooms and large spaces.
- What level of decontamination is necessary (e.g., log-reduction) to eliminate transmission risk from contaminated surfaces?
- We need to understand how different testing methods and standards affect decontamination efficacy estimates.

PPE – What PPE is effective, and who should be using it?

What do we know?

Face masks appear effective at reducing infections from SARS-CoV-2. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.

- Healthcare worker illnesses[662] demonstrates human-to-human transmission despite isolation, PPE, and infection control.[614] Risk of transmission to healthcare workers is high.[575] Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.[710] Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.[584] Universal masking policies also reduced the rate of new healthcare worker infections.[709, 792] Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.[494]
- A modeling study suggests that healthcare workers are primarily at risk from droplet and inhalation exposure (compared to contact with fomites), with greater risk while in closer proximity to patients.[328]
- "Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield)."[108] The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.[736] WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.[733] PPE that covers all skin may reduce exposure to pathogens.[213, 724]
- Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.[735] Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.[83]
- KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.[203] On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.[209]
- A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.[530]
- Particular care should be taken with "duckbill" N95 respirators, which may fail fit tests after repeated doffing.[162] Dome-shaped N95 respirators also failed fit tests after extended use.[162]
- The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.[207]
- Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.[678]
- Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.[160]

Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.[7, 10]

- On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.[109] The CDC recommends masks without exhalation vents or valves,[105] as masks with valves can allow particles to pass through unfiltered.[688] The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.[731] Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.[712]
- A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission,[136] with N95 respirators more effective than surgical masks.[136] In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.[505] N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.[505]
- Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.[155, 391, 682] Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 µm).[391] Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer's face.[690]
- Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3µm,[350] while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).[701] Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.[773] Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.[219] Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.[41] Smaller aerosol particles (e.g., <0.1µm) are more difficult to filter for most respirators and face masks.[137]

What do we need to know?

We need to continue assessing PPE effectiveness with specific regard to SARS-CoV-2 instead of surrogates.

- When and how do N95 respirators and other face coverings fail?
- How effective are homemade masks at reducing SARS-CoV-2 transmission?

Forensics – Natural vs intentional use? Tests to be used for attribution.

What do we know?

All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.

- New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate 'mixing' host.[72] Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.[72] Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.[72] These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
- Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from *Rhinolophus* (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country,[373] though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.[229]
- Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by "recombination" with other circulating strains of coronavirus.[35, 790]
- Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.[414, 416] The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.[426] The rest of the genome is more closely related to two separate bat coronaviruses[426] and coronaviruses found in pangolins.[416]
- Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.[276] These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.[276]
- Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.[745] Additional whole-genome sequencing in humans would help to confirm this finding.
- Genomic data support at least two plausible origins of SARS-CoV-2: "(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer."[35] Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
- Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses,[744] and data suggest that pangolins may be a natural host for beta-coronaviruses.[414, 416] Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.[398, 757] Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.[778] Additional research is needed.
- There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.[35, 398, 415, 778] These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor. Additional research is needed.
- A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).[148]
- A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein. While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.[788]
- Additionally, "[…] SARS-CoV-2 is not derived from any previously used virus backbone," reducing the likelihood of laboratory origination,[35] and "[…] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin."[35]
- Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.[159]
- A report claiming a laboratory origin of SARS-CoV-2[762] has been heavily disputed by scientists at Johns Hopkins University.[5]

What do we need to know?

We need to know whether there was an intermediate host species between bats and humans.

- What tests for attribution exist for coronavirus emergence?
- What is the identity of the intermediate species?
- Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2?

Genomics – How does the disease agent compare to previous strains?

What do we know?

Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.

- There have been no documented cases of SARS-CoV-2 prior to December 2019. Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 – 12/17/2019.[37, 60, 564]
- The estimated mutation rate for SARS-CoV-2 is $6x10^{-4}$ nucleotides per genome per year.[685]
- SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).[752] Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts,[752] and that additional jumps into humans may occur.
- In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.[694] The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.[694] Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.[694]

Several viral variants, including B.1.1.7, are being investigated for their effects on transmission and/or virulence.

- An existing variant (VOC 202012/01, also called B.1.1.7) that is increasing in prevalence in some areas of the UK[185] has been associated with higher transmission rates,[301] though confirmation in human or animal studies is needed. There have been no links between this variant and enhanced virulence.[444] The variant consists of several mutations linked to the viral Spike protein[339] and receptor-binding domain.[565] The variant has been confirmed in at least 4 US states and 33 countries.[288]
- Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission,[693] but no change in clinical severity in infected patients.[354] An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation,[354, 424, 548, 776] though it is possible that founder effects contributed to its prevalence.[686] Limited animal model results support the possibility of increased transmissibility,[302, 549] and the mutation slightly increased viral replication in human cell lines.[548, 776] Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.[686] The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.[723] Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.[384]
- A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies. This may affect the ability of vaccines and therapeutics that target this region.[664]

Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.[34]

- Blood type may affect COVID-19,[252] with evidence of slightly increased prevalence[31, 56, 255] and moderately increased severity in those with type A blood[296, 413] (though evidence is mixed).[374] In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.[794] Non-O-type blood has been associated with clotting issues.[169] A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.[570]
- Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation,[252] as well as those with severe disease.[516]
- Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.[53]
- In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).[517]

There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.

- Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.[579] The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.[316]
- The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.[145]
- Continued analysis of SARS-CoV-2 strains in humans and mink suggests that common mutations in humans are transmitted to mink, and subsequent mutations in mink facilitate transmission back to human populations; more work is needed to assess the consequences of such mutations in animals prior to human transmission.[91]

What do we need to know?

We need to link genotypes to phenotypes (e.g., disease severity) in infected patients, and identify differences in transmissibility or symptom severity caused by different SARS-CoV-2 mutations.

- What are the mutations in SARS-CoV-2 that allowed human infection and transmission?
- How do viral mutations affect the long-term efficacy of specific vaccines?
- Which viral variants affect transmission rates or disease severity?

Forecasting – What forecasting models and methods exist?

What do we know?

Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.

- Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.[319]
- COVID Act Now: State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds). Fundamentally uses an SEIR model fit to observed data.[501]
- ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.[503]
- The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.[483]
- The COVID Tracking Project reports the number of active COVID-19 hospitalizations in the US and each US state.[2]

The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.[107]

- Columbia University Model: Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.[600]
- Institute of Health Metrics and Evaluation (IHME): Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.[312] Also provides global forecasts.[313]
- Los Alamos National Laboratory: Forecasts of state-level cases and deaths based on statistical growth model fit to reported data. Implicitly accounts for effects of social distancing and other control measures.[367]
- Google/Harvard University: Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.[256]
- Northeastern University: Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.[499]
- Notre Dame University: Agent-based model forecasting cases and deaths for Midwest states. Includes effectiveness of control measures like social distancing.[537]
- University of California, Los Angeles: Mechanistic SIR model with statistical optimization to find best-fitting parameter values. Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.[676]
- University of Geneva: Country-level forecasts of cases, deaths, and transmissibility (R_0). Uses statistical models fit to reported data, not mechanistic models.[227]
- University of Massachusetts, Amherst: Aggregation of state and national forecasts to create ensemble model.[574]
- Youyang Gu: Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values. Forecasts deaths and infections at the state and national level, including 60 non-US countries. Includes effects of public health control efforts.[269]

Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.

- Massachusetts Institute of Technology: Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths. Also includes estimates of intervention measures, allows users to project based on different intervention scenarios.[458]
- CovidSim: SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).[129]
- Covasim: Agent-based model for testing effects of intervention measures, also available as Python library.[342]
- Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.[625]
- The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R_0), serial interval, generation time, and fatality rate.[67]
- University of Georgia: Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., "nowcasts"). Available at the state and national level for the US.[115]
- Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, R_{eff} or R_t).[13]
- Georgia Tech Applied Bioinformatics Laboratory: Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.[122]
- MITRE: Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning. Uses combinations of SEIR models and curve-fitting approaches.[460]

What do we need to know?

We need to know how different forecasting methods have fared when compared to real data and develop an understanding of which model features contribute most to accurate and inaccurate forecasts.

- We need to know how vaccine efficacy, uptake, and deployment will alter COVID-19 progression.
- How will spillover and movement between countries affect local COVID-19 resurgence after initial vaccine distribution?
- We need real-time, publicly available dashboards to estimate vaccine uptake and adherence rates across the US.
- Does modeling support the administration of initial vaccine doses to as many people as possible despite reduced efficacy?

Table 1. Definitions of commonly used acronyms

Acronym/Term	Definition	Description
ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV and SARS-CoV-2, allowing entry into human cells
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems). Particles generally <5 µm.
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
Attack rate	Proportion of "at-risk" individuals who develop infection	Defined in terms of "at-risk" population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
CCV	Canine coronavirus	Canine coronavirus
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
ELISA	Enzyme-linked immunosorbent assay	Method for serological testing of antibodies
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
MERS	Middle East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
MHV	Mouse hepatitis virus	Coronavirus surrogate
Nosocomial	Healthcare- or hospital-associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures
NPI	Non-pharmaceutical intervention	Public health control measures designed to reduce transmission, such as social distancing, movement restrictions, and face mask requirements.
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2.
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.

Acronym/Term	Definition	Description
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
R_0	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.
SEIR	Susceptible (S), exposed (E), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), exposed (E), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate R_0, and is useful for estimating the rate of outbreak spread
SIR	Susceptible (S), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
$TCID_{50}$	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection
Vertical transmission	Transmission from mother to fetus	Generally understood as intrauterine transmission via blood or placenta. Not the same as transmission during or after birth.

Literature Cited:

1. Coronavirus diagnosed at mink farms in North Brabant. *NOS* 2020. https://nos.nl/artikel/2331784-coronavirus-vastgesteld-bij-nertsenfokkerijen-in-noord-brabant.html
2. COVID Tracking Project. https://covidtracking.com/data.
3. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2022926
4. First case of SARS-CoV-2 in mink confirmed in Oregon. Oregon Department of Agriculture: 2020. https://odanews.wpengine.com/first-case-of-sars-cov-2-in-mink-confirmed-in-oregon/
5. *In Response: Yan et al. Preprint Examinations of the Origin of SARS-CoV-2*; Johns Hopkins Bloomberg School of Public Health, Center for Health Security: 2020. https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/200921-in-response-yan.pdf
6. India's new paper Covid-19 test could be a 'game changer'. *BBC* 2020. https://www.bbc.com/news/world-asia-india-54338864
7. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings. *Annals of Internal Medicine 0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-3213
8. Research Shows Virus Undetectable on Five Highly Circulated Library Materials After Three Days. Institute for Library and Museum Services: 2020. https://www.imls.gov/news/research-shows-virus-undetectable-five-highly-circulated-library-materials-after-three-days
9. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. . *MMWR* **2020**. https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w#suggestedcitation
10. Update Alert: Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings. *Annals of Internal Medicine 0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/L20-0948
11. 3M, *Decontamination of 3M Filtering Facepiece Respirators, such as N95 Respirators, in the United States - Considerations*; 3M: 2020. https://multimedia.3m.com/mws/media/1824869O/decontamination-methods-for-3m-filtering-facepiece-respirators-technical-bulletin.pdf
12. AAAS, You may be able to spread coronavirus just by breathing, new report finds. *Science* 2 April, 2020. https://www.sciencemag.org/news/2020/04/you-may-be-able-spread-coronavirus-just-breathing-new-report-finds
13. Abbott, S.; Hellewell, J.; Thompson, R.; Sherratt, K.; Gibbs, H.; Bosse, N.; Munday, J.; Meakin, S.; Doughty, E.; Chun, J.; Chan, Y.; Finger, F.; Campbell, P.; Endo, A.; Pearson, C.; Gimma, A.; Russell, T.; null, n.; Flasche, S.; Kucharski, A.; Eggo, R.; Funk, S., Estimating the time-varying reproduction number of SARS-CoV-2 using national and subnational case counts [version 1; peer review: awaiting peer review]. *Wellcome Open Research* **2020,** *5* (112). https://wellcomeopenresearch.org/articles/5-112/v1
14. Abella, B. S.; Jolkovsky, E. L.; Biney, B. T.; Uspal, J. E.; Hyman, M. C.; Frank, I.; Hensley, S. E.; Gill, S.; Vogl, D. T.; Maillard, I.; Babushok, D. V.; Huang, A. C.; Nasta, S. D.; Walsh, J. C.; Wiletyo, E. P.; Gimotty, P. A.; Milone, M. C.; Amaravadi, R. K., Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Intern Med* **2020**.
15. Ackermann, M.; Verleden, S. E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; Li, W. W.; Li, V. W.; Mentzer, S. J.; Jonigk, D., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2015432

16. Adam, D.; Wu, P.; Wong, J.; Lau, E.; Tsang, T.; Cauchemez, S.; Leung, G.; Cowling, B., Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. **2020**.
17. Adam, D. C.; Wu, P.; Wong, J. Y.; Lau, E. H. Y.; Tsang, T. K.; Cauchemez, S.; Leung, G. M.; Cowling, B. J., Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-1092-0
18. Adams, M.; Katz, D.; Grandpre, J., Updated Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. *Emerging Infectious Disease journal* **2020,** *26* (9). https://wwwnc.cdc.gov/eid/article/26/9/20-2117_article
19. Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* **2015,** *89* (7), 3659-70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/zjv3659.pdf
20. Ahmed, S.; Karim, M. M.; Ross, A. G.; Hossain, M. S.; Clemens, J. D.; Sumiya, M. K.; Phru, C. S.; Rahman, M.; Zaman, K.; Somani, J.; Yasmin, R.; Hasnat, M. A.; Kabir, A.; Aziz, A. B.; Khan, W. A., A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *Int J Infect Dis* **2020**.
21. Ahmed, W.; Bertsch, P. M.; Bibby, K.; Haramoto, E.; Hewitt, J.; Huygens, F.; Gyawali, P.; Korajkic, A.; Riddell, S.; Sherchan, S. P.; Simpson, S. L.; Sirikanchana, K.; Symonds, E. M.; Verhagen, R.; Vasan, S. S.; Kitajima, M.; Bivins, A., Decay of SARS-CoV-2 and surrogate murine hepatitis virus RNA in untreated wastewater to inform application in wastewater-based epidemiology. *Environmental Research* **2020**, 110092. http://www.sciencedirect.com/science/article/pii/S0013935120309890
22. Airora, The development, testing and verification of Airora's patented biocidal technology. https://www.airora.com/verification.html (accessed 19 Oct 2020).
23. Aleta, A.; Martin-Corral, D.; Pastore y Piontti, A.; Ajelli, M.; Litivinova, M.; Chinazzi, M.; Dean, N.; Halloran, M. E.; Longini, I.; Merler, S.; Pentland, A.; Vespignani, A.; Moro, E.; Moreno, Y., Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic. *Preprint* **2020**. https://www.mobs-lab.org/uploads/6/7/8/7/6787877/tracing_main_may4.pdf
24. Ali, S. T.; Wang, L.; Lau, E. H. Y.; Xu, X.-K.; Du, Z.; Wu, Y.; Leung, G. M.; Cowling, B. J., Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. *Science* **2020**, eabc9004. https://science.sciencemag.org/content/sci/early/2020/07/20/science.abc9004.full.pdf
25. Allen, D., Graphene Face Masks Set to Boost Coronavirus Protection. http://emag.medicalexpo.com/graphene-face-masks-set-to-boost-coronavirus-protection/ (accessed 16 Nov 2020).
26. Allotey, J.; Stallings, E.; Bonet, M.; Yap, M.; Chatterjee, S.; Kew, T.; Debenham, L.; Llavall, A. C.; Dixit, A.; Zhou, D.; Balaji, R.; Lee, S. I.; Qiu, X.; Yuan, M.; Coomar, D.; van Wely, M.; van Leeuwen, E.; Kostova, E.; Kunst, H.; Khalil, A.; Tiberi, S.; Brizuela, V.; Broutet, N.; Kara, E.; Kim, C. R.; Thorson, A.; Oladapo, O. T.; Mofenson, L.; Zamora, J.; Thangaratinam, S., Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* **2020,** *370*, m3320. https://www.bmj.com/content/bmj/370/bmj.m3320.full.pdf
27. Alsharidah, S.; Ayed, M.; Ameen, R. M.; Alhuraish, F.; Rouheldeen, N. A.; Alshammari, F. R.; Embaireeg, A.; Almelahi, M.; Adel, M.; Dawoud, M. E.; Aljasmi, M. A.; Alshammari, N.; Alsaeedi, A.; Al-Adsani, W.; Arian, H.; Awad, H.; Alenezi, H. A.; Alzafiri, A.; Gouda, E. F.; Almehanna, M.; Alqahtani, S.; Alshammari, A.; Askar, M. Z., COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study. *Int J Infect Dis* **2020**.

28. Althouse, B. M.; Wenger, E. A.; Miller, J. C.; Scarpino, S. V.; Allard, A.; Hébert-Dufresne, L.; Hu, H., Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control. *PLOS Biology* **2020,** *18* (11), e3000897. https://doi.org/10.1371/journal.pbio.3000897
29. Altmann, D. M.; Douek, D. C.; Boyton, R. J., What policy makers need to know about COVID-19 protective immunity. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30985-5
30. Alves, A. M.; Yvamoto, E. Y.; Marzinotto, M. A. N.; Teixeira, A. C. d. S.; Carrilho, F. J., SARS-CoV-2 leading to acute pancreatitis: an unusual presentation. *The Brazilian Journal of Infectious Diseases* **2020**. http://www.sciencedirect.com/science/article/pii/S1413867020301392
31. Amoroso, A.; Magistroni, P.; Vespasiano, F.; Bella, A.; Bellino, S.; Puoti, F.; Alizzi, S.; Vaisitti, T.; Boros, S.; Grossi, P. A.; Trapani, S.; Lombardini, L.; Pezzotti, P.; Deaglio, S.; Brusaferro, S.; Cardillo, M., HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. *Transplantation* **2020**.
32. An, J.; Wei, R.; Zhou, H.; Luong, T. Q.; Gould, M. K.; Mefford, M. T.; Harrison, T. N.; Creekmur, B.; Lee, M. S.; Sim, J. J.; Brettler, J. W.; Martin, J. P.; Ong-Su, A. L.; Reynolds, K., Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System. *J Am Heart Assoc* **2020**, e017773.
33. Anand, S.; Montez-Rath, M.; Han, J.; Bozeman, J.; Kerschmann, R.; Beyer, P.; Parsonnet, J.; Chertow, G. M., Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)32009-2
34. Anastassopoulou, C.; Gkizarioti, Z.; Patrinos, G. P.; Tsakris, A., Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. *Hum Genomics* **2020,** *14* (1), 40.
35. Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0820-9
36. Anderson, E. L.; Turnham, P.; Griffin, J. R.; Clarke, C. C., Consideration of the Aerosol Transmission for COVID-19 and Public Health. *Risk Analysis* **2020,** *40* (5), 902-907. https://onlinelibrary.wiley.com/doi/abs/10.1111/risa.13500
37. Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes. http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347 (accessed 01/26/2020).
38. Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.4326
39. Argenziano, M. G.; Bruce, S. L.; Slater, C. L.; Tiao, J. R.; Baldwin, M. R.; Barr, R. G.; Chang, B. P.; Chau, K. H.; Choi, J. J.; Gavin, N.; Goyal, P.; Mills, A. M.; Patel, A. A.; Romney, M.-L. S.; Safford, M. M.; Schluger, N. W.; Sengupta, S.; Sobieszczyk, M. E.; Zucker, J. E.; Asadourian, P. A.; Bell, F. M.; Boyd, R.; Cohen, M. F.; Colquhoun, M. I.; Colville, L. A.; de Jonge, J. H.; Dershowitz, L. B.; Dey, S. A.; Eiseman, K. A.; Girvin, Z. P.; Goni, D. T.; Harb, A. A.; Herzik, N.; Householder, S.; Karaaslan, L. E.; Lee, H.; Lieberman, E.; Ling, A.; Lu, R.; Shou, A. Y.; Sisti, A. C.; Snow, Z. E.; Sperring, C. P.; Xiong, Y.; Zhou, H. W.; Natarajan, K.; Hripcsak, G.; Chen, R., Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. *medRxiv* **2020**, 2020.04.20.20072116. https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.20.20072116.full.pdf
40. Arons, M. M.; Hatfield, K. M.; Reddy, S. C.; Kimball, A.; James, A.; Jacobs, J. R.; Taylor, J.; Spicer, K.; Bardossy, A. C.; Oakley, L. P.; Tanwar, S.; Dyal, J. W.; Harney, J.; Chisty, Z.; Bell, J. M.; Methner, M.; Paul, P.; Carlson, C. M.; McLaughlin, H. P.; Thornburg, N.; Tong, S.; Tamin, A.; Tao, Y.; Uehara, A.; Harcourt, J.; Clark, S.; Brostrom-Smith, C.; Page, L. C.; Kay, M.; Lewis, J.; Montgomery, P.; Stone, N. D.; Clark, T. A.; Honein, M. A.; Duchin, J. S.; Jernigan, J. A., Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2008457

41. Asadi, S.; Cappa, C. D.; Barreda, S.; Wexler, A. S.; Bouvier, N. M.; Ristenpart, W. D., Efficacy of masks and face coverings in controlling outward aerosol particle emission from expiratory activities. *Scientific Reports* **2020,** *10* (1), 15665. https://doi.org/10.1038/s41598-020-72798-7
42. Assis, M. S.; Araújo, R.; Lopes, A. M. M., Safety alert for hospital environments and health professional: chlorhexidine is ineffective for coronavirus. *Rev Assoc Med Bras (1992)* **2020,** *66Suppl 2* (Suppl 2), 124-129.
43. AstraZeneca, AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html.
44. Auger, K. A.; Shah, S. S.; Richardson, T.; Hartley, D.; Hall, M.; Warniment, A.; Timmons, K.; Bosse, D.; Ferris, S. A.; Brady, P. W.; Schondelmeyer, A. C.; Thomson, J. E., Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.14348
45. Avanzato, V. A.; Matson, M. J.; Seifert, S. N.; Pryce, R.; Williamson, B. N.; Anzick, S. L.; Barbian, K.; Judson, S. D.; Fischer, E. R.; Martens, C.; Bowden, T. A.; de Wit, E.; Riedo, F. X.; Munster, V. J., Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient. *Cell* **2020**. https://doi.org/10.1016/j.cell.2020.10.049
46. Aziz, M.; Fatima, R.; Assaly, R., Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. *J Med Virol* **2020**.
47. Baden, L. R.; El Sahly, H. M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S. A.; Rouphael, N.; Creech, C. B.; McGettigan, J.; Khetan, S.; Segall, N.; Solis, J.; Brosz, A.; Fierro, C.; Schwartz, H.; Neuzil, K.; Corey, L.; Gilbert, P.; Janes, H.; Follmann, D.; Marovich, M.; Mascola, J.; Polakowski, L.; Ledgerwood, J.; Graham, B. S.; Bennett, H.; Pajon, R.; Knightly, C.; Leav, B.; Deng, W.; Zhou, H.; Han, S.; Ivarsson, M.; Miller, J.; Zaks, T., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
48. Badr, H. S.; Du, H.; Marshall, M.; Dong, E.; Squire, M. M.; Gardner, L. M., Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30553-3
49. Bae, S. H.; Shin, H.; Koo, H.-Y.; Lee, S. W.; Yang, J. M.; Yon, D. K., Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-3353_article
50. Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*.
51. Baig, A. M., Chronic COVID Syndrome: Need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers. *Journal of Medical Virology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26624
52. Bailey, L. C.; Razzaghi, H.; Burrows, E. K.; Bunnell, H. T.; Camacho, P. E. F.; Christakis, D. A.; Eckrich, D.; Kitzmiller, M.; Lin, S. M.; Magnusen, B. C.; Newland, J.; Pajor, N. M.; Ranade, D.; Rao, S.; Sofela, O.; Zahner, J.; Bruno, C.; Forrest, C. B., Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA Pediatrics* **2020**. https://doi.org/10.1001/jamapediatrics.2020.5052
53. Baldassarri, M.; Picchiotti, N.; Fava, F.; Fallerini, C.; Benetti, E.; Daga, S.; Valentino, F.; Doddato, G.; Furini, S.; Giliberti, A.; Tita, R.; Amitrano, S.; Bruttini, M.; Croci, S.; Meloni, I.; Pinto, A. M.; Gabbi, C.; Sciarra, F.; Venneri, M. A.; Gori, M.; Sanarico, M.; Crawley, F. P.; Pagotto, U.; Fanelli, F.; Mezzullo, M.; Dominguez-Garrido, E.; Planas-Serra, L.; Schluter, A.; Colobran, R.; Soler-Palacin, P.; Lapunzina, P.; Tenorio, J.; Pujol, A.; Castagna, M. G.; Marcelli, M.; Isidori, A. M.; Renieri, A.; Frullanti, E.; Mari, F., Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in males. *medRxiv* **2020**, 2020.11.04.20225680. http://medrxiv.org/content/early/2020/11/05/2020.11.04.20225680.abstract

54. Bao, L.; Gao, H.; Deng, W.; Lv, Q.; Yu, H.; Liu, M.; Yu, P.; Liu, J.; Qu, Y.; Gong, S.; Lin, K.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Xue, J.; Song, Z.; Xiang, Z.; Wang, G.; Wang, S.; Liu, X.; Zhao, W.; Han, Y.; Wei, Q.; Qin, C., Transmission of SARS-CoV-2 via close contact and respiratory droplets among hACE2 mice. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa281
55. Barakat, T.; Muylkens, B.; Su, B.-L., Is Particulate Matter of Air Pollution a Vector of Covid-19 Pandemic? *Matter* **2020,** *3* (4), 977-980. http://www.sciencedirect.com/science/article/pii/S2590238520305129
56. Barnkob, M. B.; Pottegård, A.; Støvring, H.; Haunstrup, T. M.; Homburg, K.; Larsen, R.; Hansen, M. B.; Titlestad, K.; Aagaard, B.; Møller, B. K.; Barington, T., Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. *Blood Advances* **2020,** *4* (20), 4990-4993. https://doi.org/10.1182/bloodadvances.2020002657
57. Bartlett, S. L.; Diel, D. G.; Wang, L.; Zec, S.; Laverack, M.; Martins, M.; Caserta, L. C.; Killian, M. L.; Terio, K.; Olmstead, C.; Delaney, M. A.; Stokol, T.; Ivančić, M.; Jenkins-Moore, M.; Ingerman, K.; Teegan, T.; McCann, C.; Thomas, P.; McAloose, D.; Sykes, J. M.; Calle, P. P., SARS-CoV-2 Infection And Longitudinal Fecal Screening In Malayan Tigers (Panthera tigris jacksoni), Amur Tigers (Panthera tigris altaica), And African Lions (Panthera leo krugeri) At The Bronx Zoo, New York, USA. *bioRxiv* **2020**, 2020.08.14.250928. https://www.biorxiv.org/content/biorxiv/early/2020/08/14/2020.08.14.250928.full.pdf
58. Bazant, M. Z.; Bush, J. W. M., Beyond Six Feet: A Guideline to Limit Indoor Airborne Transmission of COVID-19. *medRxiv* **2020**, 2020.08.26.20182824. https://www.medrxiv.org/content/medrxiv/early/2020/11/03/2020.08.26.20182824.full.pdf
59. BBCNews, Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca. https://www.bbc.com/news/world-asia-india-55520658.
60. Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. https://nextstrain.org/ncov.
61. Bedrosian, N.; Mitchell, E.; Rohm, E.; Rothe, M.; Kelly, C.; String, G.; Lantagne, D., A Systematic Review of Surface Contamination, Stability, and Disinfection Data on SARS-CoV-2 (Through July 10, 2020). *Environ Sci Technol* **2020**.
62. Behzadinasab, S.; Chin, A.; Hosseini, M.; Poon, L. L. M.; Ducker, W. A., A Surface Coating that Rapidly Inactivates SARS-CoV-2. *ACS Applied Materials & Interfaces* **2020**. https://doi.org/10.1021/acsami.0c11425
63. Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.; Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R. W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T. F.; Paredes, R.; Sweeney, D. A.; Short, W. R.; Touloumi, G.; Lye, D. C.; Ohmagari, N.; Oh, M.-d.; Ruiz-Palacios, G. M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M. G.; Atmar, R. L.; Creech, C. B.; Lundgren, J.; Babiker, A. G.; Pett, S.; Neaton, J. D.; Burgess, T. H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H. C., Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine* **2020**. https://doi.org/10.1056/NEJMoa2007764
64. Bellos, I.; Pandita, A.; Panza, R., Maternal and perinatal outcomes in pregnant women infected by SARS-CoV-2: A meta-analysis. *European Journal of Obstetrics & Gynecology and Reproductive Biology* **2021,** *256*, 194-204. http://www.sciencedirect.com/science/article/pii/S0301211520307491
65. Bi, Q.; Lessler, J.; Eckerle, I.; Lauer, S. A.; Kaiser, L.; Vuilleumier, N.; Cummings, D. A.; Flahault, A.; Petrovic, D.; Guessous, I.; Stringhini, S.; Azman, A. S., Household Transmission of SARS-COV-2: Insights from a Population-based Serological Survey. *medRxiv* **2020**, 2020.11.04.20225573. https://www.medrxiv.org/content/medrxiv/early/2020/11/04/2020.11.04.20225573.full.pdf
66. Bidra, A. S.; Pelletier, J. S.; Westover, J. B.; Frank, S.; Brown, S. M.; Tessema, B., Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine

Oral Antiseptic Rinse. *Journal of Prosthodontics* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/jopr.13209
67. Biggerstaff, M.; Cowling, B.; Cucunubá, Z.; Dinh, L.; Ferguson, N.; Gao, H.; Hill, V.; Imai, N.; Johansson, M.; Kada, S.; Morgan, O.; Pastore y Piontti, A.; Polonsky, J.; Prasad, P. V.; Quandelacy, T.; Rambaut, A.; Tappero, J.; Vandemaele, K.; Vespignani, A.; Warmbrod, K. L.; Wong, J., Early Insights from Statistical and Mathematical Modeling of Key Epidemiologic Parameters of COVID-19. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-1074_article
68. Biryukov, J.; Boydston, J. A.; Dunning, R. A.; Yeager, J. J.; Wood, S.; Reese, A. L.; Ferris, A.; Miller, D.; Weaver, W.; Zeitouni, N. E.; Phillips, A.; Freeburger, D.; Hooper, I.; Ratnesar-Shumate, S.; Yolitz, J.; Krause, M.; Williams, G.; Dawson, D. G.; Herzog, A.; Dabisch, P.; Wahl, V.; Hevey, M. C.; Altamura, L. A., Increasing Temperature and Relative Humidity Accelerates Inactivation of SARS-CoV-2 on Surfaces. *mSphere* **2020,** *5* (4), e00441-20. https://msphere.asm.org/content/msph/5/4/e00441-20.full.pdf
69. Blackburn, J.; Yiannoutsos, C. T.; Carroll, A. E.; Halverson, P. K.; Menachemi, N., Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-5352
70. Blair, R. V.; Vaccari, M.; Doyle-Meyers, L. A.; Roy, C. J.; Russell-Lodrigue, K.; Fahlberg, M.; Monjure, C. J.; Beddingfield, B.; Plante, K. S.; Plante, J. A.; Weaver, S. C.; Qin, X.; Midkiff, C. C.; Lehmicke, G.; Golden, N.; Threeton, B.; Penney, T.; Allers, C.; Barnes, M. B.; Pattison, M.; Datta, P. K.; Maness, N. J.; Birnbaum, A.; Bohm, R. P.; Rappaport, J., ARDS and Cytokine Storm in SARS-CoV-2 Infected Caribbean Vervets. *bioRxiv* **2020**, 2020.06.18.157933. http://biorxiv.org/content/early/2020/06/19/2020.06.18.157933.abstract
71. Böhmer, M. M.; Buchholz, U.; Corman, V. M.; Hoch, M.; Katz, K.; Marosevic, D. V.; Böhm, S.; Woudenberg, T.; Ackermann, N.; Konrad, R.; Eberle, U.; Treis, B.; Dangel, A.; Bengs, K.; Fingerle, V.; Berger, A.; Hörmansdorfer, S.; Ippisch, S.; Wicklein, B.; Grahl, A.; Pörtner, K.; Muller, N.; Zeitlmann, N.; Boender, T. S.; Cai, W.; Reich, A.; An der Heiden, M.; Rexroth, U.; Hamouda, O.; Schneider, J.; Veith, T.; Mühlemann, B.; Wölfel, R.; Antwerpen, M.; Walter, M.; Protzer, U.; Liebl, B.; Haas, W.; Sing, A.; Drosten, C.; Zapf, A., Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet. Infectious diseases* **2020**, S1473-3099(20)30314-5. https://pubmed.ncbi.nlm.nih.gov/32422201
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228725/
72. Boni, M. F.; Lemey, P.; Jiang, X.; Lam, T. T.-Y.; Perry, B. W.; Castoe, T. A.; Rambaut, A.; Robertson, D. L., Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. *Nature Microbiology* **2020**. https://doi.org/10.1038/s41564-020-0771-4
73. Bosco-Lauth, A. M.; Hartwig, A. E.; Porter, S. M.; Gordy, P. W.; Nehring, M.; Byas, A. D.; VandeWoude, S.; Ragan, I. K.; Maison, R. M.; Bowen, R. A., Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats. *bioRxiv* **2020**, 2020.05.28.120998. http://biorxiv.org/content/early/2020/05/29/2020.05.28.120998.abstract
74. Boukli, N.; Le Mene, M.; Schnuriger, A.; Cuervo, N. S.; Laroche, C.; Morand-Joubert, L.; Gozlan, J., High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS-CoV-2 commercial chemiluminescent micro-particle immunoassay for detection of IgG anti SARS-CoV-2 antibodies. *Journal of Clinical Microbiology* **2020**, JCM.01352-20. https://jcm.asm.org/content/jcm/early/2020/08/25/JCM.01352-20.full.pdf
75. Boulware, D. R.; Pullen, M. F.; Bangdiwala, A. S.; Pastick, K. A.; Lofgren, S. M.; Okafor, E. C.; Skipper, C. P.; Nascene, A. A.; Nicol, M. R.; Abassi, M.; Engen, N. W.; Cheng, M. P.; LaBar, D.; Lother, S. A.; MacKenzie, L. J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L. E.; Schwartz, I. S.; McDonald, E. G.; Rajasingham, R.; Lee, T. C.; Hullsiek, K. H., A Randomized Trial of Hydroxychloroquine as Postexposure

Prophylaxis for Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
76. Bozzi, G.; Mangioni, D.; Minoia, F.; Aliberti, S.; Grasselli, G.; Barbetta, L.; Castelli, V.; Palomba, E.; Alagna, L.; Lombardi, A.; Ungaro, R.; Agostoni, C.; Baldini, M.; Blasi, F.; Cesari, M.; Costantino, G.; Fracanzani, A. L.; Montano, N.; Monzani, V.; Pesenti, A.; Peyvandi, F.; Sottocorno, M.; Muscatello, A.; Filocamo, G.; Gori, A.; Bandera, A., Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. *J Allergy Clin Immunol* **2020**.
77. Bradburne, A. F.; Bynoe, M. L.; Tyrrell, D. A., Effects of a "new" human respiratory virus in volunteers. *British medical journal* **1967,** *3* (5568), 767-769. https://pubmed.ncbi.nlm.nih.gov/6043624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1843247/
78. Brady, T., Irish company develops groundbreaking Covid spray that will provide near complete protection. https://www.independent.ie/irish-news/health/irish-company-develops-groundbreaking-covid-spray-that-will-provide-near-complete-protection-39717080.html (accessed 09 Nov 2020).
79. Bramante, C. T.; Ingraham, N. E.; Murray, T. A.; Marmor, S.; Hovertsen, S.; Gronski, J.; McNeil, C.; Feng, R.; Guzman, G.; Abdelwahab, N.; King, S.; Tamariz, L.; Meehan, T.; Pendleton, K. M.; Benson, B.; Vojta, D.; Tignanelli, C. J., Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. *The Lancet Healthy Longevity*. https://doi.org/10.1016/S2666-7568(20)30033-7
80. Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; Baysal, E.; Mangold, M.; Henze, L.; Lauster, R.; Mall, M.; Beyer, K.; Roehmel, J.; Schmitz, J.; Miltenyi, S.; Mueller, M. A.; Witzenrath, M.; Suttorp, N.; Kern, F.; Reimer, U.; Wenschuh, H.; Drosten, C.; Corman, V. M.; Giesecke-Thiel, C.; Sander, L.-E.; Thiel, A., Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. *medRxiv* **2020**, 2020.04.17.20061440. https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20061440.full.pdf
81. Brennan, Z., FDA issues 2nd EUA for decontamination system for N95 masks. *Regulatory Focus* 2020. https://www.raps.org/news-and-articles/news-articles/2020/4/fda-issues-2nd-eua-for-decontamination-system-for
82. Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science. http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science.
83. Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars.
84. Brotons, P.; Launes, C.; Buetas, E.; Fumado, V.; Henares, D.; de Sevilla, M. F.; Redin, A.; Fuente-Soro, L.; Cuadras, D.; Mele, M.; Jou, C.; Millat, P.; Jordan, I.; Garcia-Garcia, J. J.; Bassat, Q.; Muñoz-Almagro, C.; Group, o. b. o. K. C. S., Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1721
85. Bryan, A.; Fink, S. L.; Gattuso, M. A.; Pepper, G.; Chaudhary, A.; Wener, M. H.; Morishima, C.; Jerome, K. R.; Mathias, P. C.; Greninger, A. L., SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality. *Open Forum Infectious Diseases* **2020,** *7* (12). https://doi.org/10.1093/ofid/ofaa535
86. Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020. https://www.livescience.com/us-infant-dies-coronavirus.html
87. Buitrago-Garcia, D.; Egli-Gany, D.; Counotte, M. J.; Hossmann, S.; Imeri, H.; Ipekci, A. M.; Salanti, G.; Low, N., Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine* **2020,** *17* (9), e1003346. https://doi.org/10.1371/journal.pmed.1003346

88. Bulfone, T. C.; Malekinejad, M.; Rutherford, G. W.; Razani, N., Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa742
89. Bundgaard, H.; Bundgaard, J. S.; Raaschou-Pedersen, D. E. T.; al., e., Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-6817
90. Burbelo, P. D.; Riedo, F. X.; Morishima, C.; Rawlings, S.; Smith, D.; Das, S.; Strich, J. R.; Chertow, D. S.; Davey, R. T.; Cohen, J. I., Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. *J Infect Dis* **2020**.
91. Burkholz, S.; Pokhrel, S.; Kraemer, B. R.; Mochly-Rosen, D.; Carback, R. T.; Hodge, T.; Harris, P.; Ciotlos, S.; Wang, L.; Herst, C. V.; Rubsamen, R., Paired SARS CoV-2 Spike Protein Mutations Observed During Ongoing SARS-CoV-2 Viral Transfer from Humans to Minks and Back to Humans. *bioRxiv* **2020**, 2020.12.22.424003. http://biorxiv.org/content/early/2020/12/29/2020.12.22.424003.abstract
92. Bussani, R.; Schneider, E.; Zentilin, L.; Collesi, C.; Ali, H.; Braga, L.; Volpe, M. C.; Colliva, A.; Zanconati, F.; Berlot, G.; Silvestri, F.; Zacchigna, S.; Giacca, M., Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. *EBioMedicine* **2020**. https://doi.org/10.1016/j.ebiom.2020.103104
93. Bustin, S.; Coward, A.; Sadler, G.; Teare, L.; Nolan, T., CoV2-ID, a MIQE-compliant sub-20-min 5-plex RT-PCR assay targeting SARS-CoV-2 for the diagnosis of COVID-19. *Scientific Reports* **2020,** *10* (1), 22214. https://doi.org/10.1038/s41598-020-79233-x
94. Byambasuren, O.; Cardona, M.; Bell, K.; Clark, J.; McLaws, M.-L.; Glasziou, P., Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. *Available at SSRN 3586675* **2020**.
95. Callaway, E., Russia announces positive COVID-vaccine results from controversial trial. https://www.nature.com/articles/d41586-020-03209-0.
96. Callow, K.; Parry, H.; Sergeant, M.; Tyrrell, D., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology & Infection* **1990,** *105* (2), 435-446.
97. Callow, K. A.; Parry, H. F.; Sergeant, M.; Tyrrell, D. A., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology and infection* **1990,** *105* (2), 435-446. https://pubmed.ncbi.nlm.nih.gov/2170159
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2271881/
98. Canada, H., Health Canada authorizes Moderna COVID-19 vaccine. https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-moderna-covid-19-vaccine.html.
99. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
100. Carfì, A.; Bernabei, R.; Landi, F.; Group, f. t. G. A. C.-P.-A. C. S., Persistent Symptoms in Patients After Acute COVID-19. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.12603
101. Caronna, E.; Ballvé, A.; Llauradó, A.; Gallardo, V. J.; María Ariton, D.; Lallana, S.; Maza, S. L.; Gadea, M. O.; Quibus, L.; Restrepo, J. L.; Rodrigo-Gisbert, M.; Vilaseca, A.; Gonzalez, M. H.; Gallo, M. M.; Alpuente, A.; Torres-Ferrus, M.; Borrell, R. P.; Alvarez-Sabin, J.; Pozo-Rosich, P., Headache: A striking

prodromal and persistent symptom, predictive of COVID-19 clinical evolution. *Cephalalgia* **2020,** *40* (13), 1410-1421. https://doi.org/10.1177/0333102420965157
102. Casey, M.; Griffin, J.; McAloon, C. G.; Byrne, A. W.; Madden, J. M.; McEvoy, D.; Collins, A. B.; Hunt, K.; Barber, A.; Butler, F.; Lane, E. A.; O Brien, K.; Wall, P.; Walsh, K. A.; More, S. J., Estimating pre-symptomatic transmission of COVID-19: a secondary analysis using published data. *medRxiv* **2020**, 2020.05.08.20094870.
https://www.medrxiv.org/content/medrxiv/early/2020/05/11/2020.05.08.20094870.full.pdf
103. Cauchois, R.; Koubi, M.; Delarbre, D.; Manet, C.; Carvelli, J.; Blasco, V. B.; Jean, R.; Fouche, L.; Bornet, C.; Pauly, V.; Mazodier, K.; Pestre, V.; Jarrot, P.-A.; Dinarello, C. A.; Kaplanski, G., Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. *Proceedings of the National Academy of Sciences* **2020**, 202009017.
http://www.pnas.org/content/early/2020/07/21/2009017117.abstract
104. Cavalcanti, A. B.; Zampieri, F. G.; Rosa, R. G.; Azevedo, L. C. P.; Veiga, V. C.; Avezum, A.; Damiani, L. P.; Marcadenti, A.; Kawano-Dourado, L.; Lisboa, T.; Junqueira, D. L. M.; de Barros e Silva, P. G. M.; Tramujas, L.; Abreu-Silva, E. O.; Laranjeira, L. N.; Soares, A. T.; Echenique, L. S.; Pereira, A. J.; Freitas, F. G. R.; Gebara, O. C. E.; Dantas, V. C. S.; Furtado, R. H. M.; Milan, E. P.; Golin, N. A.; Cardoso, F. F.; Maia, I. S.; Hoffmann Filho, C. R.; Kormann, A. P. M.; Amazonas, R. B.; Bocchi de Oliveira, M. F.; Serpa-Neto, A.; Falavigna, M.; Lopes, R. D.; Machado, F. R.; Berwanger, O., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* **2020**.
https://www.nejm.org/doi/full/10.1056/NEJMoa2019014
105. CDC, About Masks. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-face-coverings.html.
106. CDC, Confirmation of COVID-19 in Two Pet Cats in New York. Centers for Disease Control and Prevention: 2020. https://www.cdc.gov/media/releases/2020/s0422-covid-19-cats-NYC.html
107. CDC, COVID-19 Forecasts. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html.
108. CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html.
109. CDC, Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. **2020**. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html
110. CDC, Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html.
111. CDC, Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission. https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html.
112. CDC, Situation summary. https://www.cdc.gov/coronavirus/2019-nCoV/summary.html.
113. CDC, Symptoms of Coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
114. CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html (accessed 01/27/2020).
115. CEID, Nowcasts for the US, states, and territories. http://2019-coronavirus-tracker.com/nowcast.html.
116. Centers for Disease Control and Prevention (CDC), Coronaivurs Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5 2020. https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/ (accessed 21 Sept 2020).

117. Centers for Disease Control and Prevention (CDC), Overview of Testing for SARS-CoV-2 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html (accessed 22 September 2020).
118. Cevik, M.; Marcus, J.; Buckee, C.; Smith, T., SARS-CoV-2 transmission dynamics should inform policy. *Available at SSRN 3692807* **2020**.
119. Cevik, M.; Tate, M.; Lloyd, O.; Maraolo, A. E.; Schafers, J.; Ho, A., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe* **2020**. https://doi.org/10.1016/S2666-5247(20)30172-5
120. Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. https://www.sciencedirect.com/science/article/pii/S0140673620301549
121. Chan, J. F.; Zhang, A. J.; Yuan, S.; Poon, V. K.; Chan, C. C.; Lee, A. C.; Chan, W. M.; Fan, Z.; Tsoi, H. W.; Wen, L.; Liang, R.; Cao, J.; Chen, Y.; Tang, K.; Luo, C.; Cai, J. P.; Kok, K. H.; Chu, H.; Chan, K. H.; Sridhar, S.; Chen, Z.; Chen, H.; To, K. K.; Yuen, K. Y., Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis* **2020**. https://www.ncbi.nlm.nih.gov/pubmed/32215622
122. Chande, A. T.; Gussler, W.; Harris, M.; Lee, S.; Rishishwar, L.; Jordan, I. K.; Andris, C. M.; Weitz, J. S., Interactive COVID-19 Event Risk Assessment Planning Tool. http://covid19risk.biosci.gatech.edu/.
123. Chandrashekar, A.; Liu, J.; Martinot, A. J.; McMahan, K.; Mercado, N. B.; Peter, L.; Tostanoski, L. H.; Yu, J.; Maliga, Z.; Nekorchuk, M.; Busman-Sahay, K.; Terry, M.; Wrijil, L. M.; Ducat, S.; Martinez, D. R.; Atyeo, C.; Fischinger, S.; Burke, J. S.; Slein, M. D.; Pessaint, L.; Van Ry, A.; Greenhouse, J.; Taylor, T.; Blade, K.; Cook, A.; Finneyfrock, B.; Brown, R.; Teow, E.; Velasco, J.; Zahn, R.; Wegmann, F.; Abbink, P.; Bondzie, E. A.; Dagotto, G.; Gebre, M. S.; He, X.; Jacob-Dolan, C.; Kordana, N.; Li, Z.; Lifton, M. A.; Mahrokhian, S. H.; Maxfield, L. F.; Nityanandam, R.; Nkolola, J. P.; Schmidt, A. G.; Miller, A. D.; Baric, R. S.; Alter, G.; Sorger, P. K.; Estes, J. D.; Andersen, H.; Lewis, M. G.; Barouch, D. H., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* **2020**, eabc4776. https://science.sciencemag.org/content/sci/early/2020/05/19/science.abc4776.full.pdf
124. Chang, S.; Pierson, E.; Koh, P. W.; Gerardin, J.; Redbird, B.; Grusky, D.; Leskovec, J., Mobility network models of COVID-19 explain inequities and inform reopening. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2923-3
125. Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. https://www.cn-healthcare.com/article/20200110/content-528579.html.
126. Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546071
127. Chen, Q.; Song, Y.; Wang, L.; Zhang, Y.; Han, L.; Liu, J.; Yang, M.; Ma, J.; Wang, T., Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study. *Expert Rev Respir Med* **2020**.
128. Cheng, H.-Y.; Jian, S.-W.; Liu, D.-P.; Ng, T.-C.; Huang, W.-T.; Lin, H.-H.; Team, f. t. T. C.-O. I., Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.2020
129. Chhatwal, J.; Ayer, T.; Linas, B. P. D., O. O.; Mueller, P.; Adee, M.; Ladd, M. A.; Xiao, J. Y. X., COVID-19. https://www.covid19sim.org/.

130. Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673. https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf
131. Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe*. https://doi.org/10.1016/S2666-5247(20)30003-3
132. Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe* **2020,** *1* (1), e10. https://doi.org/10.1016/S2666-5247(20)30003-3
133. Choe, P. G.; Kang, C. K.; Suh, H. J.; Jung, J.; Kang, E.; Lee, S. Y.; Song, K.-H.; Kim, H. B.; Kim, N. J.; Park, W. B.; Kim, E. S.; Oh, M.-d., Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. *Emerging Infectious Disease journal* **2020,** *26* (10), 2484. https://wwwnc.cdc.gov/eid/article/26/10/20-2211_article
134. Choi, E.; Chu, D. K. W.; Cheng, P. K. C.; Tsang, D. N. C.; Peiris, M.; Bausch, D.; Poon, L. L. M.; Watson-Jones, D., In-Flight Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-3254_article
135. Christensen, B.; Favaloro, E. J.; Lippi, G.; Van Cott, E. M., Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19). *Semin Thromb Hemost* **2020,** (EFirst).
136. Chu, D. K.; Akl, E. A.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J.; Chu, D. K.; Akl, E. A.; El-harakeh, A.; Bognanni, A.; Lotfi, T.; Loeb, M.; Hajizadeh, A.; Bak, A.; Izcovich, A.; Cuello-Garcia, C. A.; Chen, C.; Harris, D. J.; Borowiack, E.; Chamseddine, F.; Schünemann, F.; Morgano, G. P.; Muti Schünemann, G. E. U.; Chen, G.; Zhao, H.; Neumann, I.; Chan, J.; Khabsa, J.; Hneiny, L.; Harrison, L.; Smith, M.; Rizk, N.; Giorgi Rossi, P.; AbiHanna, P.; El-khoury, R.; Stalteri, R.; Baldeh, T.; Piggott, T.; Zhang, Y.; Saad, Z.; Khamis, A.; Reinap, M.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J., Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31142-9
137. Clapp, P. W.; Sickbert-Bennett, E. E.; Samet, J. M.; Berntsen, J.; Zeman, K. L.; Anderson, D. J.; Weber, D. J.; Bennett, W. D.; Control, U. C. f. D.; Program, P. E., Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.8168
138. Clark, K. E. N.; Collas, O.; Lachmann, H.; Singh, A.; Buckley, J.; Bhagani, S., Safety of intravenous Anakinra in COVID-19 with evidence of hyperinflammation, a case series. *Rheumatology Advances in Practice* **2020**. https://doi.org/10.1093/rap/rkaa040
139. Clean Flow, Clean Flow Healthcare Mini. https://cleanworkscorp.com/wp-content/uploads/2020/04/Clean_Works_Heathcare_Mini.pdf (accessed 09 Nov 2020).
140. Clift, A. K.; Coupland, C. A. C.; Keogh, R. H.; Hemingway, H., COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-4986
141. Clover, A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019). https://clinicaltrials.gov/ct2/show/NCT04672395.
142. Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* **2016,** *2* (2), 1-11.
143. Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* 2020. https://www.sciencemag.org/news/2020/01/mining-coronavirus-genomes-clues-outbreak-s-origins

144. Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally. https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally (accessed 01/27/2020).
145. Control, E. C. f. D. P. a., Rapid Risk Assessment: Detection of new SARS-CoV-2 variants related to mink. *European Centre for Disease Prevention and Control* **2020**. https://www.ecdc.europa.eu/en/publications-data/detection-new-sars-cov-2-variants-mink?ftag=MSF0951a18
146. Costa, V. d. O.; de Almeida, G. B. C.; Nicolini, E. M.; Rodrigues, G. d. A.; da Costa, B. M. A.; Carvalho, G. H.; dos Reis, Á. L. S.; Colen, D. P., Acute arterial occlusion of the lower limb as the main clinical manifestation in a patient with Covid-19 – Case Report. *International Journal of Surgery Case Reports* **2020,** *77*, 454-458. http://www.sciencedirect.com/science/article/pii/S2210261220310695
147. Courtemanche, C.; Garuccio, J.; Le, A.; Pinkston, J.; Yelowitz, A., Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. *Health Affairs* **2020**, 10.1377/hlthaff.2020.00608. https://doi.org/10.1377/hlthaff.2020.00608
148. Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.; Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral research* **2020,** *176*, 104742.
149. CureVac, A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults. https://clinicaltrials.gov/ct2/show/NCT04652102.
150. Cutts, T.; Kasloff, S.; Safronetz, D.; Krishnan, J., Decontamination of Common Healthcare Facility Surfaces Contaminated with SARS-CoV-2 using Peracetic Acid Dry Fogging. *bioRxiv* **2020**, 2020.12.04.412585. https://www.biorxiv.org/content/biorxiv/early/2020/12/07/2020.12.04.412585.full.pdf
151. da Rosa Mesquita, R.; Francelino Silva Junior, L. C.; Santos Santana, F. M.; Farias de Oliveira, T.; Campos Alcântara, R.; Monteiro Arnozo, G.; Rodrigues da Silva Filho, E.; Galdino dos Santos, A. G.; Oliveira da Cunha, E. J.; Salgueiro de Aquino, S. H.; Freire de Souza, C. D., Clinical manifestations of COVID-19 in the general population: systematic review. *Wiener klinische Wochenschrift* **2020**. https://doi.org/10.1007/s00508-020-01760-4
152. Damas, J.; Hughes, G. M.; Keough, K. C.; Painter, C. A.; Persky, N. S.; Corbo, M.; Hiller, M.; Koepfli, K.-P.; Pfenning, A. R.; Zhao, H.; Genereux, D. P.; Swofford, R.; Pollard, K. S.; Ryder, O. A.; Nweeia, M. T.; Lindblad-Toh, K.; Teeling, E. C.; Karlsson, E. K.; Lewin, H. A., Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. *Proceedings of the National Academy of Sciences* **2020**, 202010146. https://www.pnas.org/content/pnas/early/2020/08/20/2010146117.full.pdf
153. Dasgupta, S.; Bowen, V. B. L., A.; al., e., Association Between Social Vulnerability and a County's Risk for Becoming a COVID-19 Hotspot — United States, June 1–July 25, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1535-1541. https://www.cdc.gov/mmwr/volumes/69/wr/mm6942a3.htm
154. Dattner, I.; Goldberg, Y.; Katriel, G.; Yaari, R.; Gal, N.; Miron, Y.; Ziv, A.; Sheffer, R.; Hamo, Y.; Huppert, A., The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. *medRxiv* **2020**, 2020.06.03.20121145. https://www.medrxiv.org/content/medrxiv/early/2020/10/11/2020.06.03.20121145.full.pdf
155. Davies, A.; Thompson, K. A.; Giri, K.; Kafatos, G.; Walker, J.; Bennett, A., Testing the efficacy of homemade masks: would they protect in an influenza pandemic? *Disaster Med Public Health Prep* **2013,** *7* (4), 413-8. https://www.ncbi.nlm.nih.gov/pubmed/24229526
156. Davies, N. G.; Barnard, R. C.; Jarvis, C. I.; Kucharski, A. J.; Munday, J. D.; Pearson, C.; Russell, T. W.; Tully, D. C.; Abbott, S.; Gimma, A.; Waites, W.; Wong, K. L. M.; van Zandvoort, K.; CMMID COVID-19 Working Group; Eggo, R. M.; Funk, S.; Jit, M.; Atkins, K. E.; Edmunds, J. E., Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. *Preprint* **2020**.

https://cmmid.github.io/topics/covid19/reports/uk-novel-variant/2020_12_23_Transmissibility_and_severity_of_VOC_202012_01_in_England.pdf
157. Davies, N. G.; Barnard, R. C.; Jarvis, C. I.; Russell, T. W.; Semple, M. G.; Jit, M.; Edmunds, W. J., Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. *The Lancet Infectious Diseases* **2020**. http://www.sciencedirect.com/science/article/pii/S1473309920309841
158. De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006,** *80* (21), 10382-94. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf
159. de Haan, C. A. M.; Haijema, B. J.; Schellen, P.; Schreur, P. W.; te Lintelo, E.; Vennema, H.; Rottier, P. J. M., Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off against Heparan Sulfate Binding upon Cell Culture Adaptation. *Journal of Virology* **2008,** *82* (12), 6078-6083. https://jvi.asm.org/content/jvi/82/12/6078.full.pdf
160. de Vries, R. D.; Schmitz, K. S.; Bovier, F. T.; Noack, D.; Haagmans, B. L.; Biswas, S.; Rockx, B.; Gellman, S. H.; Alabi, C. A.; de Swart, R. L.; Moscona, A.; Porotto, M., Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets. *bioRxiv* **2020**, 2020.11.04.361154. https://www.biorxiv.org/content/biorxiv/early/2020/11/05/2020.11.04.361154.full.pdf
161. Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008,** *376* (2), 379-389. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/
162. Degesys, N. F.; Wang, R. C.; Kwan, E.; Fahimi, J.; Noble, J. A.; Raven, M. C., Correlation Between N95 Extended Use and Reuse and Fit Failure in an Emergency Department. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.9843
163. Delahoy, M. J.; Whitaker, M.; O'Halloran, A.; al., e., Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 — COVID-NET, 13 States, March 1–August 22, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 16 September 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6938e1.htm?s_cid=mm6938e1_w
164. Demichev, V.; Tober-Lau, P.; Nazarenko, T.; Thibeault, C.; Whitwell, H.; Lemke, O.; Röhl, A.; Freiwald, A.; Szyrwiel, L.; Ludwig, D.; Correia-Melo, C.; Helbig, E. T.; Stubbemann, P.; Grüning, N.-M.; Blyuss, O.; Vernardis, S.; White, M.; Messner, C. B.; Joannidis, M.; Sonnweber, T.; Klein, S. J.; Pizzini, A.; Wohlfarter, Y.; Sahanic, S.; Hilbe, R.; Schaefer, B.; Wagner, S.; Mittermaier, M.; Machleidt, F.; Garcia, C.; Ruwwe-Glösenkamp, C.; Lingscheid, T.; de Jarcy, L. B.; Stegemann, M. S.; Pfeiffer, M.; Jürgens, L.; Denker, S.; Zickler, D.; Enghard, P.; Zelezniak, A.; Campbell, A.; Hayward, C.; Porteous, D. J.; Marioni, R. E.; Uhrig, A.; Müller-Redetzky, H.; Zoller, H.; Löffler-Ragg, J.; Keller, M. A.; Tancevski, I.; Timms, J. F.; Zaikin, A.; Hippenstiel, S.; Ramharter, M.; Witzenrath, M.; Suttorp, N.; Lilley, K.; Mülleder, M.; Sander, L. E.; Ralser, M.; Kurth, F., A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome. *medRxiv* **2020**, 2020.11.09.20228015. https://www.medrxiv.org/content/medrxiv/early/2020/11/12/2020.11.09.20228015.full.pdf
165. Denas, G.; Gennaro, N.; Ferroni, E.; Fedeli, U.; Lorenzoni, G.; Gregori, D.; Iliceto, S.; Pengo, V., Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. *Int J Cardiol* **2020**. https://www.sciencedirect.com/science/article/pii/S0167527320342728?via%3Dihub
166. Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Chen, T.; Liu, X.; Zhao, W.; Han, Y.;

Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. *Nature Communications* **2020,** *11* (1), 4400. https://doi.org/10.1038/s41467-020-18149-6
167. Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* **2020**.
168. Deng, W.; Bao, L.; Liu, J.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Qi, F.; Gao, H.; Yu, P.; Xu, Y.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Liu, Y.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* **2020**, eabc5343.
https://science.sciencemag.org/content/sci/early/2020/07/01/science.abc5343.full.pdf
169. Dentali, F.; Sironi, A. P.; Ageno, W.; Turato, S.; Bonfanti, C.; Frattini, F.; Crestani, S.; Franchini, M., In *Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature*, Seminars in thrombosis and hemostasis, Thieme Medical Publishers: 2012; pp 535-548.
170. DHS, Estimated Airborne Decay of SARS-CoV-2. https://www.dhs.gov/science-and-technology/sars-airborne-calculator.
171. DHS, Estimated Natural Decay of SARS-CoV-2 (virus that causes COVID-19) on surfaces under a range of temperatures and relative humidity. https://www.dhs.gov/science-and-technology/sars-calculator.
172. DHS, *Low-Cost Decontamination of N95 Respirators*; Department of Homeland Security Science &Technology Directorate: 2020.
https://www.dhs.gov/sites/default/files/publications/multicooker_n95_decontamination_factsheet_v9_2020_06_15.pdf
173. Ding, X.; Yin, K.; Li, Z.; Lalla, R. V.; Ballesteros, E.; Sfeir, M. M.; Liu, C., Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. *Nature Communications* **2020,** *11* (1), 4711. https://doi.org/10.1038/s41467-020-18575-6
174. Doi, Y.; Hibino, M.; Hase, R.; Yamamoto, M.; Kasamatsu, Y.; Hirose, M.; Mutoh, Y.; Homma, Y.; Terada, M.; Ogawa, T.; Kashizaki, F.; Yokoyama, T.; Koba, H.; Kasahara, H.; Yokota, K.; Kato, H.; Yoshida, J.; Kita, T.; Kato, Y.; Kamio, T.; Kodama, N.; Uchida, Y.; Ikeda, N.; Shinoda, M.; Nakagawa, A.; Nakatsumi, H.; Horiguchi, T.; Iwata, M.; Matsuyama, A.; Banno, S.; Koseki, T.; Teramachi, M.; Miyata, M.; Tajima, S.; Maeki, T.; Nakayama, E.; Taniguchi, S.; Lim, C. K.; Saijo, M.; Imai, T.; Yoshida, H.; Kabata, D.; Shintani, A.; Yuzawa, Y.; Kondo, M., A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. *Antimicrob Agents Chemother* **2020**.
175. Dollard, P.; Griffin, I.; Berro, A.; al., e., Risk Assessment and Management of COVID-19 Among Travelers Arriving at Designated U.S. Airports, January 17–September 13, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1681-1685.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6945a4.htm
176. Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702.
https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf
177. Dooling, K.; Marin, M.; Wallace, M.; al., e., The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020. *Morbidity and Mortality Weekly Report* **2020,** *2021* (69:1657-1660).
https://www.cdc.gov/mmwr/volumes/69/wr/mm695152e2.htm
178. Doung-Ngern, P.; Suphanchaimat, R.; Panjangampatthana, A.; Janekrongtham, C.; Ruampoom, D.; Daochaeng, N.; Eungkanit, N.; Pisitpayat, N.; Srisong, N.; Yasopa, O.; Plernprom, P.; Promduangsi, P.; Kumphon, P.; Suangtho, P.; Watakulsin, P.; Chaiya, S.; Kripattanapong, S.; Chantian, T.; Bloss, E.; Namwat, C.; Limmathurotsakul, D., Case-Control Study of Use of Personal Protective Measures and Risk

for Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Thailand. *Emerg Infect Dis* **2020,** *26* (11).
179. Du, Z.; Xu, X.; Wang, L.; Fox, S. J.; Cowling, B. J.; Galvani, A. P.; Meyers, L. A., Effects of Proactive Social Distancing on COVID-19 Outbreaks in 58 Cities, China. *Emerg Infect Dis* **2020,** *26* (9).
180. Du, Z.; Xu, x.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., COVID-19 serial interval estimates based on confirmed cases in public reports from 86 Chinese cities. *medRxiv* **2020**, 2020.04.23.20075796. https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20075796.full.pdf
181. Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452. https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf
182. Dufort, E. M.; Koumans, E. H.; Chow, E. J.; Rosenthal, E. M.; Muse, A.; Rowlands, J.; Barranco, M. A.; Maxted, A. M.; Rosenberg, E. S.; Easton, D.; Udo, T.; Kumar, J.; Pulver, W.; Smith, L.; Hutton, B.; Blog, D.; Zucker, H., Multisystem Inflammatory Syndrome in Children in New York State. *New England Journal of Medicine* **2020,** *383* (4), 347-358. https://www.nejm.org/doi/full/10.1056/NEJMoa2021756
183. Dunker, S.; Hornick, T.; Szczepankiewicz, G.; Maier, M.; Bastl, M.; Bumberger, J.; Treudler, R.; Liebert, U. G.; Simon, J.-C., No SARS-CoV-2 detected in air samples (pollen and particulate matter) in Leipzig during the first spread. *Science of The Total Environment* **2020**, 142881. http://www.sciencedirect.com/science/article/pii/S0048969720364111
184. Dzien, C.; Halder, W.; Winner, H.; Lechleitner, M., Covid-19 screening: are forehead temperature measurements during cold outdoor temperatures really helpful? *Wiener Klinische Wochenschrift* **2020**, 1-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582437/
185. ECDC, *Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom* European Centre for Disease Prevention and Control: 20 December 2020, 2020. https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf
186. Edridge, A. W. D.; Kaczorowska, J.; Hoste, A. C. R.; Bakker, M.; Klein, M.; Jebbink, M. F.; Matser, A.; Kinsella, C. M.; Rueda, P.; Prins, M.; Sastre, P.; Deijs, M.; Hoek, L. v. d., Coronavirus protective immunity is short-lasting *Pre-print* **2020**. https://www.medrxiv.org/content/10.1101/2020.05.11.20086439v2.full.pdf
187. Eikenberry, S. E.; Mancuso, M.; Iboi, E.; Phan, T.; Eikenberry, K.; Kuang, Y.; Kostelich, E.; Gumel, A. B., To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. *Infectious Disease Modelling* **2020**.
188. Ellume Health, FDA Authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test. https://www.globenewswire.com/news-release/2020/12/15/2145612/0/en/FDA-Authorizes-Ellume-COVID-19-Home-Test-as-First-Over-the-Counter-Fully-At-Home-Diagnostic-Test.html (accessed 16 Dec 2020).
189. EMA, Comirnaty. https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty.
190. Endeman, H.; van der Zee, P.; van Genderen, M. E.; van den Akker, J. P. C.; Gommers, D., Progressive respiratory failure in COVID-19: a hypothesis. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30366-2
191. Endo, A.; Abbott, S.; Kucharski, A.; Funk, S., Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China [version 1; peer review: 1 approved, 1 approved with reservations]. *Wellcome Open Research* **2020,** *5* (67). https://wellcomeopenresearch.org/articles/5-67/v1
192. Environmental Protection Agency (EPA), List N: Disinfectants for Use Against SARS-CoV-2 (COVID-19). https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2-covid-19 (accessed 21 Sept 2020).

193. Environmental Protection Agency (EPA), Section 18 Emergency Exemption Requests and Coronavirus (COVID-19). https://www.epa.gov/pesticide-registration/section-18-emergency-exemption-requests-and-coronavirus-covid-19 (accessed 31 August 2020).
194. Eythorsson, E.; Helgason, D.; Ingvarsson, R. F.; Bjornsson, H. K.; Olafsdottir, L. B.; Bjarnadottir, V.; Runolfsdottir, H. L.; Bjarnadottir, S.; Agustsson, A. S.; Oskarsdottir, K.; Thorvaldsson, H. H.; Kristjansdottir, G.; Armannsdottir, B.; Bjarnason, A.; Johannsson, B.; Gudlaugsson, O.; Gottfredsson, M.; Sigurdsson, M. I.; Indridason, O. S.; Palsson, R., Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study. *BMJ* **2020,** *371*, m4529. https://www.bmj.com/content/bmj/371/bmj.m4529.full.pdf
195. Fabre Estremera, M.; Ruiz-Martinez, S.; Monserrat, M. E.; Cortizo Garrido, S.; Beunza Fabra, Z.; PerÃ¡n, M.; Benito, R.; Mateo, P.; Paules, C.; OrÃ³s, D., EXPRESS: SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: a false friend? *Annals of Clinical Biochemistry* **2020**, 0004563220980495. https://doi.org/10.1177/0004563220980495
196. Facchetti, F.; Bugatti, M.; Drera, E.; Tripodo, C.; Sartori, E.; Cancila, V.; Papaccio, M.; Castellani, R.; Casola, S.; Boniotti, M. B.; Cavadini, P.; Lavazza, A., SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. *EBioMedicine* **2020,** *59*. https://doi.org/10.1016/j.ebiom.2020.102951
197. Fagre, A.; Lewis, J.; Eckley, M.; Zhan, S.; Rocha, S. M.; Sexton, N. R.; Burke, B.; Geiss, B. J.; Peersen, O.; Kading, R.; Rovnak, J.; Ebel, G. D.; Tjalkens, R. B.; Aboellail, T.; Schountz, T., SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents. *bioRxiv* **2020**, 2020.08.07.241810. http://biorxiv.org/content/early/2020/08/07/2020.08.07.241810.abstract
198. Falcone, M.; Tiseo, G.; Giordano, C.; Leonildi, A.; Menichini, M.; Vecchione, A.; Pistello, M.; Guarracino, F.; Ghiadoni, L.; Forfori, F.; Barnini, S.; Menichetti, F.; Group, P. C.-S., Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. *Journal of Antimicrobial Chemotherapy* **2020**. https://doi.org/10.1093/jac/dkaa530
199. FDA, Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection. Food and Drug Administration: 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-detects-neutralizing-antibodies-recent-or
200. FDA, Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. U.S. Food and Drug Administration: 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
201. FDA, COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. Food and Drug Administration: 2020. https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized
202. FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020. https://www.fda.gov/media/136529/download
203. FDA, FAQs on Shortages of Surgical Masks and Gowns. https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/faqs-shortages-surgical-masks-and-gowns#kn95.
204. FDA, FAQs on Testing for SARS-CoV-2. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#nolonger.
205. FDA, FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. https://www.fda.gov/news-events/press-

announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid.
206. FDA, FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.
207. FDA, Protective Barrier Enclosures Without Negative Pressure Used During the COVID-19 Pandemic May Increase Risk to Patients and Health Care Providers - Letter to Health Care Providers. Food and Drug Administration: 2020. https://www.fda.gov/medical-devices/letters-health-care-providers/protective-barrier-enclosures-without-negative-pressure-used-during-covid-19-pandemic-may-increase
208. FDA, Quest Diagnostics RC COVID-19 +Flu RT-PCR. https://www.fda.gov/media/144180/download.
209. FDA, Respirator Models Removed from Appendix A. https://www.fda.gov/media/137928/download (accessed 05/15/2020).
210. FDA, U. S., FDA Approves First Treatment for COVID-19. 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
211. FDA, U. S., FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration's Fight Against Pandemic. 2020. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment
212. Fears, A.; Klimstra, W.; Duprex, P.; Hartman, A.; Weaver, S.; Plante, K.; Mirchandani, D.; Plante, J. A.; Aguilar, P.; Fernández, D.; Nalca, A.; Totura, A.; Dyer, D.; Kearney, B.; Lackemeyer, M.; Bohannon, J. K.; Johnson, R.; Garry, R.; Reed, D.; Roy, C., Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions. *Emerging Infectious Disease journal* **2020,** *26* (9). https://wwwnc.cdc.gov/eid/article/26/9/20-1806_article
213. Feldman, O.; Meir, M.; Shavit, D.; Idelman, R.; Shavit, I., Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.6633
214. Feng, Z.; Bao, Y.; Yang, Y.; Zheng, Y.; Shen, K., Severe acute respiratory syndrome coronavirus 2-induced multisystem inflammatory syndrome in children. *Pediatric Investigation* **2020,** *4* (4), 257-262. https://onlinelibrary.wiley.com/doi/abs/10.1002/ped4.12225
215. Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf
216. Figueiredo-Campos, P.; Blankenhaus, B.; Mota, C.; Gomes, A.; Serrano, M.; Ariotti, S.; Costa, C.; Nunes-Cabaço, H.; Mendes, A. M.; Gaspar, P.; Pereira-Santos, M. C.; Rodrigues, F.; Condeço, J.; Escoval, M. A.; Santos, M.; Ramirez, M.; Melo-Cristino, J.; Simas, J. P.; Vasconcelos, E.; Afonso, Â.; Veldhoen, M., Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to six months post disease onset. *European Journal of Immunology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.202048970
217. Fiolet, T.; Guihur, A.; Rebeaud, M.; Mulot, M.; Peiffer-Smadja, N.; Mahamat-Saleh, Y., Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis. *Clinical Microbiology and Infection* **2020**. http://www.sciencedirect.com/science/article/pii/S1198743X2030505X
218. Firth, J. A.; Hellewell, J.; Klepac, P.; Kissler, S. M.; Group, C. C.-W.; Kucharski, A. J.; Spurgin, L. G., Combining fine-scale social contact data with epidemic modelling reveals interactions between contact

tracing, quarantine, testing and physical distancing for controlling COVID-19. *Preprint* **2020**. https://cmmid.github.io/topics/covid19/reports/2020_05_25_firth_et_al_manuscript.pdf
219. Fischer, E. P.; Fischer, M. C.; Grass, D.; Henrion, I.; Warren, W. S.; Westman, E., Low-cost measurement of facemask efficacy for filtering expelled droplets during speech. *Science Advances* **2020,** *07 August 2020*.
220. Fischer, K. A.; Olson, S. M.; Tenforde, M. W.; al., e., Telework Before Illness Onset Among Symptomatic Adults Aged ≥18 Years With and Without COVID-19 in 11 Outpatient Health Care Facilities — United States, July 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1648-1653. https://www.cdc.gov/mmwr/volumes/69/wr/mm6944a4.htm?s_cid=mm6944a4_w
221. Fischer, R.; Morris, D.; van Doremalen, N.; Sarchette, S.; Matson, M. J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Effectiveness of N95 Respirator Decontamination and Reuse against SARS-CoV-2 Virus. *Emerging Infectious Disease journal* **2020,** *26* (9), 2253. https://wwwnc.cdc.gov/eid/article/26/9/20-1524_article
222. Fischer, R.; Morris, D. H.; van Doremalen, N.; Sarchette, S.; Matson, J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Assessment of N95 respirator decontamination and re-use for SARS-CoV-2. *medRxiv* **2020**, 2020.04.11.20062018. https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.11.20062018.full.pdf
223. Fisher, D.; Reilly, A.; Zheng, A. K. E.; Cook, A. R.; Anderson, D. E., Seeding of outbreaks of COVID-19 by contaminated fresh and frozen food. *bioRxiv* **2020**, 2020.08.17.255166. https://www.biorxiv.org/content/biorxiv/early/2020/08/18/2020.08.17.255166.full.pdf
224. Fisher, K. A.; Tenforde, M. W.; Feldstein, L. R.; al., e., Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1258-1264. https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a5.htm
225. Fisman, D. N.; Greer, A. L.; Tuite, A. R., Bidirectional impact of imperfect mask use on reproduction number of COVID-19: A next generation matrix approach. *Infectious Disease Modelling* **2020,** *5*, 405-408. http://www.sciencedirect.com/science/article/pii/S2468042720300191
226. Fitzpatrick, J.; DeSalvo, K., Helping public health officials combat COVID-19. Google: 2020. https://www.blog.google/technology/health/covid-19-community-mobility-reports?hl=en
227. Flahault, A.; Manetti, E.; Simonson, T.; Lee, G.; Choirat, C., COVID-19 Forecasting. https://renkulab.shinyapps.io/COVID-19-Epidemic-Forecasting/_w_e0463e1e/#shiny-tab-about.
228. Flannery, D. D.; Gouma, S.; Dhudasia, M. B.; Mukhopadhyay, S.; Pfeifer, M. R.; Woodford, E. C.; Gerber, J. S.; Arevalo, C. P.; Bolton, M. J.; Weirick, M. E.; Goodwin, E. C.; Anderson, E. M.; Greenplate, A. R.; Kim, J.; Han, N.; Pattekar, A.; Dougherty, J.; Kuthuru, O.; Mathew, D.; Baxter, A. E.; Vella, L. A.; Weaver, J.; Verma, A.; Leite, R.; Morris, J. S.; Rader, D. J.; Elovitz, M. A.; Wherry, E. J.; Puopolo, K. M.; Hensley, S. E., SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Science Immunology* **2020,** *5* (49), eabd5709. https://immunology.sciencemag.org/content/immunology/5/49/eabd5709.full.pdf
229. Flores-Alanis, A.; Sandner-Miranda, L.; Delgado, G.; Cravioto, A.; Morales-Espinosa, R., The receptor binding domain of SARS-CoV-2 spike protein is the result of an ancestral recombination between the bat-CoV RaTG13 and the pangolin-CoV MP789. *BMC Research Notes* **2020,** *13* (1), 398. https://doi.org/10.1186/s13104-020-05242-8
230. Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: December 16, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-december-16-2020 (accessed 17 Dec 2020).
231. Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Authorizes Antigen Test as First Over-the-Counter Fully At-Home Diagnostic Test for COVID-19. https://www.fda.gov/news-

events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic (accessed 17 Dec 2020).
232. Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Test for Self-Testing at Home. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home (accessed 30 Nov 2020).
233. Food and Drug Administration (FDA), Coronavirus (COVID-19) Update: FDA Issues New Authorization for the BinaxNOW COVID-19 Ag Card Home Test. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-authorization-binaxnow-covid-19-ag-card-home-test (accessed 17 Dec 2020).
234. Food and Drug Administration (FDA), SARS-CoV-2 Reference Panel Comparative Data. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data (accessed 28 Sept 2020).
235. Frank, S.; Brown, S. M.; Capriotti, J. A.; Westover, J. B.; Pelletier, J. S.; Tessema, B., In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2. *JAMA Otolaryngology–Head & Neck Surgery* **2020**. https://doi.org/10.1001/jamaoto.2020.3053
236. Fraser, D. D.; Slessarev, M.; Martin, C. M.; Daley, M.; Patel, M. A.; Miller, M. R.; Patterson, E. K.; O'Gorman, D. B.; Gill, S. E.; Wishart, D. S.; Mandal, R.; Cepinskas, G.; Team, O. b. o. t. L. C. S., Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and Prognostic Biomarkers. *Critical Care Explorations* **2020,** *2* (10), e0272. https://journals.lww.com/ccejournal/Fulltext/2020/10000/Metabolomics_Profiling_of_Critically_Ill.44.aspx
237. Freuling, C. M.; Breithaupt, A.; Müller, T.; Sehl, J.; Balkema-Buschmann, A.; Rissmann, M.; Klein, A.; Wylezich, C.; Höper, D.; Wernike, K.; Aebischer, A.; Hoffmann, D.; Friedrichs, V.; Dorhoi, A.; Groschup, M. H.; Beer, M.; Mettenleiter, T. C., Susceptibility of raccoon dogs for experimental SARS-CoV-2 infection. *bioRxiv* **2020**, 2020.08.19.256800. http://biorxiv.org/content/early/2020/08/20/2020.08.19.256800.abstract
238. FUJIFILM Toyama Chemical Co., L., Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients. Fujifilm, 2020. https://www.fujifilm.com/news/n200923.html
239. Gaebler, C.; Wang, Z.; Lorenzi, J. C. C.; Muecksch, F.; Finkin, S.; Tokuyama, M.; Ladinsky, M.; Cho, A.; Jankovic, M.; Schaefer-Babajew, D.; Oliveira, T. Y.; Cipolla, M.; Viant, C.; Barnes, C. O.; Hurley, A.; Turroja, M.; Gordon, K.; Millard, K. G.; Ramos, V.; Schmidt, F.; Weisblum, Y.; Jha, D.; Tankelevich, M.; Yee, J.; Shimeliovich, I.; Robbiani, D. F.; Zhao, Z.; Gazumyan, A.; Hatziioannou, T.; Bjorkman, P. J.; Mehandru, S.; Bieniasz, P. D.; Caskey, M.; Nussenzweig, M. C., Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv* **2020**, 2020.11.03.367391. https://www.biorxiv.org/content/biorxiv/early/2020/11/05/2020.11.03.367391.full.pdf
240. Gallaway, M. S.; Rigler, J.; Robinson, S.; al., e., Trends in COVID-19 Incidence After Implementation of Mitigation Measures — Arizona, January 22–August 7, 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1460-1463.
241. Gamaleya, SECOND INTERIM ANALYSIS OF CLINICAL TRIAL DATA SHOWED A 91.4% EFFICACY FOR THE SPUTNIK V VACCINE ON DAY 28 AFTER THE FIRST DOSE; VACCINE EFFICACY IS OVER 95% 42 DAYS AFTER THE FIRST DOSE. https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/.
242. Gao, G.; Wang, A.; Wang, S.; Qian, F.; Chen, M.; Yu, F.; Zhang, J.; Wang, X.; Ma, X.; Zhao, T.; Zhang, F.; Chen, Z., A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients. *J Acquir Immune Defic Syndr* **2020**.

243. Garg, M.; Sharma, A. L.; Singh, S., Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019–2020. *Biosensors and Bioelectronics* **2021,** *171*, 112703. http://www.sciencedirect.com/science/article/pii/S0956566320306928
244. Garg, S., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020,** *69*.
245. Gasser, R.; Cloutier, M.; Prévost, J.; Fink, C.; Ducas, É.; Ding, S.; Dussault, N.; Landry, P.; Tremblay, T.; Laforce-Lavoie, A.; Lewin, A.; Beaudoin-Bussières, G.; Laumaea, A.; Medjahed, H.; Larochelle, C.; Richard, J.; Dekaban, G. A.; Dikeakos, J. D.; Bazin, R.; Finzi, A., Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. *bioRxiv* **2020**, 2020.10.09.333278. https://www.biorxiv.org/content/biorxiv/early/2020/10/09/2020.10.09.333278.full.pdf
246. Gatto, M.; Bertuzzo, E.; Mari, L.; Miccoli, S.; Carraro, L.; Casagrandi, R.; Rinaldo, A., Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of Sciences* **2020**, 202004978. https://www.pnas.org/content/pnas/early/2020/04/22/2004978117.full.pdf
247. Gendelman, O.; Amital, H.; Bragazzi, N. L.; Watad, A.; Chodick, G., Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. *Autoimmunity Reviews* **2020**, 102566. http://www.sciencedirect.com/science/article/pii/S1568997220301282
248. Giacomet, V.; Stracuzzi, M.; Paradiso, L.; Di Cosimo, M. E.; Rubinacci, V.; Zuccotti, G., Defining the clinical phenotype of COVID-19 in children. *Pediatric Allergy and Immunology* **2020,** *31* (S26), 82-84. https://onlinelibrary.wiley.com/doi/abs/10.1111/pai.13355
249. GlobenNewswire, Delta 9 Develops Proprietary Decontamination Technology to Help Fight COVID-19 Pandemic. https://www.globenewswire.com/news-release/2020/11/25/2134134/0/en/Delta-9-Develops-Proprietary-Decontamination-Technology-to-Help-Fight-COVID-19-Pandemic.html (accessed 30 Nov 2020).
250. Godfred-Cato, S.; Bryant, B.; Leung, J.; Oster, M. E.; Conklin, L.; Abrams, J.; Roguski, K.; Wallace, B.; Prezzato, E.; Koumans, E. H.; Lee, E. H.; Geevarughese, A.; Lash, M. K.; Reilly, K. H.; Pulver, W. P.; Thomas, D.; Feder, K. A.; Hsu, K. K.; Plipat, N.; Richardson, G.; Reid, H.; Lim, S.; Schmitz, A.; Pierce, T.; Hrapcak, S.; Datta, D.; Morris, S. B.; Clarke, K.; Belay, E.; Team, C. M.-C. R., COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6932e2.htm?s_cid=mm6932e2_w.
251. Godoy, M., Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19. *NPR* 2020. https://www.npr.org/sections/health-shots/2020/05/07/851725443/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19
252. Gold, J. A.; Rossen, L. M.; Ahmad, F. B.; al., e., Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 16 October 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6942e1.htm
253. Goldbaum, C., Is the Subway Risky? It May Be Safer Than You Think. *The New York Times* 2020. https://www.nytimes.com/2020/08/02/nyregion/nyc-subway-coronavirus-safety.html
254. Goldstein, E.; Lipsitch, M.; Cevik, M., On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa691
255. Golinelli, D.; Boetto, E.; Maietti, E.; Fantini, M. P., The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. *PLOS ONE* **2020,** *15* (9), e0239508. https://doi.org/10.1371/journal.pone.0239508
256. Google, U.S. COVID-19 Public Forecasts. https://datastudio.google.com/reporting/52f6e744-66c6-47aa-83db-f74201a7c4df/page/EfwUB?s=ou-b6M0HXag.

257. Goren, A.; Vaño-Galván, S.; Wambier, C. G.; McCoy, J.; Gomez-Zubiaur, A.; Moreno-Arrones, O. M.; Shapiro, J.; Sinclair, R. D.; Gold, M. H.; Kovacevic, M.; Mesinkovska, N. A.; Goldust, M.; Washenik, K., A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. *Journal of Cosmetic Dermatology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13443
258. Goren, A.; Wambier, C. G.; Herrera, S.; McCoy, J.; Vaño-Galván, S.; Gioia, F.; Comeche, B.; Ron, R.; Serrano-Villar, S.; Ramos, P. M.; Cadegiani, F. A.; Kovacevic, M.; Tosti, A.; Shapiro, J.; Sinclair, R., Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. *J Eur Acad Dermatol Venereol* **2020**.
259. Gorzalski, A. J.; Hartley, P.; Laverdure, C.; Kerwin, H.; Tillett, R.; Verma, S.; Rossetto, C.; Morzunov, S.; Van Hooser, S.; Pandori, M. W., Characteristics of viral specimens collected from asymptomatic and fatal cases of COVID-19. *Journal of biomedical research* **2020,** *34* (6), 431-436. https://pubmed.ncbi.nlm.nih.gov/33243941 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718074/
260. Götzinger, F.; Santiago-García, B.; Noguera-Julián, A.; al., e., COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *The Lancet Child & Adolescent Health* **2020**. https://doi.org/10.1016/S2352-4642(20)30177-2
261. Goyal, M. K.; Simpson, J. N.; Boyle, M. D.; Badolato, G. M.; Delaney, M.; McCarter, R.; Cora-Bramble, D., Racial/Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. *Pediatrics* **2020**, e2020009951. https://pediatrics.aappublications.org/content/pediatrics/early/2020/08/03/peds.2020-009951.full.pdf
262. Griffin, B. D.; Chan, M.; Tailor, N.; Mendoza, E. J.; Leung, A.; Warner, B. M.; Duggan, A. T.; Moffat, E.; He, S.; Garnett, L.; Tran, K. N.; Banadyga, L.; Albietz, A.; Tierney, K.; Audet, J.; Bello, A.; Vendramelli, R.; Boese, A. S.; Fernando, L.; Lindsay, L. R.; Jardine, C. M.; Wood, H.; Poliquin, G.; Strong, J. E.; Drebot, M.; Safronetz, D.; Embury-Hyatt, C.; Kobasa, D., North American deer mice are susceptible to SARS-CoV-2. *bioRxiv* **2020**, 2020.07.25.221291. http://biorxiv.org/content/early/2020/07/26/2020.07.25.221291.abstract
263. Griffin, J.; Casey, M.; Collins, Á.; Hunt, K.; McEvoy, D.; Byrne, A.; McAloon, C.; Barber, A.; Lane, E. A.; More, S., Rapid review of available evidence on the serial interval and generation time of COVID-19. *BMJ Open* **2020,** *10* (11), e040263. https://bmjopen.bmj.com/content/bmjopen/10/11/e040263.full.pdf
264. Griffin, S., Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds. *BMJ* **2020,** *370*, m2650. http://www.bmj.com/content/370/bmj.m2650.abstract
265. Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S., Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* **2020**.
266. Grijalva, C. G.; Rolfes, M. A.; Zhu, Y.; al., e., Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub* (30 October 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e1.htm?s_cid=mm6944e1_w
267. Group, C. s. T. a. F., *Update on Children, Schools and Transmission*; Scientific Advisory Group for Emergencies (SAGE): 4 November 2020, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/935125/tfc-covid-19-children-transmission-s0860-041120.pdf
268. GSK, Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate. https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/.
269. Gu, Y., COVID-19 Projections Using Machine Learning. https://covid19-projections.com/#view-projections.

270. Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020,** *55* (3), 2000352. https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf
271. Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S. C.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* **2020,** *382*, 1708-1720. https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=recirc_artType_railA_article
272. Guardian, Covid patients have lung damage 'weeks after leaving hospital'. *The Guardian* 2020. https://www.theguardian.com/world/2020/sep/06/covid-patients-have-lung-damage-weeks-after-leaving-hospital
273. Gudbjartsson, D. F.; Norddahl, G. L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson, A. O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R. F.; Thorsteinsdottir, B.; Kristjansdottir, S.; Birgisdottir, K.; Kristinsdottir, A. M.; Sigurdsson, M. I.; Arnadottir, G. A.; Ivarsdottir, E. V.; Andresdottir, M.; Jonsson, F.; Agustsdottir, A. B.; Berglund, J.; Eiriksdottir, B.; Fridriksdottir, R.; Gardarsdottir, E. E.; Gottfredsson, M.; Gretarsdottir, O. S.; Gudmundsdottir, S.; Gudmundsson, K. R.; Gunnarsdottir, T. R.; Gylfason, A.; Helgason, A.; Jensson, B. O.; Jonasdottir, A.; Jonsson, H.; Kristjansson, T.; Kristinsson, K. G.; Magnusdottir, D. N.; Magnusson, O. T.; Olafsdottir, L. B.; Rognvaldsson, S.; le Roux, L.; Sigmundsdottir, G.; Sigurdsson, A.; Sveinbjornsson, G.; Sveinsdottir, K. E.; Sveinsdottir, M.; Thorarensen, E. A.; Thorbjornsson, B.; Thordardottir, M.; Saemundsdottir, J.; Kristjansson, S. H.; Josefsdottir, K. S.; Masson, G.; Georgsson, G.; Kristjansson, M.; Moller, A.; Palsson, R.; Gudnason, T.; Thorsteinsdottir, U.; Jonsdottir, I.; Sulem, P.; Stefansson, K., Humoral Immune Response to SARS-CoV-2 in Iceland. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2026116
274. Gudmundsdottir, Á.; Scheving, R.; Lindberg, F.; Stefansson, B., Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against common cold. *Journal of Medical Virology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26554
275. Guilamo-Ramos, V.; Benzekri, A.; Thimm-Kaiser, M.; Hidalgo, A.; Perlman, D. C., Reconsidering assumptions of adolescent and young adult SARS-CoV-2 transmission dynamics. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1348
276. Gussow, A. B.; Auslander, N.; Faure, G.; Wolf, Y. I.; Zhang, F.; Koonin, E. V., Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. *Proceedings of the National Academy of Sciences* **2020**, 202008176. https://www.pnas.org/content/pnas/early/2020/06/09/2008176117.full.pdf
277. Haddow, A. D.; Watt, T. R.; Bloomfield, H. A.; Fetterer, D. P.; Harbourt, D. E., Modeling the Stability of SARS-CoV-2 on Personal Protective Equipment (PPE). *The American Journal of Tropical Medicine and Hygiene* **2020**. http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-1508
278. Halfmann, P. J.; Hatta, M.; Chiba, S.; Maemura, T.; Fan, S.; Takeda, M.; Kinoshita, N.; Hattori, S. I.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kawaoka, Y., Transmission of SARS-CoV-2 in Domestic Cats. *N Engl J Med* **2020**.
279. Hall, J. S.; Knowles, S.; Nashold, S. W.; Ip, H. S.; Leon, A. E.; Rocke, T.; Keller, S.; Carossino, M.; Balasuriya, U.; Hofmeister, E., Experimental challenge of a North American bat species, big brown bat (Eptesicus fuscus), with SARS-CoV-2. *Transboundary and Emerging Diseases* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/tbed.13949
280. Han, J.; Zhang, X.; He, S.; Jia, P., Can the coronavirus disease be transmitted from food? A review of evidence, risks, policies and knowledge gaps. *Environmental Chemistry Letters* **2020**. https://doi.org/10.1007/s10311-020-01101-x

281. Hao, X.; Cheng, S.; Wu, D.; Wu, T.; Lin, X.; Wang, C., Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2554-8
282. Harbourt, D.; Haddow, A.; Piper, A.; Bloomfield, H.; Kearney, B.; Gibson, K.; Minogue, T., Modeling the Stability of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on Skin, Currency, and Clothing. *medRxiv* **2020**, 2020.07.01.20144253. https://www.medrxiv.org/content/medrxiv/early/2020/07/03/2020.07.01.20144253.full.pdf
283. Harris, J. E., Data from the COVID-19 epidemic in Florida suggest that younger cohorts have been transmitting their infections to less socially mobile older adults. *Review of Economics of the Household* **2020**. https://doi.org/10.1007/s11150-020-09496-w
284. Hart, B.; Tu, Y. P.; Jennings, R.; Verma, P.; Padgett, L. R.; Rains, D.; Vojta, D.; Berke, E. M., A comparison of health care worker-collected foam and polyester nasal swabs in convalescent COVID-19 patients. *PLoS One* **2020,** *15* (10), e0241100.
285. Hartman, A. L.; Nambulli, S.; McMillen, C. M.; White, A. G.; Tilston-Lunel, N.; Albe, J. R.; Cottle, E. L.; Dunn, M. D.; Frye, L. J.; Gilliland, T. H.; Olsen, E. L.; Malley, K. J.; Schwarz, M. M.; Tomko, J. A.; Walker, R. C.; Xia, M.; Hartman, M. S.; Klein, E.; Scanga, C.; Flynn, J. L.; Klimstra, W. B.; McElroy, A. K.; Reed, D. S.; Duprex, W. P., SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts. *bioRxiv* **2020**, 2020.06.20.137687. http://biorxiv.org/content/early/2020/06/21/2020.06.20.137687.abstract
286. Harvey, A. P.; Fuhrmeister, E. R.; Cantrell, M.; Pitol, A. K.; Swarthout, J. M.; Powers, J. E.; Nadimpalli, M. L.; Julian, T. R.; Pickering, A. J., Longitudinal monitoring of SARS-CoV-2 RNA on high-touch surfaces in a community setting. *medRxiv* **2020**, 2020.10.27.20220905. https://www.medrxiv.org/content/medrxiv/early/2020/11/01/2020.10.27.20220905.full.pdf
287. Hashem, A. M.; Alhabbab, R. Y.; Algaissi, A.; Alfaleh, M. A.; Hala, S.; Abujamel, T. S.; ElAssouli, M.-Z.; AL-Somali, A. A.; Alofi, F. S.; Khogeer, A. A.; Alkayyal, A. A.; Mahmoud, A. B.; Almontashiri, N. A. M.; Pain, A., Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies. *Pathogens* **2020,** *9* (12), 1067. https://www.mdpi.com/2076-0817/9/12/1067
288. Hauck, G., More contagious COVID-19 strain is identified in 3 states and 33 countries. *USA Today* 2021. https://www.msn.com/en-us/news/us/more-contagious-covid-19-strain-is-identified-in-3-states-and-33-countries/ar-BB1cq0DF
289. He, R.; Lu, Z.; Zhang, L.; Fan, T.; Xiong, R.; Shen, X.; Feng, H.; Meng, H.; Lin, W.; Jiang, W.; Geng, Q., The clinical course and its correlated immune status in COVID-19 pneumonia. *Journal of Clinical Virology* **2020,** *127*, 104361. http://www.sciencedirect.com/science/article/pii/S1386653220301037
290. He, X.; Lau, E. H. Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y. C.; Wong, J. Y.; Guan, Y.; Tan, X.; Mo, X.; Chen, Y.; Liao, B.; Chen, W.; Hu, F.; Zhang, Q.; Zhong, M.; Wu, Y.; Zhao, L.; Zhang, F.; Cowling, B. J.; Li, F.; Leung, G. M., Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0869-5
291. Hermine, O.; Mariette, X.; Tharaux, P.-L.; Resche-Rigon, M.; Porcher, R.; Ravaud, P.; Group, C.-C., Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.6820
292. Hernández-Mora, M. G.; Cabello Úbeda, A.; Pérez, L. P.; Álvarez, F. V.; Álvarez, B.; Rodríguez Nieto, M. J.; Acosta, I. C.; Ormaechea, I. F.; Al-Hayani, A. W. M.; Carballosa, P.; Martínez, S. C.; Ezzine, F.; González, M. C.; Naya, A.; de Las Heras, M. L.; Rodríguez Guzmán, M. J.; Guijarro, A. C.; Lavado, A. B.; Valcayo, A. M.; García, M. M.; Martínez, J. B.; Roblas, R. F.; Piris Pinilla, M.; Alen, J. F.; Pernaute, O. S.; Bueno, F. R.; Frades, S. H.; Romero, G. P. B., Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. *Int J Infect Dis* **2020**.

293. Hippich, M.; Holthaus, L.; Assfalg, R.; Zapardiel-Gonzalo, J.; Kapfelsperger, H.; Heigermoser, M.; Haupt, F.; Ewald, D. A.; Welzhofer, T. C.; Marcus, B. A.; Heck, S.; Koelln, A.; Stock, J.; Voss, F.; Secchi, M.; Piemonti, L.; de la Rosa, K.; Protzer, U.; Boehmer, M.; Achenbach, P.; Lampasona, V.; Bonifacio, E.; Ziegler, A.-G., A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. *Med* **2020**. https://doi.org/10.1016/j.medj.2020.10.003
294. Hobbs, C. V.; Martin, L. M.; Kim, S. S.; al., e., Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged <18 Years — Mississippi, September–November 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1925-1929. https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e3.htm
295. Hoehl, S.; Karaca, O.; Kohmer, N.; Westhaus, S.; Graf, J.; Goetsch, U.; Ciesek, S., Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group. *JAMA Network Open* **2020,** *3* (8), e2018044-e2018044. https://doi.org/10.1001/jamanetworkopen.2020.18044
296. Hoiland, R. L.; Fergusson, N. A.; Mitra, A. R.; Griesdale, D. E. G.; Devine, D. V.; Stukas, S.; Cooper, J.; Thiara, S.; Foster, D.; Chen, L. Y. C.; Lee, A. Y. Y.; Conway, E. M.; Wellington, C. L.; Sekhon, M. S., The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. *Blood Advances* **2020,** *4* (20), 4981-4989. https://doi.org/10.1182/bloodadvances.2020002623
297. Holmes, L.; Enwere, M.; Williams, J.; Ogundele, B.; Chavan, P.; Piccoli, T.; Chinacherem, C.; Comeaux, C.; Pelaez, L.; Okundaye, O.; Stalnaker, L.; Kalle, F.; Deepika, K.; Philipcien, G.; Poleon, M.; Ogungbade, G.; Elmi, H.; John, V.; Dabney, K. W., Black–White Risk Differentials in COVID-19 (SARS-COV2) Transmission, Mortality and Case Fatality in the United States: Translational Epidemiologic Perspective and Challenges. *International Journal of Environmental Research and Public Health* **2020,** *17* (12), 4322. https://www.mdpi.com/1660-4601/17/12/4322
298. Honein, M. A.; Christie, A.; Rose, D. A.; al., e., Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 4 December 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e2.htm
299. HongyingLi; YewLeong, F.; GeorgeXu; ZhengweiGe; WeiKang, C.; HuiLim, K., Dispersion of evaporating cough droplets in tropical outdoor environment. *Physics of Fluids* **2020,** *32* (11), 113301. https://aip.scitation.org/doi/abs/10.1063/5.0026360
300. Horby, P.; Lim, W. S.; Emberson, J.; Mafham, M.; Bell, J.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L. C.; Faust, S. N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J. K.; Haynes, R.; Landray, M. J., Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv* **2020**, 2020.06.22.20137273. https://www.medrxiv.org/content/medrxiv/early/2020/06/22/2020.06.22.20137273.full.pdf
301. Horby, P.; Openshaw, P. J. M.; Hayward, A. H.; Lim, W. S.; Edmunds, J.; Ferguson, N.; Dingwall, R.; Cevik, M.; Barclay, W.; Rubin, J.; Connell, D.; McMenamin, J.; Semple, C.; Evans, C., *NERVTAG meeting on SARS-CoV-2 variant under investigation VUI-202012/01*; New and Emerging Respiratory Virus Threats Advisory Group: 2020. https://khub.net/documents/135939561/338928724/SARS-CoV-2+variant+under+investigation%2C+meeting+minutes.pdf/962e866b-161f-2fd5-1030-32b6ab467896?t=1608470511452
302. Hou, Y. J.; Chiba, S.; Halfmann, P.; Ehre, C.; Kuroda, M.; Dinnon, K. H.; Leist, S. R.; Schäfer, A.; Nakajima, N.; Takahashi, K.; Lee, R. E.; Mascenik, T. M.; Graham, R.; Edwards, C. E.; Tse, L. V.; Okuda, K.; Markmann, A. J.; Bartelt, L.; de Silva, A.; Margolis, D. M.; Boucher, R. C.; Randell, S. H.; Suzuki, T.; Gralinski, L. E.; Kawaoka, Y.; Baric, R. S., SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* **2020**, eabe8499. https://science.sciencemag.org/content/sci/early/2020/11/11/science.abe8499.full.pdf

303. Hu, M.; Lin, H.; Wang, J.; Xu, C.; Tatem, A. J.; Meng, B.; Zhang, X.; Liu, Y.; Wang, P.; Wu, G.; Xie, H.; Lai, S., The risk of COVID-19 transmission in train passengers: an epidemiological and modelling study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1057
304. Hu, Z.; Song, C.; Xu, C.; Jin, G.; Chen, Y.; Xu, X.; Ma, H.; Chen, W.; Lin, Y.; Zheng, Y.; Wang, J.; Hu, Z.; Yi, Y.; Shen, H., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* **2020**. https://doi.org/10.1007/s11427-020-1661-4
305. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **2020**. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext
306. Huang, R.; Xia, J.; Chen, Y.; Shan, C.; Wu, C., A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. *The Lancet Infectious Diseases* **2020,** *20* (5), 534-535. https://doi.org/10.1016/S1473-3099(20)30147-X
307. Huang, Y.; Lyu, X.; Li, D.; Wang, Y.; Wang, L.; Zou, W.; Wei, Y.; Wu, X., A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19. *medRxiv* **2020**, 2020.04.18.20070656. https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.18.20070656.full.pdf
308. Huang, Z.; Tian, D.; Liu, Y.; Lin, Z.; Lyon, C. J.; Lai, W.; Fusco, D.; Drouin, A.; Yin, X.; Hu, T.; Ning, B., Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis. *Biosensors and Bioelectronics* **2020,** *164*, 112316. http://www.sciencedirect.com/science/article/pii/S0956566320303110
309. Hutchins, H. J.; Wolff, B.; Leeb, R.; al., e., COVID-19 Mitigation Behaviors by Age Group — United States, April–June 2020. *Morbidity and Mortality Weekly Report* **2020,** *2020* (69), 1584-1590. https://www.cdc.gov/mmwr/volumes/69/wr/mm6943e4.htm?s_cid=mm6943e4_w
310. Hyde, Z., COVID-19, children and schools: overlooked and at risk. *Medical Journal of Australia* **2020,** *213* (10), 444-446.e1. https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.50823
311. Ibrahim, D.; Dulipsingh, L.; Zapatka, L.; Eadie, R.; Crowell, R.; Williams, K.; Wakefield, D. B.; Cook, L.; Puff, J.; Hussain, S. A., Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial. *Infect Dis Ther* **2020**, 1-14.
312. IHME, COVID-19 Projections. https://covid19.healthdata.org/united-states-of-america.
313. IHME, First COVID-19 Global Forecast: IHME Projects Three-Quarters of a Million Lives Could be Saved by January 1. Institute for Health Metrics and Evaluation: 2020. https://www.prnewswire.com/il/news-releases/first-covid-19-global-forecast-ihme-projects-three-quarters-of-a-million-lives-could-be-saved-by-january-1-807013447.html
314. India, T. o., CDSCO recommends nod for Zydus Cadila's phase-3 vaccine trials. https://timesofindia.indiatimes.com/city/ahmedabad/cdsco-recommends-nod-for-zydus-cadilas-phase-3-vaccine-trials/articleshow/80077209.cms.
315. Institute of Museum and Library Services; OCLC; Battelle, REopening Archives, Libraries, and Museums (REALM) Test 5: Natural attenuation as a decontamination approach for SARS-CoV-2 on textile materials. https://www.webjunction.org/content/dam/WebJunction/Documents/webJunction/realm/test5-report.pdf (accessed 26 Oct 2020).
316. Institute, S. S., Public Health Authority, State Serum Institute, Report of Findings. 2020. https://coronasmitte.dk/-/media/mediefiler/corona/mink/risikovurdering-af-human-sundhed-ved-fortsat-minkavl_03112020.pdf?la=da&hash=721871D898F1D9F1F9D99E3A002C35F9537F5CEA
317. International Commission on Microbiological Specifications for Foods (ICMSF), ICMSF opinion on SARS-CoV-2 and its relationship to food safety. https://www.icmsf.org/wp-

content/uploads/2020/09/ICMSF2020-Letterhead-COVID-19-opinion-final-03-Sept-2020.BF_.pdf (accessed 08 Sept 2020).
318. Ionescu, F.; Jaiyesimi, I.; Petrescu, I.; Lawler, P. R.; Castillo, E.; Munoz-Maldonado, Y.; Imam, Z.; Narasimhan, M.; Abbas, A. E.; Konde, A.; Nair, G. B., Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis. *Eur J Haematol* **2020**.
319. IQ, H., COVID-19 Forecast for United States. https://app.hospiq.com/covid19?region=.
320. Ismail, S. A.; Saliba, V.; Lopez Bernal, J.; Ramsay, M. E.; Ladhani, S. N., SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30882-3
321. Iwata, K.; Doi, A.; Miyakoshi, C., Was School Closure Effective in Mitigating Coronavirus Disease 2019 (COVID-19)? Time Series Analysis Using Bayesian Inference. **2020**.
322. Janssen, A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). https://clinicaltrials.gov/ct2/show/NCT04505722.
323. Jarvis, C. I.; Van Zandvoort, K.; Gimma, A.; Prem, K.; Klepac, P.; Rubin, G. J.; Edmunds, W. J., Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med* **2020,** *18* (1), 124.
324. JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
325. Jiang, N.; Chen, Z.; Yin, X.; Liu, L.; Yang, H.; Tan, X.; Wang, J.; Li, H.; Tian, M.; Lu, Z.; Xiong, N.; Gong, Y., Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study. *Diabetes Research and Clinical Practice* **2020**, 108619. http://www.sciencedirect.com/science/article/pii/S0168822720308767
326. John, A. R.; Raju, S.; Cadnum, J. L.; Lee, K.; McClellan, P.; Akkus, O.; Miller, S. K.; Jennings, W. D.; Buehler, J. A.; Li, D. F.; Redmond, S. N.; Braskie, M.; Hoyen, C. K.; Donskey, C. J., Scalable In-hospital Decontamination of N95 Filtering Facepiece Respirator with a Peracetic Acid Room Disinfection System. *Infection Control & Hospital Epidemiology* **2020**, 1-26. https://www.cambridge.org/core/article/scalable-inhospital-decontamination-of-n95-filtering-facepiece-respirator-with-a-peracetic-acid-room-disinfection-system/4B56043CF6D905CA6E8EF07B19FCF054
327. Johnston, S. C.; Jay, A.; Raymond, J. L.; Rossi, F.; Zeng, X.; Scruggs, J.; Dyer, D.; Frick, O.; Moore, J.; Berrier, K.; Esham, H.; Shamblin, J.; Sifford, W.; Fiallos, J.; Klosterman, L.; Stevens, S.; White, L.; Bowling, P.; Garcia, T.; Jensen, C.; Ghering, J.; Nyakiti, D.; Bellanca, S.; Kearney, B.; Giles, W.; Alli, N.; Paz, F.; Akers, K.; Danner, D.; Barth, J.; Johnson, J. A.; Durant, M.; Kim, R.; Pitt, M. L. M.; Nalca, A., Development of a Coronavirus Disease 2019 Nonhuman Primate Model Using Airborne Exposure. *bioRxiv* **2020**, 2020.06.26.174128. http://biorxiv.org/content/early/2020/06/26/2020.06.26.174128.abstract
328. Jones, R. M., Relative contributions of transmission routes for COVID-19 among healthcare personnel providing patient care. *Journal of Occupational and Environmental Hygiene* **2020**, 1-8. https://doi.org/10.1080/15459624.2020.1784427
329. Jonmarker, S.; Hollenberg, J.; Dahlberg, M.; Stackelberg, O.; Litorell, J.; Everhov Å, H.; Järnbert-Pettersson, H.; Söderberg, M.; Grip, J.; Schandl, A.; Günther, M.; Cronhjort, M., Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. *Crit Care* **2020,** *24* (1), 653.
330. Joyner, M. J.; Bruno, K. A.; Klassen, S. A.; Kunze, K. L.; Johnson, P. W.; Lesser, E. R.; Wiggins, C. C.; Senefeld, J. W.; Klompas, A. M.; Hodge, D. O.; Shepherd, J. R. A.; Rea, R. F.; Whelan, E. R.; Clayburn, A. J.; Spiegel, M. R.; Baker, S. E.; Larson, K. F.; Ripoll, J. G.; Andersen, K. J.; Buras, M. R.; Vogt, M. N. P.; Herasevich, V.; Dennis, J. J.; Regimbal, R. J.; Bauer, P. R.; Blair, J. E.; Van Buskirk, C. M.; Winters, J. L.; Stubbs, J. R.; van Helmond, N.; Butterfield, B. P.; Sexton, M. A.; Diaz Soto, J. C.; Paneth, N. S.; Verdun, N.

C.; Marks, P.; Casadevall, A.; Fairweather, D.; Carter, R. E.; Wright, R. S., Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. *Mayo Clinic Proceedings* **2020**. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/

331. Joyner, M. J.; Senefeld, J. W.; Klassen, S. A.; Mills, J. R.; Johnson, P. W.; Theel, E. S.; Wiggins, C. C.; Bruno, K. A.; Klompas, A. M.; Lesser, E. R.; Kunze, K. L.; Sexton, M. A.; Diaz Soto, J. C.; Baker, S. E.; Shepherd, J. R. A.; van Helmond, N.; van Buskirk, C. M.; Winters, J. L.; Stubbs, J. R.; Rea, R. F.; Hodge, D. O.; Herasevich, V.; Whelan, E. R.; Clayburn, A. J.; Larson, K. F.; Ripoll, J. G.; Andersen, K. J.; Buras, M. R.; Vogt, M. N. P.; Dennis, J. J.; Regimbal, R. J.; Bauer, P. R.; Blair, J. E.; Paneth, N. S.; Fairweather, D.; Wright, R. S.; Carter, R. E.; Casadevall, A., Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. *medRxiv* **2020**, 2020.08.12.20169359. http://medrxiv.org/content/early/2020/08/12/2020.08.12.20169359.abstract

332. Jüni, P.; Rothenbühler, M.; Bobos, P.; Thorpe, K. E.; da Costa, B. R.; Fisman, D. N.; Slutsky, A. S.; Gesink, D., Impact of climate and public health interventions on the COVID-19 pandemic: A prospective cohort study. *Canadian Medical Association Journal* **2020**, cmaj.200920. https://www.cmaj.ca/content/cmaj/early/2020/05/08/cmaj.200920.full.pdf

333. Kain, M. P.; Childs, M. L.; Becker, A. D.; Mordecai, E. A., Chopping the tail: How preventing superspreading can help to maintain COVID-19 control. *Epidemics* **2021,** *34*, 100430. http://www.sciencedirect.com/science/article/pii/S1755436520300487

334. Kalil, A. C.; Patterson, T. F.; Mehta, A. K.; Tomashek, K. M.; Wolfe, C. R.; Ghazaryan, V.; Marconi, V. C.; Ruiz-Palacios, G. M.; Hsieh, L.; Kline, S.; Tapson, V.; Iovine, N. M.; Jain, M. K.; Sweeney, D. A.; El Sahly, H. M.; Branche, A. R.; Regalado Pineda, J.; Lye, D. C.; Sandkovsky, U.; Luetkemeyer, A. F.; Cohen, S. H.; Finberg, R. W.; Jackson, P. E. H.; Taiwo, B.; Paules, C. I.; Arguinchona, H.; Goepfert, P.; Ahuja, N.; Frank, M.; Oh, M.-d.; Kim, E. S.; Tan, S. Y.; Mularski, R. A.; Nielsen, H.; Ponce, P. O.; Taylor, B. S.; Larson, L.; Rouphael, N. G.; Saklawi, Y.; Cantos, V. D.; Ko, E. R.; Engemann, J. J.; Amin, A. N.; Watanabe, M.; Billings, J.; Elie, M.-C.; Davey, R. T.; Burgess, T. H.; Ferreira, J.; Green, M.; Makowski, M.; Cardoso, A.; de Bono, S.; Bonnett, T.; Proschan, M.; Deye, G. A.; Dempsey, W.; Nayak, S. U.; Dodd, L. E.; Beigel, J. H., Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *New England Journal of Medicine* **2020**. https://doi.org/10.1056/NEJMoa2031994

335. Karnakov, P.; Arampatzis, G.; Kičić, I.; Wermelinger, F.; Wälchli, D.; Papadimitriou, C.; Koumoutsakos, P., Data driven inference of the reproduction number (R0) for COVID-19 before and after interventions for 51 European countries. **2020**.

336. Kawasuji, H.; Takegoshi, Y.; Kaneda, M.; Ueno, A.; Miyajima, Y.; Kawago, K.; Fukui, Y.; Yoshida, Y.; Kimura, M.; Yamada, H.; Sakamaki, I.; Tani, H.; Morinaga, Y.; Yamamoto, Y., Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. *PLOS ONE* **2020,** *15* (12), e0243597. https://doi.org/10.1371/journal.pone.0243597

337. Keller, M. J.; Kitsis, E. A.; Arora, S.; Chen, J. T.; Agarwal, S.; Ross, M. J.; Tomer, Y.; Southern, W., Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. *Journal of Hospital Medicine* **2020,** *Online First, July 22nd, 2020*.

338. Kelly, M.; O'Connor, R.; Townsend, L.; Coghlan, M.; Relihan, E.; Moriarty, M.; Carr, B.; Melanophy, G.; Doyle, C.; Bannan, C.; O'Riordan, R.; Merry, C.; Clarke, S.; Bergin, C., Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin. *Br J Clin Pharmacol* **2020**.

339. Kemp, S. A.; Datir, R. P.; Collier, D. A.; Ferreira, I.; Carabelli, A.; Harvey, W.; Robertson, D. L.; Gupta, R. K., Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70. *bioRxiv* **2020**, 2020.12.14.422555. http://biorxiv.org/content/early/2020/12/15/2020.12.14.422555.abstract

340. Kennedy, M.; Helfand, B. K. I.; Gou, R. Y.; Gartaganis, S. L.; Webb, M.; Moccia, J. M.; Bruursema, S. N.; Dokic, B.; McCulloch, B.; Ring, H.; Margolin, J. D.; Zhang, E.; Anderson, R.; Babine, R. L.; Hshieh, T.; Wong, A. H.; Taylor, R. A.; Davenport, K.; Teresi, B.; Fong, T. G.; Inouye, S. K., Delirium in Older Patients

With COVID-19 Presenting to the Emergency Department. *JAMA Network Open* **2020,** *3* (11), e2029540-e2029540. https://doi.org/10.1001/jamanetworkopen.2020.29540
341. Kennedy, M.; Lee, S. J.; Epstein, M., Modeling aerosol transmission of SARS-CoV-2 in multi-room facility. *Journal of Loss Prevention in the Process Industries* **2020**, 104336. http://www.sciencedirect.com/science/article/pii/S0950423020306239
342. Kerr, C. C.; Stuart, R. M.; Mistry, D.; Abeysuriya, R. G.; Hart, G.; Rosenfeld, K.; Selvaraj, P.; Nunez, R. C.; Hagedorn, B.; George, L.; Izzo, A.; Palmer, A.; Delport, D.; Bennette, C.; Wagner, B.; Chang, S.; Cohen, J. A.; Panovska-Griffiths, J.; Jastrzebski, M.; Oron, A. P.; Wenger, E.; Famulare, M.; Klein, D. J., Covasim: an agent-based model of COVID-19 dynamics and interventions. *medRxiv* **2020**, 2020.05.10.20097469. https://www.medrxiv.org/content/medrxiv/early/2020/05/15/2020.05.10.20097469.full.pdf
343. Khanh, N. C.; Thai, P. Q.; Quach, H.-L.; Thi, N.-A. H.; Dinh, P. C.; Duong, T. N.; Mai, L. T. Q.; Nghia, N. D.; Tu, T. A.; Quang, L. N.; Quang, T. D.; Nguyen, T.-T.; Vogt, F.; Anh, D. D., Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 During Long Flight. *Emerging Infectious Disease journal* **2020,** *26* (11). https://wwwnc.cdc.gov/eid/article/26/11/20-3299_article
344. Kim, S. E.; Jeong, H. S.; Yu, Y.; Shin, S. U.; Kim, S.; Oh, T. H.; Kim, U. J.; Kang, S. J.; Jang, H. C.; Jung, S. I.; Park, K. H., Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. *Int J Infect Dis* **2020**.
345. Kim, U. J.; Lee, S. Y.; Lee, J. Y.; Lee, A.; Kim, S. E.; Choi, O.-J.; Lee, J. S.; Kee, S.-J.; Jang, H.-C., Air and Environmental Contamination Caused by COVID-19 Patients: a Multi-Center Study. *J Korean Med Sci* **2020,** *35* (37). https://doi.org/10.3346/jkms.2020.35.e332
346. Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Lee, S.; Casel, M. A. B.; Um, J.; Song, M.-S.; Jeong, H. W.; Lai, V. D.; Kim, Y.; Chin, B. S.; Park, J.-S.; Chung, K.-H.; Foo, S.-S.; Poo, H.; Mo, I.-P.; Lee, O.-J.; Webby, R. J.; Jung, J. U.; Choi, Y. K., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host & Microbe* **2020**. http://www.sciencedirect.com/science/article/pii/S1931312820301876
347. King, J. A.; Whitten, T. A.; Bakal, J. A.; McAlister, F. A., Symptoms associated with a positive result for a swab for SARS-CoV-2 infection among children in Alberta. *Canadian Medical Association Journal* **2020**, cmaj.202065. https://www.cmaj.ca/content/cmaj/early/2020/11/23/cmaj.202065.full.pdf
348. Knight, S. R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T. M.; Dunning, J.; Fairfield, C. J.; Gamble, C.; Green, C. A.; Gupta, R.; Halpin, S.; Hardwick, H. E.; Holden, K. A.; Horby, P. W.; Jackson, C.; Mclean, K. A.; Merson, L.; Nguyen-Van-Tam, J. S.; Norman, L.; Noursadeghi, M.; Olliaro, P. L.; Pritchard, M. G.; Russell, C. D.; Shaw, C. A.; Sheikh, A.; Solomon, T.; Sudlow, C.; Swann, O. V.; Turtle, L. C.; Openshaw, P. J.; Baillie, J. K.; Semple, M. G.; Docherty, A. B.; Harrison, E. M., Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ* **2020,** *370*, m3339. https://www.bmj.com/content/bmj/370/bmj.m3339.full.pdf
349. Koh, W. C.; Naing, L.; Chaw, L.; Rosledzana, M. A.; Alikhan, M. F.; Jamaludin, S. A.; Amin, F.; Omar, A.; Shazli, A.; Griffith, M.; Pastore, R.; Wong, J., What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. *PLOS ONE* **2020,** *15* (10), e0240205. https://doi.org/10.1371/journal.pone.0240205
350. Konda, A.; Prakash, A.; Moss, G. A.; Schmoldt, M.; Grant, G. D.; Guha, S., Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano* **2020**. https://www.ncbi.nlm.nih.gov/pubmed/32329337
351. Kong, D.; Zheng, Y.; Wu, H.; Pan, H.; Wagner, A. L.; Zheng, Y.; Gong, X.; Zhu, Y.; Jin, B.; Xiao, W.; Mao, S.; Lin, S.; Han, R.; Yu, X.; Cui, P.; Jiang, C.; Fang, Q.; Lu, Y.; Fu, C., Pre-symptomatic transmission of novel coronavirus in community settings. *Influenza and Other Respiratory Viruses* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12773

352. Kong, T.-k., Longer incubation period of coronavirus disease 2019 (COVID-19) in older adults. *AGING MEDICINE* **2020,** *3* (2), 102-109. https://onlinelibrary.wiley.com/doi/abs/10.1002/agm2.12114
353. Koo, J. R.; Cook, A. R.; Park, M.; Sun, Y.; Sun, H.; Lim, J. T.; Tam, C.; Dickens, B. L., Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. *The Lancet Infectious Diseases* **2020,** *20* (6), 678-688. https://doi.org/10.1016/S1473-3099(20)30162-6
354. Korber, B.; Fischer, W. M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E. E.; Bhattacharya, T.; Foley, B.; Hastie, K. M.; Parker, M. D.; Partridge, D. G.; Evans, C. M.; Freeman, T. M.; de Silva, T. I.; McDanal, C.; Perez, L. G.; Tang, H.; Moon-Walker, A.; Whelan, S. P.; LaBranche, C. C.; Saphire, E. O.; Montefiori, D. C.; Angyal, A.; Brown, R. L.; Carrilero, L.; Green, L. R.; Groves, D. C.; Johnson, K. J.; Keeley, A. J.; Lindsey, B. B.; Parsons, P. J.; Raza, M.; Rowland-Jones, S.; Smith, N.; Tucker, R. M.; Wang, D.; Wyles, M. D., Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **2020**. https://doi.org/10.1016/j.cell.2020.06.043
355. Korevaar, H. M.; Becker, A. D.; Miller, I. F.; Grenfell, B. T.; Metcalf, C. J. E.; Mina, M. J., Quantifying the impact of US state non-pharmaceutical interventions on COVID-19 transmission. *medRxiv* **2020**, 2020.06.30.20142877. https://www.medrxiv.org/content/medrxiv/early/2020/07/01/2020.06.30.20142877.full.pdf
356. Korte, W.; Buljan, M.; Rösslein, M.; Wick, P.; Golubov, V.; Jentsch, J.; Reut, M.; Peier, K.; Nohynek, B.; Fischer, A.; Stolz, R.; Cettuzzi, M.; Nolte, O., SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on. *Journal of Infection* **2020**. https://doi.org/10.1016/j.jinf.2020.08.032
357. Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218. https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf
358. Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711. https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf
359. Kucharski, A. J.; Klepac, P.; Conlan, A. J. K.; Kissler, S. M.; Tang, M. L.; Fry, H.; Gog, J. R.; Edmunds, W. J., Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. *Lancet Infect Dis* **2020**.
360. Kucharski, A. J.; Russell, T. W.; Diamond, C.; Liu, Y.; Edmunds, J.; Funk, S.; Eggo, R. M.; Sun, F.; Jit, M.; Munday, J. D., Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The lancet infectious diseases* **2020**.
361. Kucirka, L. M.; Lauer, S. A.; Laeyendecker, O.; Boon, D., Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-1495
362. Kupferschmidt, K., Remdesivir and interferon fall flat in WHO's megastudy of COVID-19 treatments. *Science Magazine* **2020**, 1. https://www.sciencemag.org/news/2020/10/remdesivir-and-interferon-fall-flat-who-s-megastudy-covid-19-treatments
363. Lai, S.; Ruktanonchai, N. W.; Zhou, L.; Prosper, O.; Luo, W.; Floyd, J. R.; Wesolowski, A.; Santillana, M.; Zhang, C.; Du, X.; Yu, H.; Tatem, A. J., Effect of non-pharmaceutical interventions to contain COVID-19 in China. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2293-x
364. Lalau, J. D.; Al-Salameh, A.; Hadjadj, S.; Goronflot, T.; Wiernsperger, N.; Pichelin, M.; Allix, I.; Amadou, C.; Bourron, O.; Duriez, T.; Gautier, J. F.; Dutour, A.; Gonfroy, C.; Gouet, D.; Joubert, M.; Julier,

I.; Larger, E.; Marchand, L.; Marre, M.; Meyer, L.; Olivier, F.; Prevost, G.; Quiniou, P.; Raffaitin-Cardin, C.; Roussel, R.; Saulnier, P. J.; Seret-Begue, D.; Thivolet, C.; Vatier, C.; Desailloud, R.; Wargny, M.; Gourdy, P.; Cariou, B., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. *Diabetes Metab* **2020**, 101216.
365. Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2169-0
366. Lan, F.-Y.; Suharlim, C.; Kales, S. N.; Yang, J., Association between SARS-CoV-2 infection, exposure risk and mental health among a cohort of essential retail workers in the USA. *Occupational and Environmental Medicine* **2020**, oemed-2020-106774. https://oem.bmj.com/content/oemed/early/2020/10/11/oemed-2020-106774.full.pdf
367. LANL, COVID-19 Confirmed and Forecasted Case Data. https://covid-19.bsvgateway.org/.
368. Lapin, T., About a dozen US mink farms in quarantine as officials probe COVID-19 outbreaks. *New York Post* 2020. https://nypost.com/2020/11/10/us-mink-farms-in-quarantine-as-officials-probe-covid-19-outbreaks/
369. Larosa, E.; Djuric, O.; Cassinadri, M.; Cilloni, S.; Bisaccia, E.; Vicentini, M.; Venturelli, F.; Giorgi Rossi, P.; Pezzotti, P.; Bedeschi, E.; Group, t. R. E. C.-W., Secondary transmission of COVID-19 in preschool and school settings in northern Italy after their reopening in September 2020: a population-based study. *Eurosurveillance* **2020,** *25* (49), 2001911. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.49.2001911
370. Larsen, J. R.; Martin, M. R.; Martin, J. D.; Kuhn, P.; Hicks, J. B., Modeling the Onset of Symptoms of COVID-19. *Frontiers in Public Health* **2020,** *8* (473). https://www.frontiersin.org/article/10.3389/fpubh.2020.00473
371. Lasry, A.; Kidder, D.; Hast, M.; Poovey, J.; Sunshine, G.; Zviedrite, N.; Ahmed, F.; Ethier, K. A., Timing of community mitigation and changes in reported COVID-19 and community mobility—four US metropolitan areas, February 26–April 1, 2020. *morbidity and Mortality Weekly Report* **2020,** *69*, 451-457. https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e2.htm
372. Lassaunière, R.; Frische, A.; Harboe, Z. B.; Nielsen, A. C.; Fomsgaard, A.; Krogfelt, K. A.; Jørgensen, C. S., Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* **2020**, 2020.04.09.20056325. https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.04.09.20056325.full.pdf
373. Latinne, A.; Hu, B.; Olival, K. J.; Zhu, G.; Zhang, L.; Li, H.; Chmura, A. A.; Field, H. E.; Zambrana-Torrelio, C.; Epstein, J. H.; Li, B.; Zhang, W.; Wang, L.-F.; Shi, Z.-L.; Daszak, P., Origin and cross-species transmission of bat coronaviruses in China. *Nature Communications* **2020,** *11* (1), 4235. https://doi.org/10.1038/s41467-020-17687-3
374. Latz, C. A.; DeCarlo, C.; Boitano, L.; Png, C. Y. M.; Patell, R.; Conrad, M. F.; Eagleton, M.; Dua, A., Blood type and outcomes in patients with COVID-19. *Annals of Hematology* **2020**. https://doi.org/10.1007/s00277-020-04169-1
375. Lau, M. S. Y.; Grenfell, B.; Thomas, M.; Bryan, M.; Nelson, K.; Lopman, B., Characterizing superspreading events and age-specific infectiousness of SARS-CoV-2 transmission in Georgia, USA. *Proceedings of the National Academy of Sciences* **2020**, 202011802. https://www.pnas.org/content/pnas/early/2020/08/19/2011802117.full.pdf
376. Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**. https://doi.org/10.7326/M20-0504
377. Lavery, A. M.; Preston, L. E.; Ko, J. Y.; al., e., Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission — United States, March–August 2020.

Morbidity and Mortality Weekly Report **2020,** *ePub: 9 November 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6945e2.htm

378. Lavezzo, E.; Franchin, E.; Ciavarella, C.; Cuomo-Dannenburg, G.; Barzon, L.; Del Vecchio, C.; Rossi, L.; Manganelli, R.; Loregian, A.; Navarin, N.; Abate, D.; Sciro, M.; Merigliano, S.; De Canale, E.; Vanuzzo, M. C.; Besutti, V.; Saluzzo, F.; Onelia, F.; Pacenti, M.; Parisi, S.; Carretta, G.; Donato, D.; Flor, L.; Cocchio, S.; Masi, G.; Sperduti, A.; Cattarino, L.; Salvador, R.; Nicoletti, M.; Caldart, F.; Castelli, G.; Nieddu, E.; Labella, B.; Fava, L.; Drigo, M.; Gaythorpe, K. A. M.; Ainslie, K. E. C.; Baguelin, M.; Bhatt, S.; Boonyasiri, A.; Boyd, O.; Cattarino, L.; Ciavarella, C.; Coupland, H. L.; Cucunubá, Z.; Cuomo-Dannenburg, G.; Djafaara, B. A.; Donnelly, C. A.; Dorigatti, I.; van Elsland, S. L.; FitzJohn, R.; Flaxman, S.; Gaythorpe, K. A. M.; Green, W. D.; Hallett, T.; Hamlet, A.; Haw, D.; Imai, N.; Jeffrey, B.; Knock, E.; Laydon, D. J.; Mellan, T.; Mishra, S.; Nedjati-Gilani, G.; Nouvellet, P.; Okell, L. C.; Parag, K. V.; Riley, S.; Thompson, H. A.; Unwin, H. J. T.; Verity, R.; Vollmer, M. A. C.; Walker, P. G. T.; Walters, C. E.; Wang, H.; Wang, Y.; Watson, O. J.; Whittaker, C.; Whittles, L. K.; Xi, X.; Ferguson, N. M.; Brazzale, A. R.; Toppo, S.; Trevisan, M.; Baldo, V.; Donnelly, C. A.; Ferguson, N. M.; Dorigatti, I.; Crisanti, A.; Imperial College, C.-R. T., Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2488-1

379. Laws, R. L.; Chancey, R. J.; Rabold, E. M.; Chu, V. T.; Lewis, N. M.; Fajans, M.; Reses, H. E.; Duca, L. M.; Dawson, P.; Conners, E. E.; Gharpure, R.; Yin, S.; Buono, S.; Pomeroy, M.; Yousaf, A. R.; Owusu, D.; Wadhwa, A.; Pevzner, E.; Battey, K. A.; Njuguna, H.; Fields, V. L.; Salvatore, P.; O'Hegarty, M.; Vuong, J.; Gregory, C. J.; Banks, M.; Rispens, J.; Dietrich, E.; Marcenac, P.; Matanock, A.; Pray, I.; Westergaard, R.; Dasu, T.; Bhattacharyya, S.; Christiansen, A.; Page, L.; Dunn, A.; Atkinson-Dunn, R.; Christensen, K.; Kiphibane, T.; Willardson, S.; Fox, G.; Ye, D.; Nabity, S. A.; Binder, A.; Freeman, B. D.; Lester, S.; Mills, L.; Thornburg, N.; Hall, A. J.; Fry, A. M.; Tate, J. E.; Tran, C. H.; Kirking, H. L., Symptoms and Transmission of SARS-CoV-2 Among Children — Utah and Wisconsin, March–May 2020. *Pediatrics* **2020**, e2020027268. https://pediatrics.aappublications.org/content/pediatrics/early/2020/12/01/peds.2020-027268.full.pdf

380. Laxminarayan, R.; Wahl, B.; Dudala, S. R.; Gopal, K.; Mohan, C.; Neelima, S.; Jawahar Reddy, K. S.; Radhakrishnan, J.; Lewnard, J. A., Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* **2020**, eabd7672. https://science.sciencemag.org/content/sci/early/2020/09/29/science.abd7672.full.pdf

381. Le Bert, N.; Clapham, H. E.; Tan, A. T.; Chia, W. N.; Tham, C. Y.; Lim, J. M.; Kunasegaran, K.; Tan, L.; Dutertre, C.-A.; Shankar, N.; Lim, J. M.; Sun, L. J.; Zahari, M.; Tun, Z. M.; Kumar, V.; Lim, B. L.; Lim, S. H.; Chia, A.; Tan, Y.-J.; Tambyah, P. A.; Kalimuddin, S.; Lye, D. C.; Low, J. G.; Wang, L.-F.; Wan, W. Y.; Hsu, L. Y.; Bertoletti, A.; Tam, C. C., Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. *bioRxiv* **2020**, 2020.11.25.399139. https://www.biorxiv.org/content/biorxiv/early/2020/11/27/2020.11.25.399139.full.pdf

382. Le Bert, N.; Tan, A. T.; Kunasegaran, K.; Tham, C. Y. L.; Hafezi, M.; Chia, A.; Chng, M. H. Y.; Lin, M.; Tan, N.; Linster, M.; Chia, W. N.; Chen, M. I. C.; Wang, L.-F.; Ooi, E. E.; Kalimuddin, S.; Tambyah, P. A.; Low, J. G.-H.; Tan, Y.-J.; Bertoletti, A., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2550-z

383. Leclerc, Q.; Fuller, N.; Knight, L.; null, n.; Funk, S.; Knight, G., What settings have been linked to SARS-CoV-2 transmission clusters? [version 2; peer review: 2 approved]. *Wellcome Open Research* **2020,** *5* (83). https://wellcomeopenresearch.org/articles/5-83/v2

384. Lee, C. Y.-P.; Amrun, S. N.; Chee, R. S.-L.; Goh, Y. S.; Mak, T.-M.; Octavia, S.; Yeo, N. K.-W.; Chang, Z. W.; Tay, M. Z.; Torres-Ruesta, A.; Carissimo, G.; Poh, C. M.; Fong, S.-W.; Bei, W.; Lee, S.; Young, B. E.; Tan, S.-Y.; Leo, Y.-S.; Lye, D. C.; Lin, R. T. P.; Maurer-Stroh, S.; Lee, B.; Cheng-I, W.; Renia, L.; Ng, L. F. P., Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant. *bioRxiv* **2020**, 2020.10.08.332544. https://www.biorxiv.org/content/biorxiv/early/2020/10/09/2020.10.08.332544.full.pdf

385. Lee, E. H.; Kepler, K. L.; Geevarughese, A.; Paneth-Pollak, R.; Dorsinville, M. S.; Ngai, S.; Reilly, K. H., Race/Ethnicity Among Children With COVID-19–Associated Multisystem Inflammatory Syndrome. *JAMA Network Open* **2020,** *3* (11), e2030280-e2030280. https://doi.org/10.1001/jamanetworkopen.2020.30280
386. Lee, J.; Hughes, T.; Lee, M.-H.; Field, H.; Rovie-Ryan, J. J.; Sitam, F. T.; Sipangkui, S.; Nathan, S. K. S. S.; Ramirez, D.; Kumar, S. V.; Lasimbang, H.; Epstein, J. H.; Daszak, P., No evidence of coronaviruses or other potentially zoonotic viruses in Sunda pangolins (Manis javanica) entering the wildlife trade via Malaysia. *bioRxiv* **2020**, 2020.06.19.158717. https://www.biorxiv.org/content/biorxiv/early/2020/06/19/2020.06.19.158717.full.pdf
387. Lee, Y.-H.; Hong, C. M.; Kim, D. H.; Lee, T. H.; Lee, J., Clinical Course of Asymptomatic and Mildly Symptomatic Patients with Coronavirus Disease Admitted to Community Treatment Centers, South Korea. *Emerging Infectious Disease journal* **2020,** *26* (10). https://wwwnc.cdc.gov/eid/article/26/10/20-1620_article
388. Lendvay, T. S.; Chen, J.; Harcourt, B. H.; Scholte, F. E. M.; Kilinc-Balci, F. S.; Lin, Y. L.; Lamb, M. M.; Chu, L. F.; Price, A.; Evans, D.; Lin, Y.-C.; Mores, C. N.; Sahni, J.; Kabra, K. B.; Haubruge, E.; Thiry, E.; Heyne, B.; Laperre, J.; Simmons, S.; Davies, J. M.; Cui, Y.; Wagner, T.; Clark, T.; Smit, S. J.; Parker, R.; Gallagher, T.; Timm, E.; Ludwig-Begall, L. F.; Macia, N.; Mackie, C.; Hope, K.; Page, K.; Reader, S.; Faris, P.; Jolois, O.; Patel, A.; Lemyre, J.-L.; Molloy-Simard, V.; Homdayjanakul, K.; Tritsch, S. R.; Wielick, C.; Mayo, M.; Malott, R.; Willaert, J.-F.; Nauwynck, H.; Dams, L.; De Jaeger, S.; Liao, L.; Zhao, M.; Chu, S.; Conly, J. M.; Chu, M. C., Addressing Personal Protective Equipment (PPE) Decontamination: Methylene Blue and Light Inactivates SARS-CoV-2 on N95 Respirators and Masks with Maintenance of Integrity and Fit. *medRxiv* **2020**, 2020.12.11.20236919. https://www.medrxiv.org/content/medrxiv/early/2020/12/12/2020.12.11.20236919.full.pdf
389. Lenze, E. J.; Mattar, C.; Zorumski, C. F.; Stevens, A.; Schweiger, J.; Nicol, G. E.; Miller, J. P.; Yang, L.; Yingling, M.; Avidan, M. S.; Reiersen, A. M., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.22760
390. Letizia, A. G.; Ramos, I.; Obla, A.; Goforth, C.; Weir, D. L.; Ge, Y.; Bamman, M. M.; Dutta, J.; Ellis, E.; Estrella, L.; George, M.-C.; Gonzalez-Reiche, A. S.; Graham, W. D.; van de Guchte, A.; Gutierrez, R.; Jones, F.; Kalomoiri, A.; Lizewski, R.; Lizewski, S.; Marayag, J.; Marjanovic, N.; Millar, E. V.; Nair, V. D.; Nudelman, G.; Nunez, E.; Pike, B. L.; Porter, C.; Regeimbal, J.; Rirak, S.; Santa Ana, E.; Sealfon, R. S. G.; Sebra, R.; Simons, M. P.; Soares-Schanoski, A.; Sugiharto, V.; Termini, M.; Vangeti, S.; Williams, C.; Troyanskaya, O. G.; van Bakel, H.; Sealfon, S. C., SARS-CoV-2 Transmission among Marine Recruits during Quarantine. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2029717
391. Leung, N. H. L.; Chu, D. K. W.; Shiu, E. Y. C.; Chan, K.-H.; McDevitt, J. J.; Hau, B. J. P.; Yen, H.-L.; Li, Y.; Ip, D. K. M.; Peiris, J. S. M.; Seto, W.-H.; Leung, G. M.; Milton, D. K.; Cowling, B. J., Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0843-2
392. Lewis, D., Is the coronavirus airborne? Experts can't agree. *Nature* **2020**. 10.1038/d41586-020-00974-w
393. Lewis, N. M.; Chu, V. T.; Ye, D.; al., e., Household Transmission of SARS-CoV-2 in the United States. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1166
394. Li, D.; Jin, M.; Bao, P.; Zhao, W.; Zhang, S., Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. *JAMA Network Open* **2020,** *3* (5), e208292-e208292. https://doi.org/10.1001/jamanetworkopen.2020.8292
395. Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple

Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016,** *213* (5), 712-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf
396. Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.; Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2001316 https://www.nejm.org/doi/10.1056/NEJMoa2001316
397. Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221. https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf
398. Li, X.; Giorgi, E. E.; Marichannegowda, M. H.; Foley, B.; Xiao, C.; Kong, X.-P.; Chen, Y.; Gnanakaran, S.; Korber, B.; Gao, F., Emergence of SARS-CoV-2 through recombination and strong purifying selection. *Science Advances* **2020**, eabb9153. https://advances.sciencemag.org/content/advances/early/2020/05/28/sciadv.abb9153.full.pdf
399. Li, X.; Xiao, K.; Chen, X.; Liang, X.; Zhang, X.; Zhang, Z.; Zhai, J.; Wang, R.; Zhou, N.; Chen, Z.-J.; Su, R.; Zhou, F.; Holmes, E. C.; Irwin, D. M.; Chen, R.-A.; He, Q.; Wu, Y.-J.; Wang, C.; Du, X.-Q.; Peng, S.-M.; Xie, W.-J.; Shan, F.; Li, W.-P.; Dai, J.-W.; Shen, X.; Feng, Y.; Xiao, L.; Chen, W.; Shen, Y., Pathogenicity, tissue tropism and potential vertical transmission of SARSr-CoV-2 in Malayan pangolins. *bioRxiv* **2020**, 2020.06.22.164442. http://biorxiv.org/content/early/2020/06/22/2020.06.22.164442.abstract
400. Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731
401. Li, Y.; Campbell, H.; Kulkarni, D.; Harpur, A.; Nundy, M.; Wang, X.; Nair, H., The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. *The Lancet Infectious Diseases* **2020**. https://doi.org/10.1016/S1473-3099(20)30785-4
402. Li, Y.; Qian, H.; Hang, J.; Chen, X.; Hong, L.; Liang, P.; Li, J.; Xiao, S.; Wei, J.; Liu, L.; Kang, M., Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant. *medRxiv* **2020**, 2020.04.16.20067728. https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067728.full.pdf
403. Li, Y.; Xie, Z.; Lin, W.; Cai, W.; Wen, C.; Guan, Y.; Mo, X.; Wang, J.; Wang, Y.; Peng, P.; Chen, X.; Hong, W.; Xiao, G.; Liu, J.; Zhang, L.; Hu, F.; Li, F.; Zhang, F.; Deng, X.; Li, L., Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. *Med*. https://doi.org/10.1016/j.medj.2020.04.001
404. Liao, J.; Fan, S.; Chen, J.; Wu, J.; Xu, S.; Guo, Y.; Li, C.; Zhang, X.; Wu, C.; Mou, H., Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. *The Innovation* **2020,** *1* (1), 100001.
405. Lieu, A.; Mah, J.; Zanichelli, V.; Exantus, R. C.; Longtin, Y., Impact of Extended Use and Decontamination with Vaporized Hydrogen Peroxide on N95 Respirator Fit. *American Journal of Infection Control* **2020**. https://doi.org/10.1016/j.ajic.2020.08.010
406. Lilly, E., Bamlanivimab for COVID-19. Eli Lilly: 2020. https://www.lilly.com/news/media/media-kits/bamlanivimab-covid19
407. Liotta, E. M.; Batra, A.; Clark, J. R.; Shlobin, N. A.; Hoffman, S. C.; Orban, Z. S.; Koralnik, I. J., Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. *Annals of Clinical and Translational Neurology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1002/acn3.51210

408. Liotti, F. M.; Menchinelli, G.; Marchetti, S.; Posteraro, B.; Landi, F.; Sanguinetti, M.; Cattani, P., Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results. *JAMA Internal Medicine* **2020**. https://doi.org/10.1001/jamainternmed.2020.7570
409. Lisboa Bastos, M.; Tavaziva, G.; Abidi, S. K.; Campbell, J. R.; Haraoui, L.-P.; Johnston, J. C.; Lan, Z.; Law, S.; MacLean, E.; Trajman, A.; Menzies, D.; Benedetti, A.; Ahmad Khan, F., Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* **2020,** *370*, m2516. https://www.bmj.com/content/bmj/370/bmj.m2516.full.pdf
410. Liu, D.; Thompson, J. R.; Carducci, A.; Bi, X., Potential secondary transmission of SARS-CoV-2 via wastewater. *Science of The Total Environment* **2020,** *749*, 142358. http://www.sciencedirect.com/science/article/pii/S0048969720358873
411. Liu, J.; Zhang, S.; Dong, X.; Li, Z.; Xu, Q.; Feng, H.; Cai, J.; Huang, S.; Guo, J.; Zhang, L.; Chen, Y.; Zhu, W.; Du, H.; Liu, Y.; Wang, T.; Chen, L.; Wen, Z.; Annane, D.; Qu, J.; Chen, D., Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. *J Clin Invest* **2020**.
412. Liu, M.; Li, Q.; Zhou, J.; Ai, W.; Zheng, X.; Zeng, J.; Liu, Y.; Xiang, X.; Guo, R.; Li, X.; Wu, X.; Xu, H.; Jiang, L.; Zhang, H.; Chen, J.; Tian, L.; Luo, J.; Luo, C., Value of swab types and collection time on SARS-COV-2 detection using RT-PCR assay. *Journal of Virological Methods* **2020,** *286*, 113974. http://www.sciencedirect.com/science/article/pii/S0166093420302263
413. Liu, N.; Zhang, T.; Ma, L.; Zhang, H.; Wang, H.; Wei, W.; Pei, H.; Li, H., The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. *Blood Rev* **2020**, 100785.
414. Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica). *Viruses* **2019,** *11* (11), 979. https://www.mdpi.com/1999-4915/11/11/979
415. Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Li, L.; Zhou, J.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? *PLOS Pathogens* **2020,** *16* (5), e1008421. https://doi.org/10.1371/journal.ppat.1008421
416. Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628. http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract
417. Liu, S., U of Guelph team tests produce decontamination technology on hospital gowns. https://www.cbc.ca/news/canada/kitchener-waterloo/decontaminate-hospital-gowns-1.5788587 (accessed 09 Nov 2020).
418. Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2003717
419. Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020. https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html
420. Liu, Y.; Li, T.; Deng, Y.; Liu, S.; Zhang, D.; Li, H.; Wang, X.; Jia, L.; Han, J.; Bei, Z.; Zhou, Y.; Li, L.; Li, J., Stability of SARS-CoV-2 on environmental surfaces and in human excreta. *medRxiv* **2020**, 2020.05.07.20094805. https://www.medrxiv.org/content/medrxiv/early/2020/05/12/2020.05.07.20094805.full.pdf
421. Liu, Z.; Li, J.; Long, W.; Zeng, W.; Gao, R.; Zeng, G.; Chen, D.; Wang, S.; Li, Q.; Hu, D.; Guo, L.; Li, Z.; Wu, X., Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study. *Frontiers in Medicine* **2020,** *7* (799). https://www.frontiersin.org/article/10.3389/fmed.2020.598870

422. Long, Q.-X.; Liu, B.-Z.; Deng, H.-J.; Wu, G.-C.; Deng, K.; Chen, Y.-K.; Liao, P.; Qiu, J.-F.; Lin, Y.; Cai, X.-F.; Wang, D.-Q.; Hu, Y.; Ren, J.-H.; Tang, N.; Xu, Y.-Y.; Yu, L.-H.; Mo, Z.; Gong, F.; Zhang, X.-L.; Tian, W.-G.; Hu, L.; Zhang, X.-X.; Xiang, J.-L.; Du, H.-X.; Liu, H.-W.; Lang, C.-H.; Luo, X.-H.; Wu, S.-B.; Cui, X.-P.; Zhou, Z.; Zhu, M.-M.; Wang, J.; Xue, C.-J.; Li, X.-F.; Wang, L.; Li, Z.-J.; Wang, K.; Niu, C.-C.; Yang, Q.-J.; Tang, X.-J.; Zhang, Y.; Liu, X.-M.; Li, J.-J.; Zhang, D.-C.; Zhang, F.; Liu, P.; Yuan, J.; Li, Q.; Hu, J.-L.; Chen, J.; Huang, A.-L., Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0897-1

423. Long, Q.-X.; Tang, X.-J.; Shi, Q.-L.; Li, Q.; Deng, H.-J.; Yuan, J.; Hu, J.-L.; Xu, W.; Zhang, Y.; Lv, F.-J.; Su, K.; Zhang, F.; Gong, J.; Wu, B.; Liu, X.-M.; Li, J.-J.; Qiu, J.-F.; Chen, J.; Huang, A.-L., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-0965-6

424. Long, S. W.; Olsen, R. J.; Christensen, P. A.; Bernard, D. W.; Davis, J. J.; Shukla, M.; Nguyen, M.; Saavedra, M. O.; Yerramilli, P.; Pruitt, L.; Subedi, S.; Kuo, H.-C.; Hendrickson, H.; Eskandari, G.; Nguyen, H. A. T.; Long, J. H.; Kumaraswami, M.; Goike, J.; Boutz, D.; Gollihar, J.; McLellan, J. S.; Chou, C.-W.; Javanmardi, K.; Finkelstein, I. J.; Musser, J., Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. *medRxiv* **2020**, 2020.09.22.20199125. http://medrxiv.org/content/early/2020/09/25/2020.09.22.20199125.abstract

425. Lu, J.; Plessis, L. d.; Liu, Z.; Hill, V.; Kang, M.; Lin, H.; Sun, J.; Francois, S.; Kraemer, M. U. G.; Faria, N. R.; McCrone, J. T.; Peng, J.; Xiong, Q.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Liu, J.; Xiao, J.; Hu, J.; Liu, T.; Ma, W.; Li, W.; Su, J.; Zheng, H.; Peng, B.; Fang, S.; Su, W.; Li, K.; Sun, R.; Bai, R.; Tang, X.; Liang, M.; Quick, J.; Song, T.; Rambaut, A.; Loman, N.; Raghwani, J.; Pybus, O.; Ke, C., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. *medRxiv* **2020**, 2020.04.01.20047076. https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047076.full.pdf

426. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30251-8

427. Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of nonhuman primates identified the suitable model for COVID-19. *Signal Transduction and Targeted Therapy* **2020,** *5* (1), 157. https://doi.org/10.1038/s41392-020-00269-6

428. Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* **2020**, 2020.04.08.031807. https://www.biorxiv.org/content/biorxiv/early/2020/04/12/2020.04.08.031807.full.pdf

429. Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2005073

430. Lu, Y.-f.; Pan, L.-y.; Zhang, W.-W.; Cheng, F.; Hu, S.-S.; Zhang, X.; Jiang, H.-y., A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. *International Journal of Infectious Diseases* **2020**. https://doi.org/10.1016/j.ijid.2020.08.023

431. Lu, Y.; Li, Y.; Deng, W.; Liu, M.; He, Y.; Huang, L.; Lv, M.; Li, J.; Du, H., Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan. *Pediatr Infect Dis J* **2020**.

432. Lumley, S. F.; O'Donnell, D.; Stoesser, N. E.; Matthews, P. C.; Howarth, A.; Hatch, S. B.; Marsden, B. D.; Cox, S.; James, T.; Warren, F.; Peck, L. J.; Ritter, T. G.; de Toledo, Z.; Warren, L.; Axten, D.; Cornall, R. J.; Jones, E. Y.; Stuart, D. I.; Screaton, G.; Ebner, D.; Hoosdally, S.; Chand, M.; Crook, D. W.; O'Donnell, A.-M.; Conlon, C. P.; Pouwels, K. B.; Walker, A. S.; Peto, T. E. A.; Hopkins, S.; Walker, T. M.; Jeffery, K.; Eyre, D. W., Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2034545
433. Lundgren, J. D.; Grund, B.; Barkauskas, C. E.; Holland, T. L.; Gottlieb, R. L.; Sandkovsky, U.; Brown, S. M.; Knowlton, K. U.; Self, W. H.; Files, D. C.; Jain, M. K.; Benfield, T.; Bowdish, M. E.; Leshnower, B. G.; Baker, J. V.; Jensen, J. U.; Gardner, E. M.; Ginde, A. A.; Harris, E. S.; Johansen, I. S.; Markowitz, N.; Matthay, M. A.; Østergaard, L.; Chang, C. C.; Davey, V. J.; Goodman, A.; Higgs, E. S.; Murray, D. D.; Murray, T. A.; Paredes, R.; Parmar, M. K. B.; Phillips, A. N.; Reilly, C.; Sharma, S.; Dewar, R. L.; Teitelbaum, M.; Wentworth, D.; Cao, H.; Klekotka, P.; Babiker, A. G.; Gelijns, A. C.; Kan, V. L.; Polizzotto, M. N.; Thompson, B. T.; Lane, H. C.; Neaton, J. D., A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. *N Engl J Med* **2020**.
434. Luo, K.; Lei, Z.; Hai, Z.; Xiao, S.; Rui, J.; Yang, H.; Jing, X.; Wang, H.; Xie, Z.; Luo, P.; Li, W.; Li, Q.; Tan, H.; Xu, Z.; Yang, Y.; Hu, S.; Chen, T., Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China. *Open Forum Infectious Diseases* **2020,** *7* (10). https://doi.org/10.1093/ofid/ofaa430
435. Luo, Y.; Trevathan, E.; Qian, Z.; Li, Y.; Li, J.; Xiao, W.; Tu, N.; Zeng, Z.; Mo, P.; Xiong, Y.; Ye, G., Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China. *Emerging Infectious Disease journal* **2020,** *26* (8). https://wwwnc.cdc.gov/eid/article/26/8/20-1016_article
436. Ma, J.; Qi, X.; Chen, H.; Li, X.; Zhang, Z.; Wang, H.; Sun, L.; Zhang, L.; Guo, J.; Morawska, L.; Grinshpun, S. A.; Biswas, P.; Flagan, R. C.; Yao, M., COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per hour. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1283
437. Madewell, Z. J.; Yang, Y.; Longini, I. M., Jr; Halloran, M. E.; Dean, N. E., Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Network Open* **2020,** *3* (12), e2031756-e2031756. https://doi.org/10.1001/jamanetworkopen.2020.31756
438. Magleby, R.; Westblade, L. F.; Trzebucki, A.; Simon, M. S.; Rajan, M.; Park, J.; Goyal, P.; Safford, M. M.; Satlin, M. J., Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa851
439. Maier, B. F.; Brockmann, D., Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China. *Science* **2020,** *368* (6492), 742-746. https://science.sciencemag.org/content/sci/368/6492/742.full.pdf
440. Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675
441. Malgie, J.; Schoones, J. W.; Pijls, B. G., Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. *Clin Infect Dis* **2020**.
442. Mallapaty, S., Coronavirus can infect cats — dogs, not so much. *Nature* **2020**. https://www.nature.com/articles/d41586-020-00984-8
443. Mallett, S.; Allen, A. J.; Graziadio, S.; Taylor, S. A.; Sakai, N. S.; Green, K.; Suklan, J.; Hyde, C.; Shinkins, B.; Zhelev, Z.; Peters, J.; Turner, P. J.; Roberts, N. W.; di Ruffano, L. F.; Wolff, R.; Whiting, P.; Winter, A.; Bhatnagar, G.; Nicholson, B. D.; Halligan, S., At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. *BMC Med* **2020,** *18* (1), 346.

444. Mandavilli, A., The Coronavirus Is Mutating. What Does That Mean for Us? *New York Times* 2020. https://www.nytimes.com/2020/12/20/health/coronavirus-britain-variant.html?action=click&module=Top%20Stories&pgtype=Homepage
445. Maor, Y.; Cohen, D.; Paran, N.; Israely, T.; Ezra, V.; Axelrod, O.; Shinar, E.; Izak, M.; Rahav, G.; Rahimi-Levene, N.; Bazofin, B. M.; Gelman, R.; Dicker, D.; Brosh-Nissimov, T.; Megged, O.; Dahan, D.; Benov, A.; Paz, A.; Edward, K.; Moran, A.; Rogowski, O.; Sorkine, P.; Mayo, A.; Zimhony, O.; Chen, J., Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. *EClinicalMedicine* **2020**, 100525.
446. Masana, L.; Correig, E.; Rodríguez-Borjabad, C.; Anoro, E.; Arroyo, J. A.; Jericó, C.; Pedragosa, A.; Miret, M.; Näf, S.; Pardo, A.; Perea, V.; Pérez-Bernalte, R.; Plana, N.; Ramírez-Montesinos, R.; Royuela, M.; Soler, C.; Urquizu-Padilla, M.; Zamora, A.; Pedro-Botet, J.; Group, O., EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED. *Eur Heart J Cardiovasc Pharmacother* **2020**.
447. Mateus, J.; Grifoni, A.; Tarke, A.; Sidney, J.; Ramirez, S. I.; Dan, J. M.; Burger, Z. C.; Rawlings, S. A.; Smith, D. M.; Phillips, E.; Mallal, S.; Lammers, M.; Rubiro, P.; Quiambao, L.; Sutherland, A.; Yu, E. D.; da Silva Antunes, R.; Greenbaum, J.; Frazier, A.; Markmann, A. J.; Premkumar, L.; de Silva, A.; Peters, B.; Crotty, S.; Sette, A.; Weiskopf, D., Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **2020**, eabd3871. https://science.sciencemag.org/content/sci/early/2020/08/04/science.abd3871.full.pdf
448. Mbaeyi, S., Use of Pfizer-BioNTech COVID-19 Vaccine: Clinical Considerations. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-12/COVID-03-Mbaeyi.pdf.
449. McCoy, J.; Cadegiani, F. A.; Wambier, C. G.; Herrera, S.; Vaño-Galván, S.; Mesinkovska, N. A.; Ramos, P. M.; Shapiro, J.; Sinclair, R.; Tosti, A.; Goren, A., 5-Alpha-Reductase Inhibitors are Associated with Reduced Frequency of COVID-19 Symptoms in Males with Androgenetic Alopecia. *J Eur Acad Dermatol Venereol* **2020**.
450. McElvaney, O. J.; Hobbs, B. D.; Qiao, D.; McElvaney, O. F.; Moll, M.; McEvoy, N. L.; Clarke, J.; O'Connor, E.; Walsh, S.; Cho, M. H.; Curley, G. F.; McElvaney, N. G., A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. *EBioMedicine* **2020,** *61*, 103026. http://www.sciencedirect.com/science/article/pii/S2352396420304023
451. McGurnaghan, S. J.; Weir, A.; Bishop, J.; Kennedy, S.; Blackbourn, L. A. K.; McAllister, D. A.; Hutchinson, S.; Caparrotta, T. M.; Mellor, J.; Jeyam, A.; O'Reilly, J. E.; Wild, S. H.; Hatam, S.; Höhn, A.; Colombo, M.; Robertson, C.; Lone, N.; Murray, J.; Butterly, E.; Petrie, J.; Kennon, B.; McCrimmon, R.; Lindsay, R.; Pearson, E.; Sattar, N.; McKnight, J.; Philip, S.; Collier, A.; McMenamin, J.; Smith-Palmer, A.; Goldberg, D.; McKeigue, P. M.; Colhoun, H. M.; Whettlock, A.; McLeod, A.; Gasiorowski, A.; Merrick, A.; McAuley, A.; Went, A.; Purdie, C.; Fischbacher, C.; Ramsey, C.; Bailey, D.; Henderson, D.; McDonald, E.; Drennan, G.; Gowans, G.; Reid, G.; Murdoch, H.; Carruthers, J.; Murray, J.; Heatlie, K.; Donaldson, L.; Paton, M.; Reid, M.; Llano, M.; Murphy-Hall, M.; Hall, R.; Cameron, R.; Brownlie, S.; Gaffney, A.; Milne, A.; Sullivan, C.; McArdle, E.; Glass, E.; Young, J.; Malcolm, W.; McCoubrey, J., Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. *The Lancet Diabetes & Endocrinology* **2020**. https://doi.org/10.1016/S2213-8587(20)30405-8
452. Mehta, N. S.; Mytton, O. T.; Mullins, E. W. S.; Fowler, T. A.; Falconer, C. L.; Murphy, O. B.; Langenberg, C.; Jayatunga, W. J. P.; Eddy, D. H.; Nguyen-Van-Tam, J. S., SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review. *Clinical Infectious Diseases* **2020,** *71* (9), 2469-2479. https://doi.org/10.1093/cid/ciaa556
453. Menachery, V. D.; Dinnon, K. H.; Yount, B. L.; McAnarney, E. T.; Gralinski, L. E.; Hale, A.; Graham, R. L.; Scobey, T.; Anthony, S. J.; Wang, L.; Graham, B.; Randell, S. H.; Lipkin, W. I.; Baric, R. S., Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology* **2020,** *94* (5), e01774-19. https://jvi.asm.org/content/jvi/94/5/e01774-19.full.pdf

454. Merkler, A. E.; Parikh, N. S.; Mir, S.; Gupta, A.; Kamel, H.; Lin, E.; Lantos, J.; Schenck, E. J.; Goyal, P.; Bruce, S. S.; Kahan, J.; Lansdale, K. N.; LeMoss, N. M.; Murthy, S. B.; Stieg, P. E.; Fink, M. E.; Iadecola, C.; Segal, A. Z.; Cusick, M.; Campion, T. R., Jr; Diaz, I.; Zhang, C.; Navi, B. B., Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurology* **2020**. https://doi.org/10.1001/jamaneurol.2020.2730
455. Meyerowitz, E. A.; Richterman, A.; Bogoch, I. I.; Low, N.; Cevik, M., Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. *The Lancet Infectious Diseases* **2020**. http://www.sciencedirect.com/science/article/pii/S1473309920308379
456. Millett, G. A.; Jones, A. T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C.; Honermann, B.; Lankiewicz, E.; Mena, L.; Crowley, J. S.; Sherwood, J.; Sullivan, P., Assessing Differential Impacts of COVID-19 on Black Communities. *Annals of Epidemiology* **2020**. http://www.sciencedirect.com/science/article/pii/S1047279720301769
457. Mina, M. J.; Parker, R.; Larremore, D. B., Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMp2025631
458. MIT, DELPHI Epidemiological Case Predictions. https://www.covidanalytics.io/projections.
459. Mitja, O.; Ubals, M.; Corbacho, M.; Alemany, A.; Suner, C.; Tebe, C.; Tobias, A.; Penafiel, J.; Ballana, E.; Perez, C. A.; Admella, P.; Riera-Marti, N.; Laporte, P.; Mitja, J.; Clua, M.; Bertran, L.; Gavilan, S.; Ara, J.; Sarquella, M.; Argimon, J. M.; Cuatrecasas, G.; Canadas, P.; Elizalde-Torrent, A.; Fabregat, R.; Farre, M.; Forcada, A.; Flores-Mateo, G.; Lopez, C.; Muntada, E.; Nadal, N.; Narejos, S.; Gil-Ortega, A. N.; Prat, N.; Puig, J.; Quinones, C.; Ramirez-Viaplana, F.; Reyes-Uruena, J.; Riveira-Munoz, E.; Ruiz, L.; Sanz, S.; Sentis, A.; Sierra, A.; Velasco, C.; Vivanco-Hidalgo, R. M.; Zamora, J.; Casabona, J.; Vall-Mayans, M.; G-Beiras, C.; Clotet, B., A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease. *medRxiv* **2020**, 2020.07.20.20157651. http://medrxiv.org/content/early/2020/07/26/2020.07.20.20157651.abstract
460. MITRE, COVID-19 Dashboard and Tools. https://dashboards.c19hcc.org/.
461. Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G., Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **2020,** *25* (10), 2000180. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180
462. Moderna, Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine.
463. Moderna, Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study.
464. Mody, A.; Lyons, P. G.; Guillamet, C. V.; Michelson, A.; Yu, S.; Namwase, A. S.; Sinha, P.; Powderly, W. G.; Woeltje, K.; Geng, E. H., The Clinical Course of COVID-19 Disease in a US Hospital System: a Multi-state Analysis. *American Journal of Epidemiology* **2020**. https://doi.org/10.1093/aje/kwaa286
465. Moghadam, S. A.; Dini, P.; Nassiri, S.; Motavaselian, M.; Hajibaba, M.; Sohrabi, M., Clinical features of pregnant women in Iran who died due to COVID-19. *International Journal of Gynecology & Obstetrics* **2020,** *n/a* (n/a). https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13461
466. Moiseev, S.; Avdeev, S.; Tao, E.; Brovko, M.; Bulanov, N.; Zykova, A.; Akulkina, L.; Smirnova, I.; Fomin, V., Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study. *Annals of the Rheumatic Diseases* **2020**, annrheumdis-2020-219265. http://ard.bmj.com/content/early/2020/10/30/annrheumdis-2020-219265.abstract

467. Monchatre-Leroy, E.; Lesellier, S.; Wasniewski, M.; Picard-Meyer, E.; Richomme, C.; Boué, F.; Lacôte, S.; Murri, S.; Pulido, C.; Vulin, J.; Salguero, F. J.; Gouilh, M. A.; Servat, A.; Marianneau, P., Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. *bioRxiv* **2020**, 2020.09.24.311977.
http://biorxiv.org/content/early/2020/09/24/2020.09.24.311977.abstract
468. Monk, P. D.; Marsden, R. J.; Tear, V. J.; Brookes, J.; Batten, T. N.; Mankowski, M.; Gabbay, F. J.; Davies, D. E.; Holgate, S. T.; Ho, L. P.; Clark, T.; Djukanovic, R.; Wilkinson, T. M. A., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med* **2020**.
469. Monreal, E.; Sainz de la Maza, S.; Natera-Villalba, E.; Beltrán-Corbellini, Á.; Rodríguez-Jorge, F.; Fernández-Velasco, J. I.; Walo-Delgado, P.; Muriel, A.; Zamora, J.; Alonso-Canovas, A.; Fortún, J.; Manzano, L.; Montero-Errasquín, B.; Costa-Frossard, L.; Masjuan, J.; Villar, L. M., High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. *Eur J Clin Microbiol Infect Dis* **2020**, 1-9.
470. Montopoli, M.; Zumerle, S.; Vettor, R.; Rugge, M.; Zorzi, M.; Catapano, C. V.; Carbone, G.; Cavalli, A.; Pagano, F.; Ragazzi, E., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532). *Annals of Oncology* **2020**.
471. Moore, J. T.; Ricaldi, J. N.; Rose, C. E.; al., e., Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020 — 22 States, February–June 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 14 August 2020*.
472. Morales, D. R.; Conover, M. M.; You, S. C.; Pratt, N.; Kostka, K.; Duarte-Salles, T.; Fernández-Bertolín, S.; Aragón, M.; DuVall, S. L.; Lynch, K.; Falconer, T.; van Bochove, K.; Sung, C.; Matheny, M. E.; Lambert, C. G.; Nyberg, F.; Alshammari, T. M.; Williams, A. E.; Park, R. W.; Weaver, J.; Sena, A. G.; Schuemie, M. J.; Rijnbeek, P. R.; Williams, R. D.; Lane, J. C. E.; Prats-Uribe, A.; Zhang, L.; Areia, C.; Krumholz, H. M.; Prieto-Alhambra, D.; Ryan, P. B.; Hripcsak, G.; Suchard, M. A., Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. *Lancet Digit Health* **2020**.
473. Morawska, L.; Milton, D. K., It is Time to Address Airborne Transmission of COVID-19. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa939
474. Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020,** (ePub: 23 March 2020).
https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm
475. Morley, C. P.; Anderson, K. B.; Shaw, J.; Stewart, T.; Thomas, S. J.; Wang, D., Social Distancing Metrics and Estimates of SARS-CoV-2 Transmission Rates: Associations Between Mobile Telephone Data Tracking and R. *Journal of Public Health Management and Practice* **9000,** *Publish Ahead of Print*.
https://journals.lww.com/jphmp/Fulltext/9000/Social_Distancing_Metrics_and_Estimates_of.99258.aspx
476. Morris, S. B.; Schwartz, N. G.; Patel, P.; al., e., Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020. *Morbidity and Mortality Weekly Report* **2020,** *2 October 2020*.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6940e1.htm
477. Mudd, P. A.; Crawford, J. C.; Turner, J. S.; Souquette, A.; Reynolds, D.; Bender, D.; Bosanquet, J. P.; Anand, N. J.; Striker, D. A.; Martin, R. S.; Boon, A. C. M.; House, S. L.; Remy, K. E.; Hotchkiss, R. S.; Presti, R. M.; O'Halloran, J. A.; Powderly, W. G.; Thomas, P. G.; Ellebedy, A. H., Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. *Science Advances* **2020**, eabe3024.
https://advances.sciencemag.org/content/advances/early/2020/11/13/sciadv.abe3024.full.pdf

478. Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628. https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf
479. Murat, S.; Dogruoz Karatekin, B.; Icagasioglu, A.; Ulasoglu, C.; İçten, S.; Incealtin, O., Clinical presentations of pain in patients with COVID-19 infection. *Ir J Med Sci* **2020**.
480. Murphy, N.; Boland, M.; Bambury, N.; Fitzgerald, M.; Comerford, L.; Dever, N.; O'Sullivan, M. B.; Petty-Saphon, N.; Kiernan, R.; Jensen, M.; O'Connor, L., A large national outbreak of COVID-19 linked to air travel, Ireland, summer 2020. *Eurosurveillance* **2020,** *25* (42), 2001624. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.42.2001624
481. Mutambudzi, M.; Niedwiedz, C.; Macdonald, E. B.; Leyland, A.; Mair, F.; Anderson, J.; Celis-Morales, C.; Cleland, J.; Forbes, J.; Gill, J.; Hastie, C.; Ho, F.; Jani, B.; Mackay, D. F.; Nicholl, B.; O'Donnell, C.; Sattar, N.; Welsh, P.; Pell, J. P.; Katikireddi, S. V.; Demou, E., Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. *Occupational and Environmental Medicine* **2020**, oemed-2020-106731. https://oem.bmj.com/content/oemed/early/2020/12/01/oemed-2020-106731.full.pdf
482. Mykytyn, A. Z.; Lamers, M. M.; Okba, N. M. A.; Breugem, T. I.; Schipper, D.; van den Doel, P. B.; van Run, P.; van Amerongen, G.; de Waal, L.; Koopmans, M. P. G.; Stittelaar, K. J.; van den Brand, J. M. A.; Haagmans, B. L., Susceptibility of rabbits to SARS-CoV-2. *Emerging Microbes & Infections* **2020**, 1-17. https://doi.org/10.1080/22221751.2020.1868951
483. NACCHO, U.S. COVID-19 Dashboard. https://naccho.maps.arcgis.com/apps/opsdashboard/index.html#/745860ceff004059aad1b6f82f196fb5 .
484. Nadkarni, G. N.; Lala, A.; Bagiella, E.; Chang, H. L.; Moreno, P.; Pujadas, E.; Arvind, V.; Bose, S.; Charney, A. W.; Chen, M. D.; Cordon-Cardo, C.; Dunn, A. S.; Farkouh, M. E.; Glicksberg, B.; Kia, A.; Kohli-Seth, R.; Levin, M. A.; Timsina, P.; Zhao, S.; Fayad, Z. A.; Fuster, V., Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study. *Journal of the American College of Cardiology* **2020**, 27631. https://www.onlinejacc.org/content/accj/early/2020/08/24/j.jacc.2020.08.041.full.pdf
485. Nasa, P.; Singh, A.; Upadhyay, S.; Bagadia, S.; Polumuru, S.; Shrivastava, P. K.; Sankar, R.; Vijayan, L.; Soliman, M. A.; Ali, A.; Patidar, S., Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. *Indian J Crit Care Med* **2020,** *24* (9), 771-776.
486. NASEM, *Airborne transmission of SARS-CoV-2; Proceedings of a Workshop - in Brief*; National Academies of Sciences, Engineering, and Medicine: 2020. https://www.nap.edu/read/25958/chapter/1
487. National Institutes of Health, NIH observational study of coronavirus infection and multisystem inflammatory syndrome in children begins. https://www.nih.gov/news-events/news-releases/nih-observational-study-coronavirus-infection-multisystem-inflammatory-syndrome-children-begins (accessed 16 Dec 2020).
488. National Public Radio (NPR), Still Disinfecting Surfaces? It Might Not Be Worth It. https://www.npr.org/sections/health-shots/2020/12/28/948936133/still-disinfecting-surfaces-it-might-not-be-worth-it (accessed 02 Jan 2021).
489. Ndieugnou Djangang, N.; Peluso, L.; Talamonti, M.; Izzi, A.; Gevenois, P. A.; Garufi, A.; Goffard, J.-C.; Henrard, S.; Severgnini, P.; Vincent, J.-L.; Creteur, J.; Taccone, F. S., Eosinopenia in COVID-19 Patients: A Retrospective Analysis. *Microorganisms* **2020,** *8* (12), 1929. https://www.mdpi.com/2076-2607/8/12/1929
490. Ng, K. W.; Faulkner, N.; Cornish, G. H.; Rosa, A.; Harvey, R.; Hussain, S.; Ulferts, R.; Earl, C.; Wrobel, A. G.; Benton, D. J.; Roustan, C.; Bolland, W.; Thompson, R.; Agua-Doce, A.; Hobson, P.; Heaney, J.;

Rickman, H.; Paraskevopoulou, S.; Houlihan, C. F.; Thomson, K.; Sanchez, E.; Shin, G. Y.; Spyer, M. J.; Joshi, D.; O'Reilly, N.; Walker, P. A.; Kjaer, S.; Riddell, A.; Moore, C.; Jebson, B. R.; Wilkinson, M.; Marshall, L. R.; Rosser, E. C.; Radziszewska, A.; Peckham, H.; Ciurtin, C.; Wedderburn, L. R.; Beale, R.; Swanton, C.; Gandhi, S.; Stockinger, B.; McCauley, J.; Gamblin, S. J.; McCoy, L. E.; Cherepanov, P.; Nastouli, E.; Kassiotis, G., Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science* **2020**, eabe1107.
https://science.sciencemag.org/content/sci/early/2020/11/05/science.abe1107.full.pdf
491. Ng, O. T.; Marimuthu, K.; Koh, V.; Pang, J.; Linn, K. Z.; Sun, J.; De Wang, L.; Chia, W. N.; Tiu, C.; Chan, M.; Ling, L. M.; Vasoo, S.; Abdad, M. Y.; Chia, P. Y.; Lee, T. H.; Lin, R. J.; Sadarangani, S. P.; Chen, M. I. C.; Said, Z.; Kurupatham, L.; Pung, R.; Wang, L.-F.; Cook, A. R.; Leo, Y.-S.; Lee, V. J. M., SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(20)30833-1
492. Ngonghala, C. N.; Iboi, E.; Eikenberry, S.; Scotch, M.; MacIntyre, C. R.; Bonds, M. H.; Gumel, A. B., Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus. *Mathematical Biosciences* **2020,** *325*, 108364.
http://www.sciencedirect.com/science/article/pii/S0025556420300560
493. Nguyen-Contant, P.; Embong, A. K.; Kanagaiah, P.; Chaves, F. A.; Yang, H.; Branche, A. R.; Topham, D. J.; Sangster, M. Y., S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. *mBio* **2020,** *11* (5), e01991-20.
https://mbio.asm.org/content/mbio/11/5/e01991-20.full.pdf
494. Nguyen, L. H.; Drew, D. A.; Graham, M. S.; Joshi, A. D.; Guo, C.-G.; Ma, W.; Mehta, R. S.; Warner, E. T.; Sikavi, D. R.; Lo, C.-H.; Kwon, S.; Song, M.; Mucci, L. A.; Stampfer, M. J.; Willett, W. C.; Eliassen, A. H.; Hart, J. E.; Chavarro, J. E.; Rich-Edwards, J. W.; Davies, R.; Capdevila, J.; Lee, K. A.; Lochlainn, M. N.; Varsavsky, T.; Sudre, C. H.; Cardoso, M. J.; Wolf, J.; Spector, T. D.; Ourselin, S.; Steves, C. J.; Chan, A. T., Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health* **2020**. http://www.thelancet-press.com/embargo/hcwcovid.pdf
495. NIH, *Fact Sheet for Patients And Parent/Caregivers - Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)*; National Institutes of Health: 2020.
https://www.fda.gov/media/137565/download
496. NIH, Phase 3 trial of Novavax investigational COVID-19 vaccine opens. https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens.
497. Nishiura, H.; Kobayashi, T.; Miyama, T.; Suzuki, A.; Jung, S.-m.; Hayashi, K.; Kinoshita, R.; Yang, Y.; Yuan, B.; Akhmetzhanov, A. R.; Linton, N. M., Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *International Journal of Infectious Diseases* **2020,** *94*, 154-155.
http://www.sciencedirect.com/science/article/pii/S1201971220301399
498. Niu, A.; Ning, B.; Socola, F.; Safah, H.; Reynolds, T.; Ibrahim, M.; Safa, F.; Alfonso, T.; Luk, A.; Mushatt, D. M.; Hu, T.; Saba, N. S., 313 COVID-19 in Patients with hematological Malignancies: High False Negative Rate with High Mortality. In *62nd ASH Annual Meeting and Exposition*, 2020.
https://ash.confex.com/ash/2020/webprogram/Paper138611.html
499. Northeastern, Modeling of COVID-19 epidemic in the United States.
https://covid19.gleamproject.org/#icubedproj.
500. Novelli, L.; Raimondi, F.; Ghirardi, A.; Pellegrini, D.; Capodanno, D.; Sotgiu, G.; Guagliumi, G.; Senni, M.; Russo, F. M.; Lorini, F. L.; Rizzi, M.; Barbui, T.; Rambaldi, A.; Cosentini, R.; Grazioli, L. S.; Marchesi, G.; Sferrazza Papa, G. F.; Cesa, S.; Colledan, M.; Civiletti, R.; Conti, C.; Casati, M.; Ferri, F.; Camagni, S.; Sessa, M.; Masciulli, A.; Gavazzi, A.; Falanga, A.; Da Pozzo, L. F.; Buoro, S.; Remuzzi, G.; Ruggenenti, P.; Callegaro, A.; D''''Antiga, L.; Pasulo, L.; Pezzoli, F.; Gianatti, A.; Parigi, P.; Farina, C.; Bellasi, A.; Solidoro, P.; Sironi, S.; Di Marco, F.; Fagiuoli, S., At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy. *Panminerva Med* **2020**.

501. Now, C. A., America's COVID warning system. https://covidactnow.org/?s=38532.
502. O'Hearn, K.; Gertsman, S.; Webster, R.; Tsampalieros, A.; Ng, R.; Gibson, J.; Sampson, M.; Sikora, L.; McNally, J. D., Efficacy and Safety of Disinfectants for Decontamination of N95 and SN95 Filtering Facepiece Respirators: A Systematic Review. *Journal of Hospital Infection*. https://doi.org/10.1016/j.jhin.2020.08.005
503. Observatory, U., *COVID-19 Trends for U.S. Counties*; ESRI: 2020. https://urbanobservatory.maps.arcgis.com/apps/MapSeries/index.html?appid=ad46e587a9134fcdb43ff54c16f8c39b
504. Oetjens, M. T.; Luo, J. Z.; Chang, A.; Leader, J. B.; Hartzel, D. N.; Moore, B. S.; Strande, N. T.; Kirchner, H. L.; Ledbetter, D. H.; Justice, A. E.; Carey, D. J.; Mirshahi, T., Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients. *PLoS One* **2020,** *15* (11), e0242182.
505. Offeddu, V.; Yung, C. F.; Low, M. S. F.; Tam, C. C., Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. *Clin Infect Dis* **2017,** *65* (11), 1934-1942. https://www.ncbi.nlm.nih.gov/pubmed/29140516
506. Ogega, C. O.; Skinner, N. E.; Blair, P. W.; Park, H.-S.; Littlefield, K.; Ganesan, A.; Ladiwala, P.; Antar, A. A.; Ray, S. C.; Betenbaugh, M. J.; Pekosz, A.; Klein, S.; Manabe, Y. C.; Cox, A. L.; Bailey, J. R., Durable SARS-CoV-2 B cell immunity after mild or severe disease. *medRxiv* **2020**, 2020.10.28.20220996. https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20220996.full.pdf
507. Olson, D. R.; Huynh, M.; Fine, A.; Baumgartner, J.; Castro, A.; Chan, H. T.; Daskalakis, D.; Devinney, K.; Guerra, K.; Harper, S.; Kennedy, J.; Konty, K.; Li, W.; McGibbon, E.; Shaff, J.; Thompson, C.; Vora, N. M.; Van Wye, G., Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New York City, March 11–May 2, 2020. *Morbidity and Mortality Weekly Report* **2020,** (ePub: 11 May 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e5.htm?s_cid=mm6919e5_w
508. Omrani, A. S.; Pathan, S. A.; Thomas, S. A.; Harris, T. R. E.; Coyle, P. V.; Thomas, C. E.; Qureshi, I.; Bhutta, Z. A.; Mawlawi, N. A.; Kahlout, R. A.; Elmalik, A.; Azad, A. M.; Daghfal, J.; Mustafa, M.; Jeremijenko, A.; Soub, H. A.; Khattab, M. A.; Maslamani, M. A.; Thomas, S. H., Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. *EClinicalMedicine* **2020,** *29*, 100645.
509. Onder, G.; Rezza, G.; Brusaferro, S., Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.4683
510. Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**. https://jamanetwork.com/journals/jama/articlepdf/2762692/jama_ong_2020_ld_200016.pdf
511. Oran, D. P.; Topol, E. J., Prevalence of Asymptomatic SARS-CoV-2 Infection. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-3012
512. Ortolan, A.; Lorenzin, M.; Felicetti, M.; Doria, A.; Ramonda, R., Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis. *International Journal of Infectious Diseases* **2020**. https://doi.org/10.1016/j.ijid.2020.07.076
513. Oster, A. M.; Caruso, E.; DeVies, J.; Hartnett, K. P.; Boehmer, T. K., Transmission Dynamics by Age Group in COVID-19 Hotspot Counties — United States, April–September 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub* (9 October 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6941e1.htm
514. Oude Munnink, B. B.; Sikkema, R. S.; Nieuwenhuijse, D. F.; Molenaar, R. J.; Munger, E.; Molenkamp, R.; van der Spek, A.; Tolsma, P.; Rietveld, A.; Brouwer, M.; Bouwmeester-Vincken, N.; Harders, F.; Hakze-van der Honing, R.; Wegdam-Blans, M. C. A.; Bouwstra, R. J.; GeurtsvanKessel, C.; van der Eijk, A. A.; Velkers, F. C.; Smit, L. A. M.; Stegeman, A.; van der Poel, W. H. M.; Koopmans, M. P. G., Transmission of

SARS-CoV-2 on mink farms between humans and mink and back to humans. *Science* **2020**, eabe5901. http://science.sciencemag.org/content/early/2020/11/09/science.abe5901.abstract
515. Owusu, D.; Kim, L.; O'Halloran, A.; Whitaker, M.; Piasecki, A. M.; Reingold, A.; Alden, N. B.; Maslar, A.; Anderson, E. J.; Ryan, P. A.; Kim, S.; Como-Sabetti, K.; Hancock, E. B.; Muse, A.; Bennett, N. M.; Billing, L. M.; Sutton, M.; Talbot, K.; Ortega, J.; Brammer, L.; Fry, A. M.; Hall, A. J.; Garg, S.; Team, C.-N. S., Characteristics of Adults aged 18–49 Years without Underlying Conditions Hospitalized with Laboratory-Confirmed COVID-19 in the United States, COVID-NET — March–August 2020. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1806
516. Pairo-Castineira, E.; Clohisey, S.; Klaric, L.; Bretherick, A.; Rawlik, K.; Parkinson, N.; Pasko, D.; Walker, S.; Richmond, A.; Head Fourman, M.; Law, A.; Furniss, J.; Gountouna, E.; Wrobel, N.; Russell, C. D.; Moutsianas, L.; Wang, B.; Meynert, A.; Yang, Z.; Zhai, R.; Zheng, C.; Griffith, F.; Oosthuyzen, W.; Shih, B.; Keating, S.; Zechner, M.; Haley, C.; Porteous, D. J.; Hayward, C.; Knight, J.; Summers, C.; Shankar-Hari, M.; Turtle, L.; Ho, A.; Hinds, C.; Horby, P.; Nichol, A.; Maslove, D.; Ling, L.; Klenerman, P.; McAuley, D.; Montgomery, H.; Walsh, T.; Shen, X.; Rowan, K.; Fawkes, A.; Murphy, L.; Ponting, C. P.; Tenesa, A.; Caulfield, M.; Scott, R.; Openshaw, P. J. M.; Semple, M. G.; Vitart, V.; Wilson, J. F.; Baillie, J. K., Genetic mechanisms of critical illness in Covid-19. *medRxiv* **2020**, 2020.09.24.20200048. http://medrxiv.org/content/early/2020/09/25/2020.09.24.20200048.1.abstract
517. Pairo-Castineira, E.; Clohisey, S.; Klaric, L.; Bretherick, A. D.; Rawlik, K.; Pasko, D.; Walker, S.; Parkinson, N.; Fourman, M. H.; Russell, C. D.; Furniss, J.; Richmond, A.; Gountouna, E.; Wrobel, N.; Harrison, D.; Wang, B.; Wu, Y.; Meynert, A.; Griffiths, F.; Oosthuyzen, W.; Kousathanas, A.; Moutsianas, L.; Yang, Z.; Zhai, R.; Zheng, C.; Grimes, G.; Beale, R.; Millar, J.; Shih, B.; Keating, S.; Zechner, M.; Haley, C.; Porteous, D. J.; Hayward, C.; Yang, J.; Knight, J.; Summers, C.; Shankar-Hari, M.; Klenerman, P.; Turtle, L.; Ho, A.; Moore, S. C.; Hinds, C.; Horby, P.; Nichol, A.; Maslove, D.; Ling, L.; McAuley, D.; Montgomery, H.; Walsh, T.; Pereira, A.; Renieri, A.; Millar, J.; Nichol, A.; Walsh, T.; Openshaw, P. J. M.; Shankar-Hari, M.; Ponting, C.; Meikle, J.; Finernan, P.; McMaster, E.; Law, A.; Baillie, J. K.; Paterson, T.; Wackett, T.; Armstrong, R.; Clark, R.; Coutts, A.; Donnelly, L.; Gilchrist, T.; Hafezi, K.; Macgillivray, L.; Maclean, A.; McCafferty, S.; Morrice, K.; Weaver, J.; Boz, C.; Golightly, A.; Ward, M.; Mal, H.; Szoor-McElhinney, H.; Brown, A.; Hendry, R.; Stenhouse, A.; Cullum, L.; Law, D.; Law, S.; Law, R.; Swets, M.; Day, N.; Taneski, F.; Duncan, E.; Parkinson, N.; Collier, D.; Wood, S.; Zak, A.; Borra, C.; Matharu, M.; May, P.; Alldis, Z.; Mitchelmore, O.; Bowles, R.; Easthorpe, A.; Bibi, F.; Lancoma-Malcolm, I.; Gurasashvili, J.; Pheby, J.; Shiel, J.; Bolton, M.; Patel, M.; Taylor, M.; Zongo, O.; Ebano, P.; Harding, P.; Astin-Chamberlain, R.; Choudhury, Y.; Cox, A.; Kallon, D.; Burton, M.; Hall, R.; Blowes, S.; Prime, Z.; Biddle, J.; Prysyazhna, O.; Newman, T.; Tierney, C.; Kassam, J.; Shankar-Hari, M.; Ostermann, M.; Campos, S.; Bociek, A.; Lim, R.; Grau, N.; Jones, T. O.; Whitton, C.; Marotti, M.; Arbane, G.; Bonner, S.; Hugill, K.; Reid, J.; Welters, I.; Waugh, V.; Williams, K.; Shaw, D.; Roman, J. F.; Martinez, M. L.; Johnson, E.; Waite, A.; Johnson, B.; Hamilton, O.; Mulla, S.; McPhail, M.; Smith, J.; Baillie, J. K.; Barclay, L.; Hope, D.; McCulloch, C.; McQuillan, L.; Clark, S.; Singleton, J.; Priestley, K.; Rea, N.; Callaghan, M.; Campbell, R.; Andrew, G.; Marshall, L.; McKechnie, S.; Hutton, P.; Bashyal, A.; Davidson, N.; Summers, C.; Polgarova, P.; Stroud, K.; Pathan, N.; Elston, K.; Agrawal, S.; Battle, C.; Newey, L.; Rees, T.; Harford, R.; Brinkworth, E.; Williams, M.; Murphy, C.; White, I.; Croft, M.; Bandla, N.; Gellamucho, M.; Tomlinson, J.; Turner, H.; Davies, M.; Quinn, A.; Hussain, I.; Thompson, C.; Parker, H.; Bradley, R.; Griffiths, R.; Scriven, J.; Gill, J.; Puxty, A.; Cathcart, S.; Salutous, D.; Turner, L.; Duffy, K.; Puxty, K.; Joseph, A.; Herdman-Grant, R.; Simms, R.; Swain, A.; Naranjo, A.; Crowe, R.; Sollesta, K.; Loveridge, A.; Baptista, D.; Morino, E.; Davey, M.; Golden, D.; Jones, J.; Cuesta, J. M.; Haldeos, A.; Bakthavatsalam, D.; Vincent, R.; Elhassan, M.; Xavier, K.; Ganesan, A.; Abdelrazik, D. P. M.; Morgan, J.; Akeroyd, L.; Bano, S.; Warren, D.; Bromley, M.; Sellick, K.; Gurr, L.; Wilkinson, B.; Nagarajan, V.; Szedlak, P.; Cupitt, J.; Stoddard, E.; Benham, L.; Preston, S.; Slawson, N.; Bradshaw, Z.; brown, J.; Caswell, M.; Melling, S.; Bamford, P.; Faulkner, M.; Cawley, K.; Jeffrey, H.; London, E.; Sainsbury, H.; Nagra, I.; Nasir, F.; Dunmore, C.; Jones, R.; Abraheem, A.; Al-

Moasseb, M.; Girach, R.; Brantwood, C.; Alexander, P.; Bradley-Potts, J.; Allen, S.; Felton, T.; Manna, S.; Farnell-Ward, S.; Leaver, S.; Queiroz, J.; Maccacari, E.; Dawson, D.; Delgado, C. C.; Saluzzio, R. P.; Ezeobu, O.; Ding, L.; Sicat, C.; Kanu, R.; The Gen, O. I.; Gen, O. C.; Gen, O. c.-i.; Central, m.; laboratory, t.; Data analysis, t.; Barts Health Nhs Trust, L. U. K.; Guys; St Thomas' Hospital, L. U. K.; James Cook University Hospital, M. U. K.; The Royal Liverpool University Hospital, L. U. K.; King's College Hospital, L. U. K.; Royal Infirmary of Edinburgh, E. U. K.; John Radcliffe Hospital, O. U. K.; Addenbrooke's Hospital, C. U. K.; Morriston Hospital, S. U. K.; Ashford; St Peter's Hospital, S. U. K.; Royal Stoke University Hospital, S. U. K.; Queen Elizabeth Hospital, B. U. K.; Glasgow Royal Infirmary, G. U. K.; Kingston Hospital, S. U. K.; The Tunbridge Wells, H.; Maidstone Hospital, K. U. K.; North Middlesex University Hospital Nhs Trust, L. U. K.; Bradford Royal Infirmary, B. U. K.; Blackpool Victoria Hospital, B. U. K.; Countess of Chester Hospital, C. U. K.; Wythenshawe Hospital, M. U. K.; St George's Hospital, L. U. K., Genetic mechanisms of critical illness in Covid-19. *Nature* **2020**. https://doi.org/10.1038/s41586-020-03065-y

518. Pan, D.; Sze, S.; Minhas, J. S.; Bangash, M. N.; Pareek, N.; Divall, P.; Williams, C. M. L.; Oggioni, M. R.; Squire, I. B.; Nellums, L. B.; Hanif, W.; Khunti, K.; Pareek, M., The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine*. https://doi.org/10.1016/j.eclinm.2020.100404

519. Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology 0* (0), 200370. https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370

520. Pan, H.; Peto, R.; Henao-Restrepo, A. M.; Preziosi, M. P.; Sathiyamoorthy, V.; Abdool Karim, Q.; Alejandria, M. M.; Hernández García, C.; Kieny, M. P.; Malekzadeh, R.; Murthy, S.; Reddy, K. S.; Roses Periago, M.; Abi Hanna, P.; Ader, F.; Al-Bader, A. M.; Alhasawi, A.; Allum, E.; Alotaibi, A.; Alvarez-Moreno, C. A.; Appadoo, S.; Asiri, A.; Aukrust, P.; Barratt-Due, A.; Bellani, S.; Branca, M.; Cappel-Porter, H. B. C.; Cerrato, N.; Chow, T. S.; Como, N.; Eustace, J.; García, P. J.; Godbole, S.; Gotuzzo, E.; Griskevicius, L.; Hamra, R.; Hassan, M.; Hassany, M.; Hutton, D.; Irmansyah, I.; Jancoriene, L.; Kirwan, J.; Kumar, S.; Lennon, P.; Lopardo, G.; Lydon, P.; Magrini, N.; Maguire, T.; Manevska, S.; Manuel, O.; McGinty, S.; Medina, M. T.; Mesa Rubio, M. L.; Miranda-Montoya, M. C.; Nel, J.; Nunes, E. P.; Perola, M.; Portolés, A.; Rasmin, M. R.; Raza, A.; Rees, H.; Reges, P. P. S.; Rogers, C. A.; Salami, K.; Salvadori, M. I.; Sinani, N.; Sterne, J. A. C.; Stevanovikj, M.; Tacconelli, E.; Tikkinen, K. A. O.; Trelle, S.; Zaid, H.; Røttingen, J. A.; Swaminathan, S., Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med* **2020**.

521. Papamanoli, A.; Yoo, J.; Grewal, P.; Predun, W.; Hotelling, J.; Jacob, R.; Mojahedi, A.; Skopicki, H. A.; Mansour, M.; Marcos, L. A.; Kalogeropoulos, A. P., High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia. *Eur J Clin Invest* **2020**, e13458.

522. Paranjpe, I.; Fuster, V.; Lala, A.; Russak, A.; Glicksberg, B. S.; Levin, M. A.; Charney, A. W.; Narula, J.; Fayad, Z. A.; Bagiella, E.; Zhao, S.; Nadkarni, G. N., Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. *Journal of the American College of Cardiology* **2020**, 27327. http://www.onlinejacc.org/content/accj/early/2020/05/05/j.jacc.2020.05.001.full.pdf

523. Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13.

524. Park, S. Y.; Kim, Y.-M.; Yi, S.; Lee, S.; Na, B.-J.; Kim, C. B.; Kim, J.-i.; Kim, H. S.; Kim, Y. B.; Park, Y.; Huh, I. S.; Kim, H. K.; Yoon, H. J.; Jang, H.; Kim, K.; Chang, Y.; Kim, I.; Lee, H.; Gwack, J.; Kim, S. S.; Kim, M.; Kweon, S.; Choe, Y. J.; Park, O.; Park, Y. J.; Jeong, E. K., Coronavirus Disease Outbreak in Call Center, South Korea. *Emerging Infectious Disease journal* **2020,** *26* (8), 1666. https://wwwnc.cdc.gov/eid/article/26/8/20-1274_article

525. Park, Y. J.; Choe, Y. J.; Park, O.; Park, S. Y.; Kim, Y.-M.; Kim, J.; Kweon, S.; Woo, Y.; Gwack, J.; Kim, S. S.; Lee, J.; Hyun, J.; Ryu, B.; Jang, Y. S.; Kim, H.; Shin, S. H.; Yi, S.; Lee, S.; Kim, H. K.; Lee, H.; Jin, Y.; Park, E.; Choi, S. W.; Kim, M.; Song, J.; Choi, S. W.; Kim, D.; Jeon, B.-H.; Yoo, H.; Jeong, E. K., Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. *Emerging Infectious Disease journal* **2020,** *26* (10). https://wwwnc.cdc.gov/eid/article/26/10/20-1315_article
526. Parri, N.; Lenge, M.; Buonsenso, D., Children with Covid-19 in Pediatric Emergency Departments in Italy. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2007617
527. Parshley, L., Kids catch and spread coronavirus half as much as adults, Iceland study confirms. *National Geographic* December 10, 2020, 2020. https://www.nationalgeographic.com/science/2020/12/we-now-know-how-much-children-spread-coronavirus/#close
528. Pascual Pareja, J. F.; García-Caballero, R.; Soler Rangel, L.; Vázquez-Ronda, M. A.; Roa Franco, S.; Navarro Jiménez, G.; Moreno Palanco, M. A.; González-Ruano, P.; López-Menchaca, R.; Ruíz-Seco, P.; Pagán Muñoz, B.; Gómez Gómez, A.; Pérez-Monte, B.; Fuerte Martínez, R.; Valle López, J. L.; Muñoz Blanco, A.; Rábago Lorite, I.; Martínez Martín, P.; Serralta San Martín, G.; Gómez-Cerezo, J. F., Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia. *Med Clin (Barc)* **2020**.
529. Pastor-Barriuso, R.; Pérez-Gómez, B.; Hernán, M. A.; Pérez-Olmeda, M.; Yotti, R.; Oteo-Iglesias, J.; Sanmartín, J. L.; León-Gómez, I.; Fernández-García, A.; Fernández-Navarro, P.; Cruz, I.; Martín, M.; Delgado-Sanz, C.; Fernández de Larrea, N.; León Paniagua, J.; Muñoz-Montalvo, J. F.; Blanco, F.; Larrauri, A.; Pollán, M., Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ* **2020,** *371*, m4509. https://www.bmj.com/content/bmj/371/bmj.m4509.full.pdf
530. Patolia, H.; Pan, J.; Harb, C.; Marr, L. C.; Baffoe-Bonnie, A., Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic. *Infection Control & Hospital Epidemiology* **2020**, 1-6. https://www.cambridge.org/core/article/filtration-evaluation-and-clinical-use-of-expired-elastomeric-p100-filter-cartridges-during-the-covid19-pandemic/D5EFCC5EEF65FEA210E1070149CB9DEF
531. Patterson, E. I.; Elia, G.; Grassi, A.; Giordano, A.; Desario, C.; Medardo, M.; Smith, S. L.; Anderson, E. R.; Prince, T.; Patterson, G. T.; Lorusso, E.; Lucente, M. S.; Lanave, G.; Lauzi, S.; Bonfanti, U.; Stranieri, A.; Martella, V.; Solari Basano, F.; Barrs, V. R.; Radford, A. D.; Agrimi, U.; Hughes, G. L.; Paltrinieri, S.; Decaro, N., Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. *Nature Communications* **2020,** *11* (1), 6231. https://doi.org/10.1038/s41467-020-20097-0
532. Pau, A. K.; Aberg, J.; Baker, J.; Belperio, P. S.; Coopersmith, C. M.; Crew, P.; Glidden, D. V.; Grund, B.; Gulick, R. M.; Harrison, C.; Kim, A.; Lane, H. C.; Masur, H.; Sheikh, V.; Singh, K.; Yazdany, J.; Tebas, P., Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. *Annals of Internal Medicine* **2020,** *0* (0), null. https://www.acpjournals.org/doi/abs/10.7326/M20-6448
533. Payne, D. C., SARS-CoV-2 Infections and Serologic Responses from a Sample of US Navy Service Members—USS Theodore Roosevelt, April 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020,** *69*.
534. Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.; Weinberger, D. M.; Arnold, W.; Omer, S. B., Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nature Biotechnology* **2020**. https://doi.org/10.1038/s41587-020-0684-z
535. Peltier, R. E.; Wang, J.; Hollenbeck, B. L.; Lanza, J.; Furtado, R. M.; Cyr, J.; Ellison, R.; Kobayashi, K. J., Addressing Decontaminated Respirators: Some Methods Appear to Damage Mask Integrity and Protective Function. *Infection Control & Hospital Epidemiology* **2020**, 1-9.

536. Perchetti, G. A.; Huang, M.-L.; Peddu, V.; Jerome, K. R.; Greninger, A. L., Stability of SARS-CoV-2 in PBS for Molecular Detection. *Journal of Clinical Microbiology* **2020**.
537. Perkins, A.; Espana, G., NotreDame-FRED COVID-19 forecasts. https://github.com/confunguido/covid19_ND_forecasting/blob/master/README.md.
538. Perry, R. J.; Smith, C. J.; Roffe, C.; Simister, R. J.; Narayanamoorthi, S.; Marigold, R.; Willmot, M.; Dixit, A.; Hassan, A.; Quinn, T.; Ankolekar, S.; Zhang, L.; Banerjee, S.; Ahmed, U.; Padmanabhan, N.; Ferdinand, P.; McGrane, F.; Banaras, A.; Marks, I. H.; Werring, D. J., Characteristics and outcomes of COVID-19-associated stroke: a UK multicentre case-control study. *Journal of Neurology, Neurosurgery & Psychiatry* **2020**, jnnp-2020-324927. https://jnnp.bmj.com/content/jnnp/early/2020/11/03/jnnp-2020-324927.full.pdf
539. Peto, L.; Rodger, G.; Carter, D. P.; Osman, K. L.; Yavuz, M.; Johnson, K.; Raza, M.; Parker, M. D.; Wyles, M. D.; Andersson, M.; Justice, A.; Vaughan, A.; Hoosdally, S.; Stoesser, N.; Matthews, P. C.; Eyre, D. W.; Peto, T. E.; Carroll, M. W.; de Silva, T. I.; Crook, D. W.; Evans, C. M.; Pullan, S. T., Diagnosis of SARS-CoV-2 infection with LamPORE, a high-throughput platform combining loop-mediated isothermal amplification and nanopore sequencing. *medRxiv* **2020**, 2020.09.18.20195370. https://www.medrxiv.org/content/medrxiv/early/2020/09/25/2020.09.18.20195370.full.pdf
540. Petrakis, D.; Margină, D.; Tsarouhas, K.; Tekos, F.; Stan, M.; Nikitovic, D.; Kouretas, D.; Spandidos, D. A.; Tsatsakis, A., Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review). *Mol Med Rep* **2020,** *22* (1), 9-19. https://doi.org/10.3892/mmr.2020.11127
541. Pfizer, PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against.
542. Pfizer, PFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 VACCINE CANDIDATE, MEETING ALL PRIMARY EFFICACY ENDPOINTS. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine.
543. Pfizer, PFIZER AND BIONTECH TO SUBMIT EMERGENCY USE AUTHORIZATION REQUEST TODAY TO THE U.S. FDA FOR COVID-19 VACCINE. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization.
544. Pickering, B.; Smith, G.; Pinette, M.; Embury-Hyatt, C.; Moffat, E.; Marszal, P.; Lewis, C. E., Susceptibility of domestic swine to experimental infection with SARS-CoV-2. *bioRxiv* **2020**, 2020.09.10.288548. http://biorxiv.org/content/early/2020/09/10/2020.09.10.288548.abstract
545. Pigoga, J. L.; Friedman, A.; Broccoli, M.; Hirner, S.; Naidoo, A. V.; Singh, S.; Werner, K.; Wallis, L. A., Clinical and historical features associated with severe COVID-19 infection: a systematic review. *medRxiv* **2020**, 2020.04.23.20076653. https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20076653.full.pdf
546. Piroth, L.; Cottenet, J.; Mariet, A.-S.; Bonniaud, P.; Blot, M.; Tubert-Bitter, P.; Quantin, C., Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. *The Lancet Respiratory Medicine* **2020**. https://doi.org/10.1016/S2213-2600(20)30527-0
547. Pitman-Hunt, C.; Leja, J.; Jiwani, Z. M.; Rondot, D.; Ang, J.; Kannikeswaran, N., SARS-CoV-2 Transmission in an Urban Community: The Role of Children and Household Contacts. *Journal of the Pediatric Infectious Diseases Society* **2020**. https://doi.org/10.1093/jpids/piaa158
548. Plante, J. A.; Liu, Y.; Liu, J.; Xia, H.; Johnson, B. A.; Lokugamage, K. G.; Zhang, X.; Muruato, A. E.; Zou, J.; Fontes-Garfias, C. R.; Mirchandani, D.; Scharton, D.; Bilello, J. P.; Ku, Z.; An, Z.; Kalveram, B.; Freiberg, A. N.; Menachery, V. D.; Xie, X.; Plante, K. S.; Weaver, S. C.; Shi, P.-Y., Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. *bioRxiv* **2020**, 2020.09.01.278689. http://biorxiv.org/content/early/2020/09/02/2020.09.01.278689.abstract

549. Plante, J. A.; Liu, Y.; Liu, J.; Xia, H.; Johnson, B. A.; Lokugamage, K. G.; Zhang, X.; Muruato, A. E.; Zou, J.; Fontes-Garfias, C. R.; Mirchandani, D.; Scharton, D.; Bilello, J. P.; Ku, Z.; An, Z.; Kalveram, B.; Freiberg, A. N.; Menachery, V. D.; Xie, X.; Plante, K. S.; Weaver, S. C.; Shi, P. Y., Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* **2020**.
550. Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Pérez Marc, G.; Moreira, E. D.; Zerbini, C.; Bailey, R.; Swanson, K. A.; Roychoudhury, S.; Koury, K.; Li, P.; Kalina, W. V.; Cooper, D.; Frenck, R. W.; Hammitt, L. L.; Türeci, Ö.; Nell, H.; Schaefer, A.; Ünal, S.; Tresnan, D. B.; Mather, S.; Dormitzer, P. R.; Şahin, U.; Jansen, K. U.; Gruber, W. C., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* **2020,** *383* (27), 2603-2615. https://www.nejm.org/doi/full/10.1056/NEJMoa2034577
551. Pollán, M.; Pérez-Gómez, B.; Pastor-Barriuso, R.; al., e., Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31483-5
552. Popa, A.; Genger, J.-W.; Nicholson, M. D.; Penz, T.; Schmid, D.; Aberle, S. W.; Agerer, B.; Lercher, A.; Endler, L.; Colaço, H.; Smyth, M.; Schuster, M.; Grau, M. L.; Martínez-Jiménez, F.; Pich, O.; Borena, W.; Pawelka, E.; Keszei, Z.; Senekowitsch, M.; Laine, J.; Aberle, J. H.; Redlberger-Fritz, M.; Karolyi, M.; Zoufaly, A.; Maritschnik, S.; Borkovec, M.; Hufnagl, P.; Nairz, M.; Weiss, G.; Wolfinger, M. T.; von Laer, D.; Superti-Furga, G.; Lopez-Bigas, N.; Puchhammer-Stöckl, E.; Allerberger, F.; Michor, F.; Bock, C.; Bergthaler, A., Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. *Science Translational Medicine* **2020**, eabe2555. https://stm.sciencemag.org/content/scitransmed/early/2020/11/20/scitranslmed.abe2555.full.pdf
553. Poston, D.; Weisblum, Y.; Wise, H.; Templeton, K.; Jenks, S.; Hatziioannou, T.; Bieniasz, P. D., Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection. *medRxiv* **2020**, 2020.10.08.20209650. https://www.medrxiv.org/content/medrxiv/early/2020/10/11/2020.10.08.20209650.full.pdf
554. Potter, D.; Riffon, M.; Kakamada, S.; Miller, R. S.; Komatsoulis, G. A., Disproportionate impact of COVID-19 disease among racial and ethnic minorities in the U.S. cancer population as seen in CancerLinQ Discovery data. *Journal of Clinical Oncology* **2020,** *38* (29_suppl), 84-84. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.29_suppl.84
555. Prentiss, M.; Chu, A.; Berggren, K. K., Superspreading Events Without Superspreaders: Using High Attack Rate Events to Estimate N_º for Airborne Transmission of COVID-19. *medRxiv* **2020**, 2020.10.21.20216895. https://www.medrxiv.org/content/medrxiv/early/2020/10/23/2020.10.21.20216895.full.pdf
556. Press, A., Finland deploys coronavirus-sniffing dogs at main airport. https://www.msn.com/en-us/news/world/finland-deploys-coronavirus-sniffing-dogs-at-main-airport/ar-BB19li6Z?li=BBnbcA1 (accessed 23 SEP 2020).
557. Price-Haywood, E. G.; Burton, J.; Fort, D.; Seoane, L., Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMsa2011686
558. Qin, J.; You, C.; Lin, Q.; Hu, T.; Yu, S.; Zhou, X., Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. *Science Advances* **2020,** *07 Aug 2020*. https://advances.sciencemag.org/content/early/2020/08/07/sciadv.abc1202
559. Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(20)30198-5
560. Rahimi, N. R.; Fouladi-Fard, R.; Aali, R.; Shahryari, A.; Rezaali, M.; Ghafouri, Y.; Ghalhari, M. R.; Ghalhari, M. A.; Farzinnia, B.; Fiore, M.; Gea, O. C., Bidirectional Association Between COVID-19 and the

Environment: a Systematic Review. *Environmental Research* **2020**, 110692. http://www.sciencedirect.com/science/article/pii/S0013935120315917
561. Rai, B.; Shukla, A.; Dwivedi, L. K., Estimates of serial interval for COVID-19: A systematic review and meta-analysis. *Clinical Epidemiology and Global Health* **2020**. http://www.sciencedirect.com/science/article/pii/S2213398420301895
562. Rajasingham, R.; Bangdiwala, A. S.; Nicol, M. R.; Skipper, C. P.; Pastick, K. A.; Axelrod, M. L.; Pullen, M. F.; Nascene, A. A.; Williams, D. A.; Engen, N. W.; Okafor, E. C.; Rini, B. I.; Mayer, I. A.; McDonald, E. G.; Lee, T. C.; Li, P.; MacKenzie, L. J.; Balko, J. M.; Dunlop, S. J.; Hullsiek, K. H.; Boulware, D. R.; Lofgren, S. M.; team, o. b. o. t. C. P., Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1571
563. Ramasamy, M. N.; Minassian, A. M.; Ewer, K. J.; al., e., Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet* **2020**. http://www.sciencedirect.com/science/article/pii/S0140673620324661
564. Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020. http://virological.org/t/phylodynamic-analysis-of-ncov-2019-genomes-27-jan-2020/353.
565. Rambaut, A.; Nick Loman2; Oliver Pybus3; Wendy Barclay4; Jeff Barrett5; Alesandro Carabelli6; Tom Connor7; Tom Peacock4; David L Robertson8; Erik Volz4; (CoG-UK)9., C.-G. C. U., Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.
566. Rapid Expert Consultation, *Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020)*. The National Academies Press: Washington, DC, 2020. https://www.nap.edu/read/25763/chapter/1
567. Rapkiewicz, A. V.; Mai, X.; Carsons, S. E.; Pittaluga, S.; Kleiner, D. E.; Berger, J. S.; Thomas, S.; Adler, N. M.; Charytan, D. M.; Gasmi, B.; Hochman, J. S.; Reynolds, H. R., Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *EClinicalMedicine* **2020**, 100434. http://www.sciencedirect.com/science/article/pii/S2589537020301784
568. Rasheed, A. M.; Fatak, D. F.; Hashim, H. A.; Maulood, M. F.; Kabah, K. K.; Almusawi, Y. A.; Abdulamir, A. S., The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *Infez Med* **2020,** *28* (3), 357-366.
569. Ratnesar-Shumate, S.; Williams, G.; Green, B.; Krause, M.; Holland, B.; Wood, S.; Bohannon, J.; Boydston, J.; Freeburger, D.; Hooper, I.; Beck, K.; Yeager, J.; Altamura, L. A.; Biryukov, J.; Yolitz, J.; Schuit, M.; Wahl, V.; Hevey, M.; Dabisch, P., Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa274
570. Ray, J. G.; Schull, M. J.; Vermeulen, M. J.; Park, A. L., Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness : A Population-Based Cohort Study. *Ann Intern Med* **2020**. https://www.acpjournals.org/doi/abs/10.7326/M20-4511
571. Regeneron, REGN-COV2 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS HOLDING ENROLLMENT IN HOSPITALIZED PATIENTS WITH HIGH OXYGEN REQUIREMENTS AND CONTINUING ENROLLMENT IN PATIENTS WITH LOW OR NO OXYGEN REQUIREMENTS. Regeneron: 2020. https://investor.regeneron.com/news-releases/news-release-details/regn-cov2-independent-data-monitoring-committee-recommends
572. Regeneron Pharmaceuticals, I., REGENERON'S REGN-COV2 ANTIBODY COCKTAIL REDUCED VIRAL LEVELS AND IMPROVED SYMPTOMS IN NON-HOSPITALIZED COVID-19 PATIENTS. 2020; p 3. https://newsroom.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and

573. Regeneron Pharmaceuticals, I., REGENERON'S CASIRIVIMAB AND IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 IS FIRST COMBINATION THERAPY TO RECEIVE FDA EMERGENCY USE AUTHORIZATION. 2020. https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive
574. Reich, N., Ensemble. https://reichlab.io/.
575. Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)30627-9
576. Ren, L.; Yu, S.; Xu, W.; Overton, J. L.; Chiamvimonvat, N.; Thai, P. N., Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. *J Cardiol* **2020**.
577. Ren, X.; Li, Y.; Yang, X.; Li, Z.; Cui, J.; Zhu, A.; Zhao, H.; Yu, J.; Nie, T.; Ren, M.; Dong, S.; Cheng, Y.; Chen, Q.; Chang, Z.; Sun, J.; Wang, L.; Feng, L.; Gao, G. F.; Feng, Z.; Li, Z., Evidence for pre-symptomatic transmission of coronavirus disease 2019 (COVID-19) in China. *Influenza and Other Respiratory Viruses* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12787
578. Reuters, Frozen food package polluted by living coronavirus could cause infection, China's CDC says. https://www.reuters.com/article/us-health-coronavirus-china-packaging-idUKKBN2720MD (accessed 01 Nov 2020).
579. Reuters, WHO looks at mink farm biosecurity globally after Danish coronavirus cases. Farge, E.; Kelland, K., Eds. 2020. https://in.reuters.com/article/health-coronavirus-who/who-looking-at-biosecurity-in-other-countries-after-danish-covid-19-mink-outbreak-idINKBN27M1F4?il=0
580. RIBSP, Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine. https://clinicaltrials.gov/ct2/show/NCT04691908.
581. Rice, K.; Wynne, B.; Martin, V.; Ackland, G. J., Effect of school closures on mortality from coronavirus disease 2019: old and new predictions. *BMJ* **2020,** *371*, m3588. https://www.bmj.com/content/bmj/371/bmj.m3588.full.pdf
582. Richard, M.; Kok, A.; de Meulder, D.; Bestebroer, T. M.; Lamers, M. M.; Okba, N. M. A.; Fentener van Vlissingen, M.; Rockx, B.; Haagmans, B. L.; Koopmans, M. P. G.; Fouchier, R. A. M.; Herfst, S., SARS-CoV-2 is transmitted via contact and via the air between ferrets. *Nature Communications* **2020,** *11* (1), 3496. https://doi.org/10.1038/s41467-020-17367-2
583. Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. http://wayback.archive-it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf
584. Rickman, H. M.; Rampling, T.; Shaw, K.; Martinez-Garcia, G.; Hail, L.; Coen, P.; Shahmanesh, M.; Shin, G. Y.; Nastouli, E.; Houlihan, C. F., Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa816
585. Riddell, S.; Goldie, S.; Hill, A.; Eagles, D.; Drew, T. W., The effect of temperature on persistence of SARS-CoV-2 on common surfaces. *Virology Journal* **2020,** *17* (1), 145. https://doi.org/10.1186/s12985-020-01418-7
586. Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020,** *25* (4), 2000058. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058
587. Riphagen, S.; Gomez, X.; Gonzalez-Martinez, C.; Wilkinson, N.; Theocharis, P., Hyperinflammatory shock in children during COVID-19 pandemic. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)31094-1
588. Roberts, M., Oxford/AstraZeneca Covid vaccine 'dose error' explained. https://www.bbc.com/news/health-55086927.

589. Robertson, L. J.; Moore, J. S.; Blighe, K.; Ng, K. Y.; Quinn, N.; Jennings, F.; Warnock, G.; Sharpe, P.; Clarke, M.; Maguire, K.; Rainey, S.; Price, R.; Burns, W.; Kowalczyk, A.; Awuah, A.; McNamee, S.; Wallace, G.; Sager, S.; Chao Shern, C.; Nesbit, M. A.; McLaughlin, J.; Moore, T., SARS-CoV-2 antibody testing in a UK population: detectable IgG for up to 20 weeks post infection. *medRxiv* **2020**, 2020.09.29.20201509. https://www.medrxiv.org/content/medrxiv/early/2020/10/01/2020.09.29.20201509.full.pdf
590. Rocco, P. R. M.; Silva, P. L.; Cruz, F. F.; Junior, M.; Tierno, P.; Moura, M. A.; De Oliveira, L. F. G.; Lima, C. C.; Dos Santos, E. A.; Junior, W. F.; Fernandes, A.; Franchini, K. G.; Magri, E.; de Moraes, N. F.; Gonçalves, J. M. J.; Carbonieri, M. N.; Dos Santos, I. S.; Paes, N. F.; Maciel, P. V. M.; Rocha, R. P.; de Carvalho, A. F.; Alves, P. A.; Modena, J. L. P.; Cordeiro, A. T.; Trivella, D. B. B.; Marques, R. E.; Luiz, R. R.; Pelosi, P.; Lapa, E. S. J. R., Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. *Eur Respir J* **2020**.
591. Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M. M.; Oude Munnink, B. B.; de Meulder, D.; van Amerongen, G.; van den Brand, J.; Okba, N. M. A.; Schipper, D.; van Run, P.; Leijten, L.; Sikkema, R.; Verschoor, E.; Verstrepen, B.; Bogers, W.; Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R.; Koopmans, M.; Haagmans, B. L., Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* **2020**, eabb7314. https://science.sciencemag.org/content/sci/early/2020/04/16/science.abb7314.full.pdf
592. Rodda, L. B.; Netland, J.; Shehata, L.; Pruner, K. B.; Morawski, P. M.; Thouvenel, C.; Takehara, K. K.; Eggenberger, J.; Hemann, E. A.; Waterman, H. R.; Fahning, M. L.; Chen, Y.; Rathe, J.; Stokes, C.; Wrenn, S.; Fiala, B.; Carter, L. P.; Hamerman, J. A.; King, N. P.; Gale, M.; Campbell, D. J.; Rawlings, D.; Pepper, M., Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *medRxiv* **2020**, 2020.08.11.20171843. https://www.medrxiv.org/content/medrxiv/early/2020/08/15/2020.08.11.20171843.full.pdf
593. Rokkas, T., Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. *Annals of Gastroenterology* **2020,** *33* (4), 355-365. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315709/
594. Rolfes, M. A.; Grijalva, C. G.; Zhu, Y.; al., e., Implications of Shortened Quarantine Among Household Contacts of Index Patients with Confirmed SARS-CoV-2 Infection — Tennessee and Wisconsin, April–September 2020. *Morbidity and Mortality Weekly Report* **2021,** *2021* (69), 1633-1637. https://www.cdc.gov/mmwr/volumes/69/wr/mm695152a1.htm
595. Roschewski, M.; Lionakis, M. S.; Sharman, J. P.; Roswarski, J.; Goy, A.; Monticelli, M. A.; Roshon, M.; Wrzesinski, S. H.; Desai, J. V.; Zarakas, M. A.; Collen, J.; Rose, K.; Hamdy, A.; Izumi, R.; Wright, G. W.; Chung, K. K.; Baselga, J.; Staudt, L. M.; Wilson, W. H., Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Science Immunology* **2020,** *5* (48), eabd0110. http://immunology.sciencemag.org/content/5/48/eabd0110.abstract
596. Rosenke, K.; Meade-White, K.; Letko, M.; Clancy, C.; Hansen, F.; Liu, Y.; Okumura, A.; Tang-Huau, T.-L.; Li, R.; Saturday, G.; Feldmann, F.; Scott, D.; Wang, Z.; Munster, V.; Jarvis, M. A.; Feldmann, H., Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. *Emerging Microbes & Infections* **2020**, 1-36. https://doi.org/10.1080/22221751.2020.1858177
597. Ross, C., CDC says people with history of severe allergic reactions can get Covid-19 vaccine. https://www.statnews.com/2020/12/13/cdc-says-people-with-history-of-severe-allergic-reactions-can-get-covid-19-vaccine/.
598. Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirglmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001468 https://www.nejm.org/doi/10.1056/NEJMc2001468

599. Ruktanonchai, N. W.; Floyd, J. R.; Lai, S.; Ruktanonchai, C. W.; Sadilek, A.; Rente-Lourenco, P.; Ben, X.; Carioli, A.; Gwinn, J.; Steele, J. E.; Prosper, O.; Schneider, A.; Oplinger, A.; Eastham, P.; Tatem, A. J., Assessing the impact of coordinated COVID-19 exit strategies across Europe. *Science* **2020**, eabc5096. https://science.sciencemag.org/content/sci/early/2020/07/16/science.abc5096.full.pdf
600. Rundle, A., Severe COVID-19 Risk Mapping. https://columbia.maps.arcgis.com/apps/webappviewer/index.html?id=ade6ba85450c4325a12a5b9c09ba796c.
601. Russell, T. W.; Wu, J. T.; Clifford, S.; Edmunds, W. J.; Kucharski, A. J.; Jit, M., Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. *The Lancet Public Health* **2020**. https://doi.org/10.1016/S2468-2667(20)30263-2
602. RUSSO, R.; Levine, C.; Veilleux, C.; Peixoto, B.; McCormick-Ell, J.; Block, T.; Gresko, A.; Delmas, G.; Chitale, P.; Frees, A.; Ruiz, A.; Alland, D., Decontaminating N95 respirators during the Covid-19 pandemic: simple and practical approaches to increase decontamination capacity, speed, safety and ease of use. *medRxiv* **2020**, 2020.08.17.20177022. https://www.medrxiv.org/content/medrxiv/early/2020/08/21/2020.08.17.20177022.full.pdf
603. Ryan, D. J.; Toomey, S.; Madden, S. F.; Casey, M.; Breathnach, O. S.; Morris, P. G.; Grogan, L.; Branagan, P.; Costello, R. W.; De Barra, E.; Hurley, K.; Gunaratnam, C.; McElvaney, N. G.; OBrien, M. E.; Sulaiman, I.; Morgan, R. K.; Hennessy, B. T., Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19). *Thorax* **2020**, thoraxjnl-2020-215705. https://thorax.bmj.com/content/thoraxjnl/early/2020/10/23/thoraxjnl-2020-215705.full.pdf
604. Ryan, K. A.; Bewley, K. R.; Fotheringham, S. A.; Brown, P.; Hall, Y.; Marriott, A. C.; Tree, J. A.; Allen, L.; Aram, M. J.; Brunt, E.; Buttigieg, K. R.; Cavell, B. E.; Carter, D. P.; Cobb, R.; Coombes, N. S.; Godwin, K. J.; Gooch, K. E.; Gouriet, J.; Halkerston, R.; Harris, D. J.; Humphries, H. E.; Hunter, L.; Ho, C. M. K.; Kennard, C. L.; Leung, S.; Ngabo, D.; Osman, K. L.; Paterson, J.; Penn, E. J.; Pullan, S. T.; Rayner, E.; Slack, G. S.; Steeds, K.; Taylor, I.; Tipton, T.; Thomas, S.; Wand, N. I.; Watson, R. J.; Wiblin, N. R.; Charlton, S.; Hallis, B.; Hiscox, J. A.; Funnell, S.; Dennis, M. J.; Whittaker, C. J.; Catton, M. G.; Druce, J.; Salguero, F. J.; Carroll, M. W., Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge. *bioRxiv* **2020**, 2020.05.29.123810. https://www.biorxiv.org/content/biorxiv/early/2020/05/29/2020.05.29.123810.full.pdf
605. Saeed, O.; Castagna, F.; Agalliu, I.; Xue, X.; Patel, S. R.; Rochlani, Y.; Kataria, R.; Vukelic, S.; Sims, D. B.; Alvarez, C.; Rivas-Lasarte, M.; Garcia, M. J.; Jorde, U. P., Statin Use and In-Hospital Mortality in Diabetics with COVID-19. *J Am Heart Assoc* **2020**, e018475.
606. Safewell, SafeSpace. https://www.safewellsolutions.co.uk/products/safespace/ (accessed 10 Oct 2020).
607. Sakoulas, G.; Geriak, M.; Kullar, R.; Greenwood, K. L.; Habib, M.; Vyas, A.; Ghafourian, M.; Dintyala, V. N. K.; Haddad, F., Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019. *Crit Care Explor* **2020,** *2* (11), e0280.
608. Salama, C.; Han, J.; Yau, L.; Reiss, W. G.; Kramer, B.; Neidhart, J. D.; Criner, G. J.; Kaplan-Lewis, E.; Baden, R.; Pandit, L.; Cameron, M. L.; Garcia-Diaz, J.; Chávez, V.; Mekebeb-Reuter, M.; Lima de Menezes, F.; Shah, R.; González-Lara, M. F.; Assman, B.; Freedman, J.; Mohan, S. V., Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *New England Journal of Medicine* **2020**. https://doi.org/10.1056/NEJMoa2030340
609. Salazar, E.; Christensen, P. A.; Graviss, E. A.; Nguyen, D. T.; Castillo, B.; Chen, J.; Lopez, B. V.; Eagar, T. N.; Yi, X.; Zhao, P.; Rogers, J.; Shehabeldin, A.; Joseph, D.; Masud, F.; Leveque, C.; Olsen, R. J.; Bernard, D. W.; Gollihar, J.; Musser, J. M., Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG. *The American Journal of Pathology* **2020**. http://www.sciencedirect.com/science/article/pii/S0002944020304892

610. Sanchez, G. V.; Biedron, C.; Fink, L. R.; al., e., Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities — Detroit, Michigan, March–May 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 1 July 2020*. https://www.cdc.gov/mmwr/volumes/69/wr/mm6927e1.htm?s_cid=mm6927e1_w#suggestedcitation
611. Sandhu, T.; Tieng, A.; Chilimuri, S.; Franchin, G., A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. *Can J Infect Dis Med Microbiol* **2020,** *2020*, 8865954.
612. Santarpia, J. L.; Rivera, D. N.; Herrera, V.; Morwitzer, M. J.; Creager, H.; Santarpia, G. W.; Crown, K. K.; Brett-Major, D.; Schnaubelt, E.; Broadhurst, M. J.; Lawler, J. V.; Reid, S. P.; Lowe, J. J., Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. *medRxiv* **2020**, 2020.03.23.20039446. https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.23.20039446.1.full.pdf
613. Schlottau, K.; Rissmann, M.; Graaf, A.; Schön, J.; Sehl, J.; Wylezich, C.; Höper, D.; Mettenleiter, T. C.; Balkema-Buschmann, A.; Harder, T.; Grund, C.; Hoffmann, D.; Breithaupt, A.; Beer, M., SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. *The Lancet Microbe* **2020**. https://doi.org/10.1016/S2666-5247(20)30089-6
614. Schnirring, L., New coronavirus infects health workers, spreads to Korea. http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workers-spreads-korea.
615. Schuit, M.; Ratnesar-Shumate, S.; Yolitz, J.; Williams, G.; Weaver, W.; Green, B.; Miller, D.; Krause, M.; Beck, K.; Wood, S.; Holland, B.; Bohannon, J.; Freeburger, D.; Hooper, I.; Biryukov, J.; Altamura, L. A.; Wahl, V.; Hevey, M.; Dabisch, P., Airborne SARS-CoV-2 is Rapidly Inactivated by Simulated Sunlight. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa334
616. Sciences, C. A. o. M., The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. https://clinicaltrials.gov/ct2/show/NCT04659239.
617. Self, W. H.; Semler, M. W.; Leither, L. M.; Casey, J. D.; Angus, D. C.; Brower, R. G.; Chang, S. Y.; Collins, S. P.; Eppensteiner, J. C.; Filbin, M. R.; Files, D. C.; Gibbs, K. W.; Ginde, A. A.; Gong, M. N.; Harrell, F. E., Jr; Hayden, D. L.; Hough, C. L.; Johnson, N. J.; Khan, A.; Lindsell, C. J.; Matthay, M. A.; Moss, M.; Park, P. K.; Rice, T. W.; Robinson, B. R. H.; Schoenfeld, D. A.; Shapiro, N. I.; Steingrub, J. S.; Ulysse, C. A.; Weissman, A.; Yealy, D. M.; Thompson, B. T.; Brown, S. M.; National Heart, L.; Network, B. I. P. C. T., Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.22240
618. Self, W. H.; Tenforde, M. W.; Stubblefield, W. B.; Feldstein, L. R.; Steingrub, J. S.; Shapiro, N. I.; Ginde, A. A.; Prekker, M. E.; Brown, S. M.; Peltan, I. D.; Gong, M. N.; Aboodi, M. S.; Khan, A.; Exline, M. C.; Files, D. C.; Gibbs, K. W.; Lindsell, C. J.; Rice, T. W.; Jones, I. D.; Halasa, N.; Talbot, H. K.; Grijalva, C. G.; Casey, J. D.; Hager, D. N.; Qadir, N.; Henning, D. J.; Coughlin, M. M.; Schiffer, J.; Semenova, V.; Li, H.; Thornburg, N. J.; Patel, M. M., Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6947a2.htm?s_cid=mm6947a2_w.
619. Seow, J.; Graham, C.; Merrick, B.; Acors, S.; Steel, K. J. A.; Hemmings, O.; O'Bryne, A.; Kouphou, N.; Pickering, S.; Galao, R.; Betancor, G.; Wilson, H. D.; Signell, A. W.; Winstone, H.; Kerridge, C.; Temperton, N.; Snell, L.; Bisnauthsing, K.; Moore, A.; Green, A.; Martinez, L.; Stokes, B.; Honey, J.; Izquierdo-Barras, A.; Arbane, G.; Patel, A.; OConnell, L.; O Hara, G.; MacMahon, E.; Douthwaite, S.; Nebbia, G.; Batra, R.; Martinez-Nunez, R.; Edgeworth, J. D.; Neil, S. J. D.; Malim, M. H.; Doores, K., Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv* **2020**, 2020.07.09.20148429. https://www.medrxiv.org/content/medrxiv/early/2020/07/11/2020.07.09.20148429.full.pdf
620. sermet, i.; temmam, s.; huon, c.; behillil, s.; gadjos, v.; bigot, t.; lurier, t.; chretien, d.; backovick, m.; Moisan-Delaunay, A.; donati, f.; albert, m.; foucaud, e.; Mesplees, B.; benoist, g.; fayes, a.; duval-

arnould, m.; cretolle, c.; charbit, m.; aubart, m.; Auriau, J.; lorrot, m.; Kariyawasam, D.; fertita, l.; Orliaguet, G.; pigneur, b.; Bader-Meunier, B.; briand, c.; toubiana, j.; Guilleminot, T.; van der werf, s.; leruez-ville, m.; eloit, m., Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated Multisystem Inflammatory Syndrome in children. *medRxiv* **2020**, 2020.06.29.20142596.
https://www.medrxiv.org/content/medrxiv/early/2020/06/30/2020.06.29.20142596.full.pdf
621. Services, I. o. M. a. L., REALM Project Releases Results from Latest Tests of Coronavirus on Leather, Summary of Research. https://www.imls.gov/news/realm-project-releases-results-latest-tests-coronavirus-leather-summary-research.
622. Shacham, E.; Scroggins, S.; Ellis, M.; Garza, A., Association of County-Wide Mask Ordinances with Reductions in Daily CoVID-19 Incident Case Growth in a Midwestern Region Over 12 Weeks. *medRxiv* **2020**, 2020.10.28.20221705.
https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20221705.full.pdf
623. Shan, B.; Broza, Y. Y.; Li, W.; Wang, Y.; Wu, S.; Liu, Z.; Wang, J.; Gui, S.; Wang, L.; Zhang, Z.; Liu, W.; Zhou, S.; Jin, W.; Zhang, Q.; Hu, D.; Lin, L.; Zhang, Q.; Li, W.; Wang, J.; Liu, H.; Pan, Y.; Haick, H., Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath. *ACS Nano* **2020**. https://doi.org/10.1021/acsnano.0c05657
624. Shekerdemian, L. S.; Mahmood, N. R.; Wolfe, K. K.; Riggs, B. J.; Ross, C. E.; McKiernan, C. A.; Heidemann, S. M.; Kleinman, L. C.; Sen, A. I.; Hall, M. W.; Priestley, M. A.; McGuire, J. K.; Boukas, K.; Sharron, M. P.; Burns, J. P.; Collaborative, f. t. I. C.-P., Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatrics* **2020**. https://doi.org/10.1001/jamapediatrics.2020.1948
625. Shen, M.; Zu, J.; Fairley, C. K.; Pagán, J. A.; An, L.; Du, Z.; Guo, Y.; Rong, L.; Xiao, Y.; Zhuang, G.; Li, Y.; Zhang, L., Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use. *medRxiv* **2020**, 2020.10.28.20221234.
https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20221234.full.pdf
626. Shepardson, D., U.S. CDC issues 'strong recommendation' for mask mandate on airplanes, trains. *Reuters* 2020. https://ca.reuters.com/article/instant-article/idUSL1N2HA24V
627. Sherina, N.; Piralla, A.; Du, L.; Wan, H.; Kumagai-Braesh, M.; Andrell, J.; Braesch-Andersen, S.; Cassaniti, I.; Percivalle, E.; Sarasini, A.; Bergami, F.; Di Martino, R.; Colaneri, M.; Vecchia, M.; Sambo, M.; Zuccaro, V.; Bruno, R.; Oggionni, T.; Meloni, F.; Abolhassani, H.; Bertoglio, F.; Schubert, M.; Byrne-Steele, M.; Han, J.; Hust, M.; Xue, Y.; Hammarstrom, L.; Baldanti, F.; Marcotte, H.; Pan-Hammarstrom, Q., Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection. *bioRxiv* **2020**, 2020.11.06.371617.
https://www.biorxiv.org/content/biorxiv/early/2020/11/06/2020.11.06.371617.full.pdf
628. Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science* **2020**, eabb7015.
https://science.sciencemag.org/content/sci/early/2020/04/07/science.abb7015.full.pdf
629. Shi, Q.; Hu, Y.; Peng, B.; Tang, X.-J.; Wang, W.; Su, K.; Luo, C.; Wu, B.; Zhang, F.; Zhang, Y.; Anderson, B.; Zhong, X.-N.; Qiu, J.-F.; Yang, C. Y.; Huang, A.-L., Effective control of SARS-CoV-2 transmission in Wanzhou, China. *Nature Medicine* **2020**. https://doi.org/10.1038/s41591-020-01178-5
630. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* **2020**. https://doi.org/10.1001/jamacardio.2020.0950

631. Sia, S. F.; Yan, L. M.; Chin, A. W. H.; Fung, K.; Choy, K. T.; Wong, A. Y. L.; Kaewpreedee, P.; Perera, R.; Poon, L. L. M.; Nicholls, J. M.; Peiris, M.; Yen, H. L., Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **2020**.
632. Silcott, D.; Kinahan, S.; Santarpia, J.; Silcott, B.; Silcott, R.; Silcott, P.; Silcott, B.; Distelhorst, S.; Herrera, V.; Rivera, D.; Crown, K.; Lucero, G.; Bryden, W.; McLoughlin, M.; Cetta, M.; Accardi, R., *TRANSCOM/AMC Commercial Aircraft Cabin Aerosol Dispersion Tests*; USATRANSCOM and AMC: 2020. https://www.ustranscom.mil/cmd/docs/TRANSCOM%20Report%20Final.pdf
633. Simmons, S.; Carrion, R.; Alfson, K.; Staples, H.; Jinadatha, C.; Jarvis, W.; Sampathkumar, P.; Chemaly, R. F.; Khawaja, F.; Povroznik, M.; Jackson, S.; Kaye, K. S.; Rodriguez, R. M.; Stibich, M., Deactivation of SARS-CoV-2 with Pulsed Xenon Ultraviolet: implications for environmental COVID-19 control. *Infection Control & Hospital Epidemiology* **2020**, 1-19. https://www.cambridge.org/core/article/deactivation-of-sarscov2-with-pulsed-xenon-ultraviolet-implications-for-environmental-covid19-control/AD5CF52419E27E86E0114059FBA78D4C
634. Simonovich, V. A.; Burgos Pratx, L. D.; Scibona, P.; Beruto, M. V.; Vallone, M. G.; Vázquez, C.; Savoy, N.; Giunta, D. H.; Pérez, L. G.; Sánchez, M. D. L.; Gamarnik, A. V.; Ojeda, D. S.; Santoro, D. M.; Camino, P. J.; Antelo, S.; Rainero, K.; Vidiella, G. P.; Miyazaki, E. A.; Cornistein, W.; Trabadelo, O. A.; Ross, F. M.; Spotti, M.; Funtowicz, G.; Scordo, W. E.; Losso, M. H.; Ferniot, I.; Pardo, P. E.; Rodriguez, E.; Rucci, P.; Pasquali, J.; Fuentes, N. A.; Esperatti, M.; Speroni, G. A.; Nannini, E. C.; Matteaccio, A.; Michelangelo, H. G.; Follmann, D.; Lane, H. C.; Belloso, W. H., A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med* **2020**.
635. Simpson, J. N.; Goyal, M. K.; Cohen, J. S.; Badolato, G. M.; McGuire, M.; Ralph, A.; Boyle, M. D.; Hamburger, E. K.; Gorman, K. C.; Cora-Bramble, D.; Delaney, M., Results of Testing Children for SARS-CoV-2 through a Community-based Testing Site. *The Journal of Pediatrics* **2020**. http://www.sciencedirect.com/science/article/pii/S0022347620315122
636. Singh, K.; Mittal, S.; Gollapudi, S.; Butzmann, A.; Kumar, J.; Ohgami, R. S., A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. *International Journal of Laboratory Hematology n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/ijlh.13354
637. Sinovac, Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=covid-19&draw=2&rank=1.
638. Sit, T. H. C.; Brackman, C. J.; Ip, S. M.; Tam, K. W. S.; Law, P. Y. T.; To, E. M. W.; Yu, V. Y. T.; Sims, L. D.; Tsang, D. N. C.; Chu, D. K. W.; Perera, R.; Poon, L. L. M.; Peiris, M., Infection of dogs with SARS-CoV-2. *Nature* **2020**.
639. Skalina, K. A.; Goldstein, D. Y.; Sulail, J.; Hahm, E.; Narlieva, M.; Szymczak, W.; Fox, A. S., Extended Storage of SARS-CoV2 Nasopharyngeal Swabs Does Not Negatively Impact Results of Molecular-Based Testing. *medRxiv* **2020**, 2020.05.16.20104158. https://www.medrxiv.org/content/medrxiv/early/2020/05/20/2020.05.16.20104158.full.pdf
640. Smarr, B. L.; Aschbacher, K.; Fisher, S. M.; Chowdhary, A.; Dilchert, S.; Puldon, K.; Rao, A.; Hecht, F. M.; Mason, A. E., Feasibility of continuous fever monitoring using wearable devices. *Scientific Reports* **2020,** *10* (1), 21640. https://doi.org/10.1038/s41598-020-78355-6
641. Sobel Leonard, A.; Weissman, D. B.; Greenbaum, B.; Ghedin, E.; Koelle, K., Transmission Bottleneck Size Estimation from Pathogen Deep-Sequencing Data, with an Application to Human Influenza A Virus. *Journal of Virology* **2017,** *91* (14), e00171-17. https://jvi.asm.org/content/jvi/91/14/e00171-17.full.pdf
642. Song, J.-Y.; Yun, J.-G.; Noh, J.-Y.; Cheong, H.-J.; Kim, W.-J., Covid-19 in South Korea — Challenges of Subclinical Manifestations. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001801

643. Soni, M., Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. *International Journal of Laboratory Hematology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/ijlh.13425
644. Ssentongo, A. E.; Ssentongo, P.; Heilbrunn, E. S.; Lekoubou, A.; Du, P.; Liao, D.; Oh, J. S.; Chinchilli, V. M., Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. *Open Heart* **2020,** *7* (2), e001353. http://openheart.bmj.com/content/7/2/e001353.abstract
645. Stadnytskyi, V.; Bax, C. E.; Bax, A.; Anfinrud, P., The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. *Proceedings of the National Academy of Sciences* **2020**, 202006874. https://www.pnas.org/content/pnas/early/2020/05/12/2006874117.full.pdf
646. Staff, G. B., Originally Built for Bioterrorism Agents, This Decontamination System Now Clears SARS-CoV-2 from Military Aircraft. *Global Biodefense* 2020. https://globalbiodefense.com/2020/11/05/military-aircraft-sars-cov-2-sanitization-with-hot-air-system/
647. Sterne, J. A. C.; Murthy, S.; Diaz, J. V.; Slutsky, A. S.; Villar, J.; Angus, D. C.; Annane, D.; Azevedo, L. C. P.; Berwanger, O.; Cavalcanti, A. B.; Dequin, P. F.; Du, B.; Emberson, J.; Fisher, D.; Giraudeau, B.; Gordon, A. C.; Granholm, A.; Green, C.; Haynes, R.; Heming, N.; Higgins, J. P. T.; Horby, P.; Jüni, P.; Landray, M. J.; Le Gouge, A.; Leclerc, M.; Lim, W. S.; Machado, F. R.; McArthur, C.; Meziani, F.; Møller, M. H.; Perner, A.; Petersen, M. W.; Savovic, J.; Tomazini, B.; Veiga, V. C.; Webb, S.; Marshall, J. C., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *Jama* **2020**. https://jamanetwork.com/journals/jama/fullarticle/2770279
648. Strohbehn, G. W.; Heiss, B. L.; Rouhani, S. J.; Trujillo, J. A.; Yu, J.; Kacew, A. J.; Higgs, E. F.; Bloodworth, J. C.; Cabanov, A.; Wright, R. C.; Koziol, A. K.; Weiss, A.; Danahey, K.; Karrison, T. G.; Edens, C. C.; Ventura, I. B.; Pettit, N. N.; Patel, B. K.; Pisano, J.; Strek, M. E.; Gajewski, T. F.; Ratain, M. J.; Reid, P. D., COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia. *Clin Pharmacol Ther* **2020**.
649. Su, H.; Yang, M.; Wan, C.; Yi, L.-X.; Tang, F.; Zhu, H.-Y.; Yi, F.; Yang, H.-C.; Fogo, A. B.; Nie, X.; Zhang, C., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. https://doi.org/10.1016/j.kint.2020.04.003
650. Suarez, D. L.; Pantin-Jackwood, M. J.; Swayne, D. E.; Lee, S. A.; DeBlois, S. M.; Spackman, E., Lack of susceptibility of poultry to SARS-CoV-2 and MERS-CoV. *bioRxiv* **2020**, 2020.06.16.154658. http://biorxiv.org/content/early/2020/06/16/2020.06.16.154658.abstract
651. Sugano, N.; Ando, W.; Fukushima, W., Cluster of SARS-CoV-2 infections linked to music clubs in Osaka, Japan: asymptomatically infected persons can transmit the virus as soon as 2 days after infection. *The Journal of Infectious Diseases* **2020**. https://doi.org/10.1093/infdis/jiaa542
652. Sukhyun, R.; Seikh Taslim, A.; Cheolsun, J.; Baekjin, K.; Benjamin, J. C., Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020. *Emerging Infectious Disease journal* **2020,** *26* (10). https://wwwnc.cdc.gov/eid/article/26/10/20-1886_article
653. Sun, J.; Zhu, A.; Li, H.; Zheng, K.; Zhuang, Z.; Chen, Z.; Shi, Y.; Zhang, Z.; Chen, S. B.; Liu, X.; Dai, J.; Li, X.; Huang, S.; Huang, X.; Luo, L.; Wen, L.; Zhuo, J.; Li, Y.; Wang, Y.; Zhang, L.; Zhang, Y.; Li, F.; Feng, L.; Chen, X.; Zhong, N.; Yang, Z.; Huang, J.; Zhao, J.; Li, Y. M., Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. *Emerg Microbes Infect* **2020**, 1-8.
654. Sun, K.; Wang, W.; Gao, L.; Wang, Y.; Luo, K.; Ren, L.; Zhan, Z.; Chen, X.; Zhao, S.; Huang, Y.; Sun, Q.; Liu, Z.; Litvinova, M.; Vespignani, A.; Ajelli, M.; Viboud, C.; Yu, H., Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science* **2020**, eabe2424. https://science.sciencemag.org/content/sci/early/2020/11/23/science.abe2424.full.pdf

655. Sun, S.; Cai, X.; Wang, H.; He, G.; Lin, Y.; Lu, B.; Chen, C.; Pan, Y.; Hu, X., Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta* **2020,** *507*, 174-180. http://www.sciencedirect.com/science/article/pii/S0009898120301790
656. Suthar, M. S.; Zimmerman, M. G.; Kauffman, R. C.; Mantus, G.; Linderman, S. L.; Hudson, W. H.; Vanderheiden, A.; Nyhoff, L.; Davis, C. W.; Adekunle, S.; Affer, M.; Sherman, M.; Reynolds, S.; Verkerke, H. P.; Alter, D. N.; Guarner, J.; Bryksin, J.; Horwath, M.; Arthur, C. M.; Saakadze, N.; Smith, G. H.; Edupuganti, S.; Scherer, E. M.; Hellmeister, K.; Cheng, A.; Morales, J. A.; Neish, A. S.; Stowell, S. R.; Frank, F.; Ortlund, E.; Anderson, E.; Menachery, V. D.; Rouphael, N.; Mehta, A.; Stephens, D. S.; Ahmed, R.; Roback, J. D.; Wrammert, J., Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell Reports Medicine* **2020**. https://doi.org/10.1016/j.xcrm.2020.100040
657. Tabata, S.; Imai, K.; Kawano, S.; Ikeda, M.; Kodama, T.; Miyoshi, K.; Obinata, H.; Mimura, S.; Kodera, T.; Kitagaki, M.; Sato, M.; Suzuki, S.; Ito, T.; Uwabe, Y.; Tamura, K., Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(20)30482-5
658. Takahashi, T.; Ellingson, M. K.; Wong, P.; Israelow, B.; Lucas, C.; Klein, J.; Silva, J.; Mao, T.; Oh, J. E.; Tokuyama, M.; Lu, P.; Venkataraman, A.; Park, A.; Liu, F.; Meir, A.; Sun, J.; Wang, E. Y.; Casanovas-Massana, A.; Wyllie, A. L.; Vogels, C. B. F.; Earnest, R.; Lapidus, S.; Ott, I. M.; Moore, A. J.; Anastasio, K.; Askenase, M. H.; Batsu, M.; Beatty, H.; Bermejo, S.; Bickerton, S.; Brower, K.; Bucklin, M. L.; Cahill, S.; Campbell, M.; Cao, Y.; Courchaine, E.; Datta, R.; DeIuliis, G.; Geng, B.; Glick, L.; Handoko, R.; Kalinich, C.; Khoury-Hanold, W.; Kim, D.; Knaggs, L.; Kuang, M.; Kudo, E.; Lim, J.; Linehan, M.; Lu-Culligan, A.; Malik, A. A.; Martin, A.; Matos, I.; McDonald, D.; Minasyan, M.; Mohanty, S.; Muenker, M. C.; Naushad, N.; Nelson, A.; Nouws, J.; Nunez-Smith, M.; Obaid, A.; Ott, I.; Park, H.-J.; Peng, X.; Petrone, M.; Prophet, S.; Rahming, H.; Rice, T.; Rose, K.-A.; Sewanan, L.; Sharma, L.; Shepard, D.; Silva, E.; Simonov, M.; Smolgovsky, M.; Song, E.; Sonnert, N.; Strong, Y.; Todeasa, C.; Valdez, J.; Velazquez, S.; Vijayakumar, P.; Wang, H.; Watkins, A.; White, E. B.; Yang, Y.; Shaw, A.; Fournier, J. B.; Odio, C. D.; Farhadian, S.; Dela Cruz, C.; Grubaugh, N. D.; Schulz, W. L.; Ring, A. M.; Ko, A. I.; Omer, S. B.; Iwasaki, A.; Yale, I. r. t., Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2700-3
659. Tan, C. W.; Ho, L. P.; Kalimuddin, S.; Cherng, B. P. Z.; Teh, Y. E.; Thien, S. Y.; Wong, H. M.; Tern, P. J. W.; Chandran, M.; Chay, J. W. M.; Nagarajan, C.; Sultana, R.; Low, J. G. H.; Ng, H. J., Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). *Nutrition* **2020,** *79-80*, 111017. http://www.sciencedirect.com/science/article/pii/S0899900720303002
660. Tan, F.; Wang, K.; Liu, J.; Liu, D.; Luo, J.; Zhou, R., Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China. *Frontiers in Medicine* **2020,** *7* (547). https://www.frontiersin.org/article/10.3389/fmed.2020.00547
661. Tenforde, M. W.; Kim, S. S.; Lindsell, C. J.; al., e., Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: 24 July 2020*.
662. The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly* **2020,** *2*, 1-10. http://weekly.chinacdc.cn//article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51
663. Thomas, P.; Alexander, P. E.; Ahmed, U.; Elderhorst, E.; El-Khechen, H.; Mammen, M. J.; Debono, V. B.; Aponte Torres, Z.; Aryal, K.; Brocard, E.; Sagastuy, B.; Alhazzani, W., Vertical transmission risk of SARS-CoV-2 infection in the third trimester: a systematic scoping review. *The Journal of Maternal-Fetal & Neonatal Medicine* **2020**, 1-8. https://doi.org/10.1080/14767058.2020.1786055

664. Thomson, E. C.; Rosen, L. E.; Shepherd, J. G.; Spreafico, R.; da Silva Filipe, A.; Wojcechowskyj, J. A.; Davis, C.; Piccoli, L.; Pascall, D. J.; Dillen, J.; Lytras, S.; Czudnochowski, N.; Shah, R.; Meury, M.; Jesudason, N.; De Marco, A.; Li, K.; Bassi, J.; Toole, A.; Pinto, D.; Colquhoun, R. M.; Culap, K.; Jackson, B.; Zatta, F.; Rambaut, A.; Jaconi, S.; Sreenu, V. B.; Nix, J.; Jarrett, R. F.; Beltramello, M.; Nomikou, K.; Pizzuto, M.; Tong, L.; Cameroni, E.; Johnson, N.; Wickenhagen, A.; Ceschi, A.; Mair, D.; Ferrari, P.; Smollett, K.; Sallusto, F.; Carmichael, S.; Garzoni, C.; Nichols, J.; Galli, M.; Hughes, J.; Riva, A.; Ho, A.; Semple, M. G.; Openshaw, P. J. M.; Baillie, K.; Rihn, S. J.; Lycett, S. J.; Virgin, H. W.; Telenti, A.; Corti, D.; Robertson, D. L.; Snell, G., The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. *bioRxiv* **2020**, 2020.11.04.355842. http://biorxiv.org/content/early/2020/11/05/2020.11.04.355842.abstract
665. TILLETT, R.; SEVINSKY, J.; HARTLEY, P.; KERWIN, H.; CRAWFORD, N.; GORZALSKI, A.; LAVERDURE, C.; VERMA, S.; ROSSETTO, C.; FARRELL, M.; JACKSON, D.; Pandori, M.; VAN HOOSER, S., Genomic Evidence for a Case of Reinfection with SARS-CoV-2. *The Lancet* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3681489
666. To, K. K.-W.; Tsang, O. T.-Y.; Leung, W.-S.; Tam, A. R.; Wu, T.-C.; Lung, D. C.; Yip, C. C.-Y.; Cai, J.-P.; Chan, J. M.-C.; Chik, T. S.-H., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* **2020**.
667. Torres, J. P.; Piñera, C.; De La Maza, V.; Lagomarcino, A. J.; Simian, D.; Torres, B.; Urquidi, C.; Valenzuela, M. T.; O'Ryan, M., Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence in Blood in a Large School Community Subject to a Coronavirus Disease 2019 Outbreak: A Cross-sectional Study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa955
668. Tortajada, C.; Colomer, E.; Andreu-Ballester, J. C.; Esparcia, A.; Oltra, C.; Flores, J., Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and Intensive Care Unit admission in patients with COVID-19 according to patients' oxygen requirements. *J Med Virol* **2020**.
669. Tosif, S.; Neeland, M. R.; Sutton, P.; Licciardi, P. V.; Sarkar, S.; Selva, K. J.; Do, L. A. H.; Donato, C.; Quan Toh, Z.; Higgins, R.; Van de Sandt, C.; Lemke, M. M.; Lee, C. Y.; Shoffner, S. K.; Flanagan, K. L.; Arnold, K. B.; Mordant, F. L.; Mulholland, K.; Bines, J.; Dohle, K.; Pellicci, D. G.; Curtis, N.; McNab, S.; Steer, A.; Saffery, R.; Subbarao, K.; Chung, A. W.; Kedzierska, K.; Burgner, D. P.; Crawford, N. W., Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. *Nature Communications* **2020,** *11* (1), 5703. https://doi.org/10.1038/s41467-020-19545-8
670. Toubiana, J.; Levy, C.; Allali, S.; Jung, C.; Leruez-Ville, M.; Varon, E.; Bajolle, F.; Ouldali, N.; Chareyre, J.; Béchet, S.; Elbez, A.; Casanova, J.-L.; Chalumeau, M.; Cohen, R.; Cohen, J. F., Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case–control study, Paris, France, April to May 2020. *Eurosurveillance* **2020,** *25* (48), 2001813. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.48.2001813
671. Treibel, T. A.; Manisty, C.; Burton, M.; McKnight, Á.; Lambourne, J.; Augusto, J. B.; Couto-Parada, X.; Cutino-Moguel, T.; Noursadeghi, M.; Moon, J. C., COVID-19: PCR screening of asymptomatic health-care workers at London hospital. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)31100-4
672. Tsay, C.; Lejarza, F.; Stadtherr, M. A.; Baldea, M., Modeling, state estimation, and optimal control for the US COVID-19 outbreak. *Scientific Reports* **2020,** *10* (1), 10711. https://doi.org/10.1038/s41598-020-67459-8
673. Tso, F. Y.; Lidenge, S. J.; Peña, P. B.; Clegg, A. A.; Ngowi, J. R.; Mwaiselage, J.; Ngalamika, O.; Julius, P.; West, J. T.; Wood, C., High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa. *International Journal of Infectious Diseases* **2020**. https://doi.org/10.1016/j.ijid.2020.10.104

674. Twin FM, NHS Trials "Unique" New Decontamination Tech to Reduce COVID Transmission Indoors. https://www.twinfm.com/article/nhs-trials-unique-new-decontamination-tech-to-reduce-covid-transmission-indoors (accessed 19 Oct 2020).
675. U.S. Food and Drug Administration (FDA), Enforcement Policy for Bioburden Reduction Systems Using Dry Heat to Support Single-User Resuse of Certain Filtering Facepiece Respirators During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. Guidance for Industry, Healthcare Organizations, Healthcare Personnel, and Food and Drug Administration Staff. https://www.fda.gov/media/143985/download (accessed 30 No 2020).
676. UCLA, COVID-19 Cases in the United States. https://covid19.uclaml.org/model.html.
677. Udwadia, Z. F.; Singh, P.; Barkate, H.; Patil, S.; Rangwala, S.; Pendse, A.; Kadam, J.; Wu, W.; Caracta, C. F.; Tandon, M., Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial. *Int J Infect Dis* **2020**.
678. Ueki, H.; Furusawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kabata, H.; Nishimura, H.; Kawaoka, Y., Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2. *mSphere* **2020,** *5* (5), e00637-20. https://msphere.asm.org/content/msph/5/5/e00637-20.full.pdf
679. Ulrich, L.; Michelitsch, A.; Halwe, N.; Wernike, K.; Hoffmann, D.; Beer, M., Experimental SARS-CoV-2 infection of bank voles - general susceptibility but lack of direct transmission. *bioRxiv* **2020**, 2020.12.24.424203. http://biorxiv.org/content/early/2020/12/24/2020.12.24.424203.abstract
680. Ulrich, L.; Wernike, K.; Hoffmann, D.; Mettenleiter, T. C.; Beer, M., Experimental infection of cattle with SARS-CoV-2. *bioRxiv* **2020**, 2020.08.25.254474. http://biorxiv.org/content/early/2020/08/25/2020.08.25.254474.abstract
681. Urigo, C.; Soin, S.; Sahu, A., Spontaneous pneumomediastinum as a complication of a COVID-19 related pneumonia: case report and review of literature. *Radiology Case Reports* **2020,** *15* (12), 2577-2581. http://www.sciencedirect.com/science/article/pii/S1930043320305148
682. van der Sande, M.; Teunis, P.; Sabel, R., Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population. *Plos One* **2008,** *3* (7). <Go to ISI>://WOS:000264065800020
683. van Doorn, A. S.; Meijer, B.; Frampton, C. M. A.; Barclay, M. L.; de Boer, N. K. H., Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. *Alimentary Pharmacology & Therapeutics n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.16036
684. van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **2020**. https://doi.org/10.1056/NEJMc2004973
685. van Dorp, L.; Acman, M.; Richard, D.; Shaw, L. P.; Ford, C. E.; Ormond, L.; Owen, C. J.; Pang, J.; Tan, C. C. S.; Boshier, F. A. T.; Ortiz, A. T.; Balloux, F., Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution* **2020**, 104351. http://www.sciencedirect.com/science/article/pii/S1567134820301829
686. van Dorp, L.; Richard, D.; Tan, C. C. S.; Shaw, L. P.; Acman, M.; Balloux, F., No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. *Nature Communications* **2020,** *11* (1), 5986. https://doi.org/10.1038/s41467-020-19818-2
687. Varga, Z.; Flammer, A. J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A. S.; Mehra, M. R.; Schuepbach, R. A.; Ruschitzka, F.; Moch, H., Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* **2020,** *395* (10234), 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
688. Verma, S.; Dhanak, M.; Frankenfield, J., Visualizing droplet dispersal for face shields and masks with exhalation valves. *arXiv preprint arXiv:2008.00125* **2020**.

689. Vilke, G. M.; Brennan, J. J.; Cronin, A. O.; Castillo, E. M., Clinical features of covid-19 patients: is temperature screening useful? *The Journal of Emergency Medicine* **2020**. http://www.sciencedirect.com/science/article/pii/S073646792030977X
690. Viola, I. M.; Peterson, B.; Pisetta, G.; Pavar, G.; Akhtar, H.; Menolascina, F.; Mangano, E.; Dunn, K.; Gabl, R.; Nila, A.; Molinari, E.; Cummins, C.; Thompson, G.; Lo, M.; Denison, F.; Digard, P.; Malik, O.; Dunn, M. J. G.; Mehendale, F., Face Coverings, Aerosol Dispersion and Mitigation of Virus Transmission Risk. arXiv.org: 2020.
691. Vivanti, A. J.; Vauloup-Fellous, C.; Prevot, S.; Zupan, V.; Suffee, C.; Do Cao, J.; Benachi, A.; De Luca, D., Transplacental transmission of SARS-CoV-2 infection. *Nature Communications* **2020,** *11* (1), 3572. https://doi.org/10.1038/s41467-020-17436-6
692. Volz, E.; Swapnil, M.; Chand, M.; Barrett, J. C.; Johnson, R.; Geidelberg, L.; Hinsley, W.; Laydon, D. J.; Dabrera, G.; O'Toole, A.; Amato, R.; Ragonnet-Cronin, M.; Harrison, I.; Jackson, B.; Ariani, C. V.; Boyd, O.; Loman, N.; McCrone, J. T.; Goncalves, S.; Jorgensen, D.; Myers, R.; Hill, V.; Jackson, D. K.; Gaythorpe, K.; Groves, N.; Sillitoe, J.; Kwiatkowski, D. P.; COG-UK; Flaxman, S.; Ratmann, O.; Bhatt, S.; Hopkins, S.; Gandy, A.; Rambaut, A.; Ferguson, N. M., *Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data*; Imperial College London: 2020. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-12-31-COVID19-Report-42-Preprint-VOC.pdf
693. Volz, E. M.; Hill, V.; McCrone, J. T.; Price, A.; Jorgensen, D.; Toole, A.; Southgate, J. A.; Johnson, R.; Jackson, B.; Nascimento, F. F.; Rey, S. M.; Nicholls, S. M.; Colquhoun, R. M.; da Silva Filipe, A.; Shepherd, J. G.; Pascall, D. J.; Shah, R.; Jesudason, N.; Li, K.; Jarrett, R.; Pacchiarini, N.; Bull, M.; Geidelberg, L.; Siveroni, I.; Goodfellow, I. G.; Loman, N. J.; Pybus, O.; Robertson, D. L.; Thomson, E. C.; Rambaut, A.; Connor, T. R., Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity. *medRxiv* **2020**, 2020.07.31.20166082. http://medrxiv.org/content/early/2020/09/01/2020.07.31.20166082.abstract
694. Voss, J. D.; Skarzynski, M.; McAuley, E. M.; Maier, E. J.; Gibbons, T.; Fries, A. C.; Chapleau, R. R., Variants in SARS-CoV-2 Associated with Mild or Severe Outcome. *medRxiv* **2020**, 2020.12.01.20242149. http://medrxiv.org/content/early/2020/12/03/2020.12.01.20242149.abstract
695. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D. R.; Bailey, M. J.; Mansour, M.; McMahon, M.; Meade, P.; Mendu, D. R.; Muellers, K.; Stadlbauer, D.; Stone, K.; Strohmeier, S.; Simon, V.; Aberg, J.; Reich, D. L.; Krammer, F.; Cordon-Cardo, C., Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* **2020**, eabd7728. https://science.sciencemag.org/content/sci/early/2020/10/27/science.abd7728.full.pdf
696. Walsh, K. A.; Jordan, K.; Clyne, B.; Rohde, D.; Drummond, L.; Byrne, P.; Ahern, S.; Carty, P. G.; O'Brien, K. K.; O'Murchu, E.; O'Neill, M.; Smith, S. M.; Ryan, M.; Harrington, P., SARS-CoV-2 Detection, Viral Load and Infectivity over the Course of an Infection: SARS-CoV-2 Detection, Viral Load and Infectivity. *The Journal of infection* **2020**, S0163-4453(20)30449-7. https://pubmed.ncbi.nlm.nih.gov/32615199 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323671/
697. Walsh, K. A.; Spillane, S.; Comber, L.; Cardwell, K.; Harrington, P.; Connell, J.; Teljeur, C.; Broderick, N.; de Gascun, C. F.; Smith, S. M.; Ryan, M.; O'Neill, M., The duration of infectiousness of individuals infected with SARS-CoV-2. *Journal of Infection*. https://doi.org/10.1016/j.jinf.2020.10.009
698. Wambier, C. G.; Vaño-Galván, S.; McCoy, J.; Gomez-Zubiaur, A.; Herrera, S.; Hermosa-Gelbard, Á.; Moreno-Arrones, O. M.; Jiménez-Gómez, N.; González-Cantero, A.; Pascual, P. F.; Segurado-Miravalles, G.; Shapiro, J.; Pérez-García, B.; Goren, A., Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign&#x201d. *Journal of the American Academy of Dermatology*. https://doi.org/10.1016/j.jaad.2020.05.079

699. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.1585 https://jamanetwork.com/journals/jama/articlepdf/2761044/jama_wang_2020_oi_200019.pdf
700. Wang, D.; Li, R.; Wang, J.; Jiang, Q.; Gao, C.; Yang, J.; Ge, L.; Hu, Q., Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. *BMC Infectious Diseases* **2020,** *20* (1), 519. https://doi.org/10.1186/s12879-020-05242-w
701. Wang, D.; You, Y.; Zhou, X.; Zong, Z.; Huang, H.; Zhang, H.; Yong, X.; Cheng, Y.; Yang, L.; Guo, Q.; Long, Y.; Liu, Y.; Huang, J.; Du, L., Selection of homemade mask materials for preventing transmission of COVID-19: a laboratory study. *medRxiv* **2020**.
702. Wang, K.; Zhao, S.; Li, H.; Song, Y.; Wang, L.; Wang, M. H.; Peng, Z.; Li, H.; He, D., Real-time estimation of the reproduction number of the novel coronavirus disease (COVID-19) in China in 2020 based on incidence data. *Annals of Translational Medicine* **2020,** *8* (11), 689. http://atm.amegroups.com/article/view/43447
703. Wang, L.; Didelot, X.; Yang, J.; Wong, G.; Shi, Y.; Liu, W.; Gao, G. F.; Bi, Y., Inference of person-to-person transmission of COVID-19 reveals hidden super-spreading events during the early outbreak phase. *Nature Communications* **2020,** *11* (1), 5006. https://doi.org/10.1038/s41467-020-18836-4
704. Wang, Q.; Berger, N. A.; Xu, R., Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. *JAMA Oncology* **2020**. https://doi.org/10.1001/jamaoncol.2020.6178
705. Wang, R.; Qian, C.; Pang, Y.; Li, M.; Yang, Y.; Ma, H.; Zhao, M.; Qian, F.; Yu, H.; Liu, Z.; Ni, T.; Zheng, Y.; Wang, Y., opvCRISPR: One-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection. *Biosensors and Bioelectronics* **2021,** *172*, 112766. http://www.sciencedirect.com/science/article/pii/S0956566320307533
706. Wang, S.; Ma, P.; Zhang, S.; Song, S.; Wang, Z.; Ma, Y.; Xu, J.; Wu, F.; Duan, L.; Yin, Z.; Luo, H.; Xiong, N.; Xu, M.; Zeng, T.; Jin, Y., Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. *Diabetologia* **2020**. https://doi.org/10.1007/s00125-020-05209-1
707. Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.3786
708. Wang, X.; Du, Z.; Huang, G.; Pasco, R.; Fox, S.; Galvani, A.; Pignone, M.; Johnston, S. C.; Meyers, L. A., Effects of Cocooning on Coronavirus Disease Rates after Relaxing Social Distancing. *Emerging Infectious Disease journal* **2020,** *26* (12), 3066. https://wwwnc.cdc.gov/eid/article/26/12/20-1930_article
709. Wang, X.; Ferro, E. G.; Zhou, G.; Hashimoto, D.; Bhatt, D. L., Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.12897
710. Wang, X.; Pan, Y.; Zhang, D.; Chen, L.; Jia, L.; Li, X.; Yang, P.; Wang, Q.; Macintyre, C. R., Basic epidemiological parameter values from data of real-world in mega-cities: the characteristics of COVID-19 in Beijing, China. *BMC Infectious Diseases* **2020,** *20* (1), 526. https://doi.org/10.1186/s12879-020-05251-9
711. Wang, Y.; Chen, B.; Li, Y.; Zhang, L.; Wang, Y.; Yang, S.; Xiao, X.; Qin, Q., The Use of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis. *J Med Virol* **2020**.
712. Wang, Y.; Tian, H.; Zhang, L.; Zhang, M.; Guo, D.; Wu, W.; Zhang, X.; Kan, G. L.; Jia, L.; Huo, D.; Liu, B.; Wang, X.; Sun, Y.; Wang, Q.; Yang, P.; MacIntyre, C. R., Reduction of secondary transmission of SARS-

CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Global Health* **2020,** *5* (5), e002794.
https://gh.bmj.com/content/bmjgh/5/5/e002794.full.pdf
713. Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet* **2020,** *395* (10236), 1569-1578.
http://www.sciencedirect.com/science/article/pii/S0140673620310229
714. Ward, H.; Cooke, G.; Atchison, C.; Whitaker, M.; Elliott, J.; Moshe, M.; Brown, J. C.; Flower, B.; Daunt, A.; Ainslie, K.; Ashby, D.; Donnelly, C.; Riley, S.; Darzi, A.; Barclay, W.; Elliott, P., Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults *Preprint* **2020**.
https://www.imperial.ac.uk/media/imperial-college/institute-of-global-health-innovation/MEDRXIV-2020-219725v1-Elliott.pdf
715. Wathore, R.; Gupta, A.; Bherwani, H.; Labhasetwar, N., Understanding air and water borne transmission and survival of coronavirus: Insights and way forward for SARS-CoV-2. *Science of The Total Environment* **2020,** *749*, 141486.
http://www.sciencedirect.com/science/article/pii/S0048969720350154
716. WCS, A Tiger at Bronx Zoo Tests Positive for COVID-19; The Tiger and the Zoo's Other Cats Are Doing Well at This Time. https://newsroom.wcs.org/News-Releases/articleType/ArticleView/articleId/14010/A-Tiger-at-Bronx-Zoo-Tests-Positive-for-COVID-19-The-Tiger-and-the-Zoos-Other-Cats-Are-Doing-Well-at-This-Time.aspx (accessed April 6, 2020).
717. Wee, S.-L.; Qin, A., China Approves Covid-19 Vaccine as It Moves to Inoculate Millions.
https://www.nytimes.com/2020/12/30/business/china-vaccine.html.
718. Wei, W. E.; Li, Z.; Chiew, C. J.; Yong, S. E.; Toh, M. P.; Lee, V. J., Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub* (1 April 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm
719. Wei, Y.; Wei, L.; Liu, Y.; Huang, L.; Shen, S.; Zhang, R.; Chen, J.; Zhao, Y.; Shen, H.; Chen, F., A systematic review and meta-analysis reveals long and dispersive incubation period of COVID-19. *medRxiv* **2020**, 2020.06.20.20134387.
https://www.medrxiv.org/content/medrxiv/early/2020/06/22/2020.06.20.20134387.full.pdf
720. Weill, J. A.; Stigler, M.; Deschenes, O.; Springborn, M. R., Social distancing responses to COVID-19 emergency declarations strongly differentiated by income. *Proceedings of the National Academy of Sciences* **2020**, 202009412. https://www.pnas.org/content/pnas/early/2020/07/28/2009412117.full.pdf
721. Weinreich, D. M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Gao, H.; Bhore, R.; Musser, B. J.; Soo, Y.; Rofail, D.; Im, J.; Perry, C.; Pan, C.; Hosain, R.; Mahmood, A.; Davis, J. D.; Turner, K. C.; Hooper, A. T.; Hamilton, J. D.; Baum, A.; Kyratsous, C. A.; Kim, Y.; Cook, A.; Kampman, W.; Kohli, A.; Sachdeva, Y.; Graber, X.; Kowal, B.; DiCioccio, T.; Stahl, N.; Lipsich, L.; Braunstein, N.; Herman, G.; Yancopoulos, G. D., REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMoa2035002
722. Weisberg, S. P.; Connors, T. J.; Zhu, Y.; Baldwin, M. R.; Lin, W.-H.; Wontakal, S.; Szabo, P. A.; Wells, S. B.; Dogra, P.; Gray, J.; Idzikowski, E.; Stelitano, D.; Bovier, F. T.; Davis-Porada, J.; Matsumoto, R.; Poon, M. M. L.; Chait, M.; Mathieu, C.; Horvat, B.; Decimo, D.; Hudson, K. E.; Zotti, F. D.; Bitan, Z. C.; La Carpia, F.; Ferrara, S. A.; Mace, E.; Milner, J.; Moscona, A.; Hod, E.; Porotto, M.; Farber, D. L., Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nature Immunology* **2020**. https://doi.org/10.1038/s41590-020-00826-9

723. Weissman, D.; Alameh, M. G.; de Silva, T.; Collini, P.; Hornsby, H.; Brown, R.; LaBranche, C. C.; Edwards, R. J.; Sutherland, L.; Santra, S.; Mansouri, K.; Gobeil, S.; McDanal, C.; Pardi, N.; Hengartner, N.; Lin, P. J. C.; Tam, Y.; Shaw, P. A.; Lewis, M. G.; Boesler, C.; Şahin, U.; Acharya, P.; Haynes, B. F.; Korber, B.; Montefiori, D. C., D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. *Cell Host Microbe* **2020**.
724. Weissman, D. N.; de Perio, M. A.; Radonovich, L. J., Jr, COVID-19 and Risks Posed to Personnel During Endotracheal Intubation. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.6627
725. Wellinghausen, N.; Plonné, D.; Voss, M.; Ivanova, R.; Frodl, R.; Deininger, S., SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. *Journal of Clinical Virology* **2020,** *130*, 104542. http://www.sciencedirect.com/science/article/pii/S1386653220302845
726. Westblade, L. F.; Brar, G.; Pinheiro, L. C.; Paidoussis, D.; Rajan, M.; Martin, P.; Goyal, P.; Sepulveda, J. L.; Zhang, L.; George, G.; Liu, D.; Whittier, S.; Plate, M.; Small, C. B.; Rand, J. H.; Cushing, M. M.; Walsh, T. J.; Cooke, J.; Safford, M. M.; Loda, M.; Satlin, M. J., SARS-CoV-2 Viral Load Predicts Mortality in Patients with and Without Cancer Who Are Hospitalized with COVID-19. *Cancer Cell* **2020**. http://www.sciencedirect.com/science/article/pii/S1535610820304815
727. Whitman, J. D.; Hiatt, J.; Mowrey, C. T.; al., e., Test performance evaluation of SARS-CoV-2 serological assays. *Unpublished Preprint* **2020**. https://www.dropbox.com/s/cd1628cau09288a/SARS-CoV-2_Serology_Manuscript.pdf?dl=0
728. Whittaker, E.; Bamford, A.; Kenny, J.; Kaforou, M.; Jones, C. E.; Shah, P.; Ramnarayan, P.; Fraisse, A.; Miller, O.; Davies, P.; Kucera, F.; Brierley, J.; McDougall, M.; Carter, M.; Tremoulet, A.; Shimizu, C.; Herberg, J.; Burns, J. C.; Lyall, H.; Levin, M.; Group, f. t. P.-T. S.; EUCLIDS; Consortia, P., Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *JAMA* **2020,** *324* (3), 259-269. https://doi.org/10.1001/jama.2020.10369
729. Whitworth, C.; Mu, Y.; Houston, H.; Martinez-Smith, M.; Noble-Wang, J.; Coulliette-Salmond, A.; Rose, L., Persistence of Bacteriophage Phi 6 on Porous and Nonporous Surfaces and the Potential for Its Use as an Ebola Virus or Coronavirus Surrogate. *Applied and Environmental Microbiology* **2020,** *86* (17), e01482-20. https://aem.asm.org/content/aem/86/17/e01482-20.full.pdf
730. Whitworth, J., U.S. FDA 'aware' of China testing food for coronavirus. https://www.foodsafetynews.com/2020/06/u-s-fda-aware-of-china-testing-food-for-coronavirus/ (accessed 06/22/2020).
731. WHO, *Advice on the use of masks on the context of COVID-19. Interim Guidance. 5 June 2020.*; World Health Organization: 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks
732. WHO, *"Immunity passports" in the context of COVID-19*; World Health Organization: 2020. https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19
733. WHO, *Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected*; 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125
734. WHO, International Nonproprietary Names for Pharmaceutical Substances (INN). https://www.who.int/medicines/publications/druginformation/issues/WHO_DI_34-3_PL124-SpecialEdition.pdf.
735. WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
736. WHO, *Mask use in the context of COVID-19*; World Health Organization: 1 December 2020, 2020. https://apps.who.int/iris/rest/bitstreams/1319378/retrieve
737. WHO, *Transmission of SARS-CoV-2: implications for infection prevention precautions*; World Health Organization: 2020. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions

738. WHO, WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access.
739. Widge, A. T.; Rouphael, N. G.; Jackson, L. A.; Anderson, E. J.; Roberts, P. C.; Makhene, M.; Chappell, J. D.; Denison, M. R.; Stevens, L. J.; Pruijssers, A. J.; McDermott, A. B.; Flach, B.; Lin, B. C.; Doria-Rose, N. A.; O'Dell, S.; Schmidt, S. D.; Neuzil, K. M.; Bennett, H.; Leav, B.; Makowski, M.; Albert, J.; Cross, K.; Edara, V.-V.; Floyd, K.; Suthar, M. S.; Buchanan, W.; Luke, C. J.; Ledgerwood, J. E.; Mascola, J. R.; Graham, B. S.; Beigel, J. H., Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2032195
740. Wiersinga, W. J.; Rhodes, A.; Cheng, A. C.; Peacock, S. J.; Prescott, H. C., Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.12839
741. Williams, S.; Sheard, N.; Stuart, B.; Phan, H. T. T.; Borca, F.; Wilkinson, T. M. A.; Burke, H.; Freeman, A.; Investigators, R. C., Comparisons of early and late presentation to hospital in COVID-19 patients. *Respirology* **2020,** *n/a* (n/a). https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13985
742. Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirglmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**. https://doi.org/10.1038/s41586-020-2196-x
743. Wong, F.; Collins, J. J., Evidence that coronavirus superspreading is fat-tailed. *Proceedings of the National Academy of Sciences* **2020**, 202018490. https://www.pnas.org/content/pnas/early/2020/10/30/2018490117.full.pdf
744. Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf
745. Wong, Y. C.; Lau, S. Y.; Wang To, K. K.; Mok, B. W. Y.; Li, X.; Wang, P.; Deng, S.; Woo, K. F.; Du, Z.; Li, C.; Zhou, J.; Woo Chan, J. F.; Yuen, K. Y.; Chen, H.; Chen, Z., Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa953
746. Woodworth, K. R.; Olsen, E. O. M.; Neelam, V.; Lewis, E. L.; Galang, R. R.; Oduyebo, T.; Aveni, K.; Yazdy, M. M.; Harvey, E.; Longcore, N. D.; Barton, J.; Fussman, C.; Siebman, S.; Lush, M.; Patrick, P. H.; Halai, U.-A.; Valencia-Prado, M.; Orkis, L.; Sowunmi, S.; Schlosser, L.; Khuwaja, S.; Read, J. S.; Hall, A. J.; Meaney-Delman, D.; Ellington, S. R.; Gilboa, S. M.; Tong, V. T., Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy
SET-NET, 16 Jurisdictions, March 29–October 14, 2020.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e2.htm?s_cid=mm6944e2_w.
747. Woolf, S. H.; Chapman, D. A.; Sabo, R. T.; Weinberger, D. M.; Hill, L., Excess Deaths From COVID-19 and Other Causes, March-April 2020. *JAMA* **2020**. https://doi.org/10.1001/jama.2020.11787
748. Woolsey, C. B.; Borisevich, V.; Prasad, A. N.; Agans, K. N.; Deer, D. J.; Dobias, N. S.; Heymann, J. C.; Foster, S. L.; Levine, C. B.; Medina, L.; Melody, K.; Geisbert, J. B.; Fenton, K. A.; Geisbert, T. W.; Cross, R. W., Establishment of an African green monkey model for COVID-19. *bioRxiv* **2020**, 2020.05.17.100289. http://biorxiv.org/content/early/2020/05/17/2020.05.17.100289.abstract
749. World Health Organization, SARS-CoV-2 Variants. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/ (accessed 02 Jan 2021).
750. Worthham, J. M.; Lee, J. T.; Althomsons, S.; al., e., Characteristics of Persons Who Died with COVID-19 — United States, February 12–May 18, 2020. *Morbidity and Mortality Weekly Report* **2020,** *ePub: July 10, 2020* (69). https://www.cdc.gov/mmwr/volumes/69/wr/mm6928e1.htm

751. Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462. https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf
752. Wright, E. S.; Lakdawala, S. S.; Cooper, V. S., SARS-CoV-2 genome evolution exposes early human adaptations. *bioRxiv* **2020**, 2020.05.26.117069. https://www.biorxiv.org/content/biorxiv/early/2020/05/26/2020.05.26.117069.full.pdf
753. Wu, C.; Hou, D.; Du, C.; Cai, Y.; Zheng, J.; Xu, J.; Chen, X.; Chen, C.; Hu, X.; Zhang, Y.; Song, J.; Wang, L.; Chao, Y. C.; Feng, Y.; Xiong, W.; Chen, D.; Zhong, M.; Hu, J.; Jiang, J.; Bai, C.; Zhou, X.; Xu, J.; Song, Y.; Gong, F., Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. *Crit Care* **2020,** *24* (1), 643.
754. Wu, G.; Yang, P.; Xie, Y.; Woodruff, H. C.; Rao, X.; Guiot, J.; Frix, A.-N.; Louis, R.; Moutschen, M.; Li, J.; Li, J.; Yan, C.; Du, D.; Zhao, S.; Ding, Y.; Liu, B.; Sun, W.; Albarello, F.; D'Abramo, A.; Schininà, V.; Nicastri, E.; Occhipinti, M.; Barisione, G.; Barisione, E.; Halilaj, I.; Lovinfosse, P.; Wang, X.; Wu, J.; Lambin, P., Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study. *European Respiratory Journal* **2020**, 2001104. https://erj.ersjournals.com/content/erj/early/2020/06/25/13993003.01104-2020.full.pdf
755. Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext
756. Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G.-D., Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases* **2007,** *13* (10), 1562. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576_finalD.pdf
757. Xiao, K.; Zhai, J.; Feng, Y.; Zhou, N.; Zhang, X.; Zou, J. J.; Li, N.; Guo, Y.; Li, X.; Shen, X.; Zhang, Z.; Shu, F.; Huang, W.; Li, Y.; Zhang, Z.; Chen, R. A.; Wu, Y. J.; Peng, S. M.; Huang, M.; Xie, W. J.; Cai, Q. H.; Hou, F. H.; Chen, W.; Xiao, L.; Shen, Y., Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature* **2020**.
758. Xie, Y.; Bowe, B.; Maddukuri, G.; Al-Aly, Z., Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. *BMJ* **2020,** *371*, m4677. https://www.bmj.com/content/bmj/371/bmj.m4677.full.pdf
759. Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm.
760. Xu, X. K.; Liu, X. F.; Wu, Y.; Ali, S. T.; Du, Z.; Bosetti, P.; Lau, E. H. Y.; Cowling, B. J.; Wang, L., Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. *Clin Infect Dis* **2020**.
761. Yan, C. H.; Faraji, F.; Prajapati, D. P.; Boone, C. E.; DeConde, A. S., In *Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms*, International Forum of Allergy & Rhinology, Wiley Online Library: 2020.
762. Yan, L.; Shu, K.; Guan, J.; Shanchang, H., Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route. *Zenodo* **2020**. https://zenodo.org/record/4028830#.X3JdatpKiUn
763. Yang, C.; Jiang, M.; Wang, X.; Tang, X.; Fang, S.; Li, H.; Zuo, L.; Jiang, Y.; Zhong, Y.; Chen, Q.; Zheng, C.; Wang, L.; Wu, S.; Wu, W.; Liu, H.; Yuan, J.; Liao, X.; Zhang, Z.; Shi, X.; Geng, Y.; Zhang, H.; Zheng, H.; Wan, M.; Lu, L.; Ren, X.; Cui, Y.; Zou, X.; Feng, T.; Xia, J.; Yang, R.; Liu, Y.; Mei, S.; Li, B.; Yang, Z.; Hu, Q., Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study.

Emerging Microbes & Infections **2020,** *9* (1), 2368-2378. https://doi.org/10.1080/22221751.2020.1837018

764. Yang, L.; Dai, J.; Zhao, J.; Wang, Y.; Deng, P.; Wang, J., Estimation of incubation period and serial interval of COVID-19: analysis of 178 cases and 131 transmission chains in Hubei province, China. *Epidemiology and Infection* **2020,** *148*, e117. https://www.cambridge.org/core/article/estimation-of-incubation-period-and-serial-interval-of-covid19-analysis-of-178-cases-and-131-transmission-chains-in-hubei-province-china/C1B194C01268F005AAFBE8D50CB5F945

765. Yang, P.; Qi, J.; Zhang, S.; Bi, G.; Wang, X.; Yang, Y.; Sheng, B.; Mao, X., Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions. *medRxiv* **2020**, 2020.04.05.20054429. https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20054429.full.pdf

766. Yap, T. F.; Liu, Z.; Shveda, R. A.; Preston, D. J., A predictive model of the temperature-dependent inactivation of coronaviruses. *Applied Physics Letters* **2020,** *117* (6), 060601. https://aip.scitation.org/doi/abs/10.1063/5.0020782

767. Yehya, N.; Venkataramani, A.; Harhay, M. O., Statewide Interventions and Covid-19 Mortality in the United States: An Observational Study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa923

768. Yekta, R.; Vahid-Dastjerdi, L.; Norouzbeigi, S.; Mortazavian, A. M., Food Products as Potential Carriers of SARS-CoV-2. *Food Control* **2020**, 107754. http://www.sciencedirect.com/science/article/pii/S0956713520306708

769. Yonker, L. M.; Neilan, A. M.; Bartsch, Y.; Patel, A. B.; Regan, J.; Arya, P.; Gootkind, E.; Park, G.; Hardcastle, M.; St. John, A.; Appleman, L.; Chiu, M. L.; Fialkowski, A.; De la Flor, D.; Lima, R.; Bordt, E. A.; Yockey, L. J.; D'Avino, P.; Fischinger, S.; Shui, J. E.; Lerou, P. H.; Bonventre, J. V.; Yu, X. G.; Ryan, E. T.; Bassett, I. V.; Irimia, D.; Edlow, A. G.; Alter, G.; Li, J. Z.; Fasano, A., Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. *The Journal of Pediatrics* **2020**. https://doi.org/10.1016/j.jpeds.2020.08.037

770. Yu, B.; Li, C.; Sun, Y.; Wang, D. W., Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. *Cell Metab* **2020**.

771. Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**. http://www.chinaxiv.org/abs/202002.00033

772. Yuki, F.; Eiichiro, S.; Naho, T.; Reiko, M.; Ikkoh, Y.; Yura, K. K.; Mayuko, S.; Konosuke, M.; Takeaki, I.; Yugo, S.; Shohei, N.; Kazuaki, J.; Tadatsugu, I.; Tomimasa, S.; Motoi, S.; Hiroshi, N.; Hitoshi, O., Clusters of Coronavirus Disease in Communities, Japan, January–April 2020. *Emerging Infectious Disease journal* **2020,** *26* (9). https://wwwnc.cdc.gov/eid/article/26/9/20-2272_article

773. Zangmeister, C. D.; Radney, J. G.; Vicenzi, E. P.; Weaver, J. L., Filtration Efficiencies of Nanoscale Aerosol by Cloth Mask Materials Used to Slow the Spread of SARS CoV-2. *ACS Nano* **2020**. https://doi.org/10.1021/acsnano.0c05025

774. Zeng, H.-L.; Lu, Q.-B.; Yang, Q.; Wang, X.; Yue, D.-Y.; Zhang, L.-K.; Li, H.; Liu, W.; Li, H.-J., Longitudinal Profile of Laboratory Parameters and Their Application in the Prediction for Fatal Outcome Among Patients Infected With SARS-CoV-2: A Retrospective Cohort Study. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa574

775. Zhang, J.; Wu, J.; Sun, X.; Xue, H.; Shao, J.; Cai, W.; Jing, Y.; Yue, M.; Dong, C., Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiology and Infection* **2020**, 1-19. https://www.cambridge.org/core/article/associations-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15

776. Zhang, L.; Jackson, C. B.; Mou, H.; Ojha, A.; Rangarajan, E. S.; Izard, T.; Farzan, M.; Choe, H., The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *bioRxiv* **2020**, 2020.06.12.148726. http://biorxiv.org/content/early/2020/06/12/2020.06.12.148726.abstract

777. Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M., SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. *bioRxiv* **2020**, 2020.04.01.021196. http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract
778. Zhang, T.; Wu, Q.; Zhang, Z., Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology* **2020,** *30* (7), 1346-1351.e2. http://www.sciencedirect.com/science/article/pii/S0960982220303602
779. Zhang, Y.; Muscatello, D.; Tian, Y.; Chen, Y.; Li, S.; Duan, W.; Ma, C.; Sun, Y.; Wu, S.; Ge, L.; Yang, P.; Jia, L.; Wang, Q.; MacIntyre, C. R., Role of presymptomatic transmission of COVID-19: evidence from Beijing, China. *Journal of Epidemiology and Community Health* **2020**, jech-2020-214635. https://jech.bmj.com/content/jech/early/2020/08/26/jech-2020-214635.full.pdf
780. Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020,** *9* (2), 388.
781. Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015,** *10* (12), e0145561. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf
782. Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546052#
783. Zhao, L.; Qi, Y.; Luzzatto-Fegiz, P.; Cui, Y.; Zhu, Y., COVID-19: Effects of Environmental Conditions on the Propagation of Respiratory Droplets. *Nano Letters* **2020,** *20* (10), 7744-7750. https://doi.org/10.1021/acs.nanolett.0c03331
784. Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease journal* **2020,** *26* (5). https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article
785. Zheng, H.; Li, H.; Guo, L.; Liang, Y.; Li, J.; Wang, X.; Hu, Y.; Wang, L.; Liao, Y.; Yang, F.; Li, Y.; Fan, S.; Li, D.; Cui, P.; Wang, Q.; Shi, H.; Chen, Y.; Yang, Z.; Yang, J.; Shen, D.; Cun, W.; Zhou, X.; Dong, X.; Wang, Y.; Chen, Y.; Dai, Q.; Jin, W.; He, Z.; Li, Q.; Liu, L., Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. *PLOS Pathogens* **2020,** *16* (11), e1008949. https://doi.org/10.1371/journal.ppat.1008949
786. Zhifei, A., Vaccine to undergo 3rd phase of trials. http://en.nhc.gov.cn/2020-11/20/c_82209.htm.
787. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. https://doi.org/10.1016/S0140-6736(20)30566-3
788. Zhou, H.; Chen, X.; Hu, T.; Li, J.; Song, H.; Liu, Y.; Wang, P.; Liu, D.; Yang, J.; Holmes, E. C.; Hughes, A. C.; Bi, Y.; Shi, W., A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19. *bioRxiv* **2020**, 2020.03.02.974139. https://www.biorxiv.org/content/biorxiv/early/2020/03/11/2020.03.02.974139.full.pdf
789. Zhou, L.; Yao, M.; Zhang, X.; Hu, B.; Li, X.; Chen, H.; Zhang, L.; Liu, Y.; Du, M.; Sun, B.; Jiang, Y.; Zhou, K.; Hong, J.; Yu, N.; Ding, Z.; Xu, Y.; Hu, M.; Morawska, L.; Grinshpun, S. A.; Biswas, P.; Flagan, R. C.; Zhu, B.; Liu, W.; Zhang, Y., Breath-, air- and surface-borne SARS-CoV-2 in hospitals. *Journal of Aerosol Science* **2020**, 105693. http://www.sciencedirect.com/science/article/pii/S0021850220301786
790. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-

S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952. https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf

791. Zhu, F.-C.; Guan, X.-H.; Li, Y.-H.; Huang, J.-Y.; Jiang, T.; Hou, L.-H.; Li, J.-X.; Yang, B.-F.; Wang, L.; Wang, W.-J.; Wu, S.-P.; Wang, Z.; Wu, X.-H.; Xu, J.-J.; Zhang, Z.; Jia, S.-Y.; Wang, B.-S.; Hu, Y.; Liu, J.-J.; Zhang, J.; Qian, X.-A.; Li, Q.; Pan, H.-X.; Jiang, H.-D.; Deng, P.; Gou, J.-B.; Wang, X.-W.; Wang, X.-H.; Chen, W., Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet* **2020**. https://doi.org/10.1016/S0140-6736(20)31605-6

792. Zhu, S.; Zong, Z., Why did so few healthcare workers in China get COVID-19 infection. *QJM: An International Journal of Medicine* **2020**.

793. Zhu, Y.; Bloxham, C. J.; Hulme, K. D.; Sinclair, J. E.; Tong, Z. W. M.; Steele, L. E.; Noye, E. C.; Lu, J.; Xia, Y.; Chew, K. Y.; Pickering, J.; Gilks, C.; Bowen, A. C.; Short, K. R., A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters. *Clinical Infectious Diseases* **2020**. https://doi.org/10.1093/cid/ciaa1825

794. Zietz, M.; Zucker, J.; Tatonetti, N. P., Associations between blood type and COVID-19 infection, intubation, and death. *Nature Communications* **2020,** *11* (1), 5761. https://doi.org/10.1038/s41467-020-19623-x

795. Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **2020**. https://www.nejm.org/doi/full/10.1056/NEJMc2001737

796. Zuo, J.; Dowell, A.; Pearce, H.; Verma, K.; Long, H.; Begum, J.; Aiano, F.; Amin-Chowdhury, Z.; Hallis, B.; Stapley, L.; Borrow, R.; Linley, E.; Ahmad, S.; Parker, B.; Horsley, A.; Amirthalingam, G.; Brown, K.; Ramsay, M. E.; Ladhani, S.; Moss, P., Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. *bioRxiv* **2020**, 2020.11.01.362319. https://www.biorxiv.org/content/biorxiv/early/2020/11/02/2020.11.01.362319.full.pdf